<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2217594-B1" country="EP" doc-number="2217594" kind="B1" date="20140108" family-id="40577704" file-reference-id="270083" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588160" ucid="EP-2217594-B1"><document-id><country>EP</country><doc-number>2217594</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08846160-A" is-representative="NO"><document-id mxw-id="PAPP154850352" load-source="docdb" format="epo"><country>EP</country><doc-number>08846160</doc-number><kind>A</kind><date>20081031</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140551189" ucid="IB-2007054437-W" load-source="docdb"><document-id format="epo"><country>IB</country><doc-number>2007054437</doc-number><kind>W</kind><date>20071101</date></document-id></priority-claim><priority-claim mxw-id="PPC140553443" ucid="IB-2008054543-W" load-source="docdb"><document-id format="epo"><country>IB</country><doc-number>2008054543</doc-number><kind>W</kind><date>20081031</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130731</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989324859" load-source="ipcr">A61P  37/00        20060101ALI20091203BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324860" load-source="ipcr">C07D 417/04        20060101ALI20091203BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324861" load-source="ipcr">C07D 413/04        20060101AFI20091203BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324862" load-source="ipcr">A61K  31/506       20060101ALI20091203BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989631314" load-source="docdb" scheme="CPC">C07D 413/04        20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989634362" load-source="docdb" scheme="CPC">C07D 417/04        20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369113" lang="DE" load-source="patent-office">NEUARTIGE PYRIMIDINDERIVATE</invention-title><invention-title mxw-id="PT132369114" lang="EN" load-source="patent-office">NOVEL PYRIMIDINE DERIVATIVES</invention-title><invention-title mxw-id="PT132369115" lang="FR" load-source="patent-office">NOUVEAUX DÉRIVÉS DE PYRIMIDINE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919533318" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ACTELION PHARMACEUTICALS LTD</last-name><address><country>CH</country></address></addressbook></applicant><applicant mxw-id="PPAR919528019" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ACTELION PHARMACEUTICALS LTD.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919538277" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BOLLI MARTIN</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919513950" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BOLLI, MARTIN</last-name></addressbook></inventor><inventor mxw-id="PPAR919021785" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BOLLI, MARTIN</last-name><address><street>Bachgrabenweg 21</street><city>CH-4123 Allschwil</city><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919546061" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>LESCOP CYRILLE</last-name><address><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919508511" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>LESCOP, CYRILLE</last-name></addressbook></inventor><inventor mxw-id="PPAR919021786" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>LESCOP, CYRILLE</last-name><address><street>32 rue du Noyer</street><city>F-68680 Kembs</city><country>FR</country></address></addressbook></inventor><inventor mxw-id="PPAR919534122" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>MATHYS BORIS</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919505121" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>MATHYS, BORIS</last-name></addressbook></inventor><inventor mxw-id="PPAR919021783" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>MATHYS, BORIS</last-name><address><street>Wartenbergstrasse 48</street><city>CH-4133 Pratteln</city><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919538345" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>MUELLER CLAUS</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR919504420" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>MUELLER, CLAUS</last-name></addressbook></inventor><inventor mxw-id="PPAR919021782" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>MUELLER, CLAUS</last-name><address><street>Wittlinger Strasse 37</street><city>79576 Weil am Rhein</city><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR919518646" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>NAYLER OLIVER</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919513834" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>NAYLER, OLIVER</last-name></addressbook></inventor><inventor mxw-id="PPAR919021784" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>NAYLER, OLIVER</last-name><address><street>Hangstrasse 38</street><city>CH-4144 Arlesheim</city><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919514574" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>STEINER BEAT</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919525292" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>STEINER, BEAT</last-name></addressbook></inventor><inventor mxw-id="PPAR919021781" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>STEINER, BEAT</last-name><address><street>Zugerstrasse 3</street><city>CH-4143 Dornach</city><country>CH</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919021787" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Actelion Pharmaceuticals Ltd.</last-name><iid>100070980</iid><address><street>Gewerbestrasse 16</street><city>4123 Allschwil</city><country>CH</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919021788" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Gschwend, Thomas Peter</last-name><iid>100748541</iid><address><street>Actelion Pharmaceuticals Ltd Gewerbestrasse 16</street><city>CH-4123 Allschwil</city><country>CH</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="IB-2008054543-W"><document-id><country>IB</country><doc-number>2008054543</doc-number><kind>W</kind><date>20081031</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009057079-A2"><document-id><country>WO</country><doc-number>2009057079</doc-number><kind>A2</kind><date>20090507</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549799132" load-source="docdb">AT</country><country mxw-id="DS549874414" load-source="docdb">BE</country><country mxw-id="DS549870522" load-source="docdb">BG</country><country mxw-id="DS549783226" load-source="docdb">CH</country><country mxw-id="DS549889955" load-source="docdb">CY</country><country mxw-id="DS549799145" load-source="docdb">CZ</country><country mxw-id="DS549874415" load-source="docdb">DE</country><country mxw-id="DS549889956" load-source="docdb">DK</country><country mxw-id="DS549889961" load-source="docdb">EE</country><country mxw-id="DS549782052" load-source="docdb">ES</country><country mxw-id="DS549870523" load-source="docdb">FI</country><country mxw-id="DS549870524" load-source="docdb">FR</country><country mxw-id="DS549874416" load-source="docdb">GB</country><country mxw-id="DS549889962" load-source="docdb">GR</country><country mxw-id="DS549874417" load-source="docdb">HR</country><country mxw-id="DS549799146" load-source="docdb">HU</country><country mxw-id="DS549783227" load-source="docdb">IE</country><country mxw-id="DS549874422" load-source="docdb">IS</country><country mxw-id="DS549870525" load-source="docdb">IT</country><country mxw-id="DS549889963" load-source="docdb">LI</country><country mxw-id="DS549867722" load-source="docdb">LT</country><country mxw-id="DS549799147" load-source="docdb">LU</country><country mxw-id="DS549867723" load-source="docdb">LV</country><country mxw-id="DS549867724" load-source="docdb">MC</country><country mxw-id="DS549922940" load-source="docdb">MT</country><country mxw-id="DS549782057" load-source="docdb">NL</country><country mxw-id="DS549799148" load-source="docdb">NO</country><country mxw-id="DS549782058" load-source="docdb">PL</country><country mxw-id="DS549889964" load-source="docdb">PT</country><country mxw-id="DS549782059" load-source="docdb">RO</country><country mxw-id="DS549782060" load-source="docdb">SE</country><country mxw-id="DS549889973" load-source="docdb">SI</country><country mxw-id="DS549922941" load-source="docdb">SK</country><country mxw-id="DS549783228" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960588" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>Field of the invention</u></b></heading><p id="p0001" num="0001">The present invention relates to S1P1/EDG1 receptor agonists of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing a compound of the formula (I), and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.</p><heading id="h0002"><b><u>Background of the invention</u></b></heading><p id="p0002" num="0002">The human immune system is designed to defend the body against foreign microorganisms and substances that cause infection or disease. Complex regulatory mechanisms ensure that the immune response is targeted against the intruding substance or organism and not against the host. In some cases, these control mechanisms are unregulated and autoimmune responses can develop. A consequence of the uncontrolled inflammatory response is severe organ, cell, tissue or joint damage. With current treatment, the whole immune system is usually suppressed and the body's ability to react to infections is also severely compromised. Typical drugs in this class include azathioprine, chlorambucil, cyclophosphamide, cyclosporin, or methotrexate. Corticosteroids which reduce inflammation and suppress the immune response, may cause side effects when used in long term treatment. Nonsteroidal anti-infammatory drugs (NSAIDs) can reduce pain and inflammation, however, they exhibit considerable side effects. Alternative treatments include agents that activate or block cytokine signaling.</p><p id="p0003" num="0003">Orally active compounds with immunomodulating properties, without compromising immune responses and with reduced side effects would significantly improve current treatments of uncontrolled inflammatory disease.</p><p id="p0004" num="0004">In the field of organ transplantation the host immune response must be suppressed to prevent organ rejection. Organ transplant recipients can experience some rejection even when they are taking immunosuppressive drugs. Rejection occurs most frequently in the first few weeks after transplantation, but rejection episodes can also happen months or even years after transplantation. Combinations of up to three or four medications are<!-- EPO <DP n="2"> --> commonly used to give maximum protection against rejection while minimizing side effects. Current standard drugs used to treat the rejection of transplanted organs interfere with discrete intracellular pathways in the activation of T-type or B-type white blood cells. Examples of such drugs are cyclosporin, daclizumab, basiliximab, everolimus, or FK506, which interfere with cytokine release or signaling; azathioprine or leflunomide, which inhibit nucleotide synthesis; or 15-deoxyspergualin, an inhibitor of leukocyte differentiation.</p><p id="p0005" num="0005">The beneficial effects of broad immunosuppressive therapies relate to their effects; however, the generalized immunosuppression which these drugs produce diminishes the immune system's defense against infection and malignancies. Furthermore, standard immunosuppressive drugs are often used at high dosages and can cause or accelerate organ damage.</p><heading id="h0003"><b><u>Description of the invention</u></b></heading><p id="p0006" num="0006">The present invention provides novel compounds of formula (I) that are agonists for the G protein-coupled receptor S1P1/EDG1 and have a powerful and long-lasting immunomodulating effect which is achieved by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion. The reduction of circulating T- / B-lymphocytes as a result of S1P1/EDG1 agonism, possibly in combination with the observed improvement of endothelial cell layer function associated with S1P1/EDG1 activation, makes such compounds useful to treat uncontrolled inflammatory disease and to improve vascular functionality.</p><p id="p0007" num="0007">The compounds of the present invention can be utilized alone or in combination with standard drugs inhibiting T-cell activation, to provide a new immunomodulating therapy with a reduced propensity for infections when compared to standard immunosuppressive therapy. Furthermore, the compounds of the present invention can be used in combination with reduced dosages of traditional immunosuppressant therapies, to provide on the one hand effective immunomodulating activity, while on the other hand reducing end organ damage associated with higher doses of standard immunosuppressive drugs. The observation of improved endothelial cell layer function associated with S1P1/EDG1 activation provides additional benefits of compounds to improve vascular function.</p><p id="p0008" num="0008">The nucleotide sequence and the amino acid sequence for the human S1P1/EDG1 receptor are known in the art and are published in e.g.:<nplcit id="ncit0001" npl-type="s"><text> Hla, T., and Maciag, T. J. Biol Chem. 265 (1990), 9308-9313</text></nplcit>; <patcit id="pcit0001" dnum="WO9115583A"><text>WO 91/15583 published 17 October 1991</text></patcit>; <patcit id="pcit0002" dnum="WO9946277A"><text>WO 99/46277 published 16 September 1999</text></patcit>. The potency and efficacy of the compounds of formula (I)<!-- EPO <DP n="3"> --> are assessed using a GTPγS assay to determine EC<sub>50</sub> values and by measuring the circulating lymphocytes in the rat after oral administration, respectively (see in Examples).
<ul><li>i) The invention relates to novel pyrimidine compounds of the formula (I)
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="74" he="50" img-content="chem" img-format="tif"/></chemistry>
wherein
<ul><li>A represents
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="134" he="21" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="135" he="22" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="111" he="22" img-content="chem" img-format="tif"/></chemistry></li></ul>
wherein the asterisks indicate the bond that is linked to the pyrimidine group of formula (I);
<ul><li><b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylamino, N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino, C<sub>3-5</sub>-cycloalkylamino, C<sub>3-5</sub>-cycloalkylmethylamino, pyrrolidine (such as pyrrolidin-1-yl), or piperidine;</li><li><b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl or C<sub>3-4</sub>-alkyl;<!-- EPO <DP n="4"> --></li><li><b>R<sup>3</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;</li><li><b>R<sup>4</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;</li><li><b>R<sup>5</sup></b> represents 2,3-dihydroxypropyl, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, 1-(3-carboxy-azetidinyl)-2-acetyl, 1-(2-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy (such as preferably (S)-2,3-dihydroxy-propoxy), 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(azetidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, -OCH<sub>2</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 3-[(azetidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, -OCH<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> (wherein the carbon atom to which the hydroxy group is attached is preferably in the S-configuration);</li><li><b>R<sup>51</sup></b> represents hydrogen, C<sub>1-3</sub>-alkyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxypropyl, carboxymethyl, (C<sub>1-5</sub>-alkylcarboxy)methyl, 2-carboxyethyl, 2-(C<sub>1-5</sub>-alkylcarboxy)ethyl, or 2-aminoethyl;</li><li><b>R<sup>52</sup></b> represents hydrogen, methyl, or ethyl;</li><li><b>R<sup>53</sup></b> represents C<sub>1-3</sub>-alkyl, methylamino, ethylamino, or dimethylamino;</li><li><b>R<sup>54</sup></b> represents hydroxy-C<sub>1-2</sub>-alkyl or R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyl;</li><li><b>R<sup>55</sup></b> and <b>R<sup>56</sup></b> independently represent hydrogen or methyl;</li><li>k represents the integer 1, 2, or 3;</li><li>m represents the integer 1 or 2;</li><li>n represents 0, 1, or 2; and<!-- EPO <DP n="5"> --></li><li><b>R<sup>6</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or halogen.
<br/>
The general terms used hereinbefore and hereinafter preferably have, within this disclosure, the following meanings, unless otherwise indicated:
<ul><li>The term <b>C<sub>x-y</sub>-alkyl</b>, x and y being an integer, means saturated, branched or straight chain alkyl groups with x to y carbon atoms. Likewise, the term <b>C<sub>1-4</sub>-alkyl</b> means saturated, branched or straight chain alkyl groups with one to four carbon atoms. Examples of C<sub>1-4</sub>-alkyl groups are methyl, ethyl, <i>n</i>-propyl, <i>iso</i>-propyl, <i>n</i>-butyl, and <i>iso</i>-butyl (preferably methyl, ethyl, <i>n</i>-propyl, <i>iso</i>-propyl, or <i>iso</i>-butyl). Likewise, the term <b>C<sub>1-3</sub>-alkyl</b> means saturated, branched or straight chain alkyl groups with one to three carbon atoms. Examples of C<sub>1-3</sub>-alkyl groups are methyl, ethyl, <i>n</i>-propyl, and <i>iso</i>-propyl (preferably methyl, or ethyl).</li><li>The term <b>C<sub>x-y</sub>-alkoxy</b> means a R-O group, wherein R is a C<sub>x-y</sub>-alkyl. Examples of C<sub>1-4</sub>-alkoxy groups are methoxy, ethoxy, n-propoxy, <i>iso</i>-propoxy, and <i>iso</i>-butoxy.</li><li>The term <b>C<sub>3-5</sub>-cycloalkyl</b> refers to a saturated cyclic hydrocarbon ring system with 3 to 5 carbon atoms, i.e. cyclopropyl, cyclobutyl, or cyclopentyl.</li><li>The term <b>halogen</b> means fluoro, chloro, bromo or iodo (preferably fluoro or chloro; especially preferred chloro).</li></ul>
</li></ul></li><li>ii) A further embodiment of the invention relates to pyrimidine derivatives according to embodiment i), wherein <b>A</b> represents
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="127" he="23" img-content="chem" img-format="tif"/></chemistry>
or
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="38" he="21" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisks indicate the bond that is linked to the pyrimidine group of formula (I).</li><li>iii) Another embodiment of the invention relates to pyrimidine derivatives according to embodiment i), wherein <b>A</b> represents<!-- EPO <DP n="6"> -->
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="130" he="22" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisks indicate the bond that is linked to the pyrimidine group of formula (I).</li><li>iv) Another embodiment of the invention relates to pyrimidine derivatives according to embodiment i), wherein <b>A</b> represents
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="46" he="21" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisk indicates the bond that is linked to the pyrimidine group of formula (I).</li><li>v) Another embodiment of the invention relates to pyrimidine derivatives according to embodiment i), wherein A represents
<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="40" he="20" img-content="chem" img-format="tif"/></chemistry></li><li>vi) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to v), wherein <b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkylamino or N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino.</li><li>vii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to v), wherein <b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkylamino.</li><li>viii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to vii), wherein <b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl.</li><li>ix) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to vii), wherein <b>R<sup>2</sup></b> represents methyl.</li><li>x) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to ix), wherein <b>R<sup>3</sup></b> represents hydrogen.<!-- EPO <DP n="7"> --></li><li>xi) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to ix), wherein <b>R<sup>3</sup></b> represents methoxy, and <b>R<sup>4</sup></b> and <b>R<sup>6</sup></b> represent hydrogen.</li><li>xii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to ix), wherein <b>R<sup>3</sup></b> represents hydrogen, <b>R<sup>4</sup></b> represents C<sub>1-3</sub>-alkyl or methoxy, and <b>R<sup>6</sup></b> represents C<sub>1-2</sub>-alkyl or chloro.</li><li>xiii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to ix), wherein <b>R<sup>3</sup></b> represents hydrogen, <b>R<sup>4</sup></b> represents methyl or ethyl, and <b>R<sup>6</sup></b> represents methyl.</li><li>xiv) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to ix), wherein <b>R<sup>3</sup></b> represents hydrogen, <b>R<sup>4</sup></b> represents methoxy or methyl, and <b>R<sup>6</sup></b> represents chloro.</li><li>xv) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xiv), wherein <b>R<sup>5</sup></b> represents 2,3-dihydroxypropyl, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>.</li><li>xvi) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xiv), wherein <b>R<sup>5</sup></b> represents 2,3-dihydroxypropyl, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>.</li><li>xvii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xiv), wherein <b>R<sup>5</sup></b> represents -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>.<!-- EPO <DP n="8"> --></li><li>xviii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xiv), wherein <b>R<sup>5</sup></b> represents hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>.</li><li>xix) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xiv), wherein <b>R<sup>5</sup></b> represents 2,3-dihydroxy-propoxy or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>.</li><li>xx) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xviii), wherein <b>R<sup>51</sup></b> represents 2-hydroxyethyl or 2-carboxyethyl.</li><li>xxi) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xviii), wherein <b>R<sup>52</sup></b> represents hydrogen.</li><li>xxii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xviii), wherein <b>R<sup>53</sup></b> represents methyl or methylamino.</li><li>xxiii) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xix), wherein <b>R<sup>54</sup></b> represents hydroxymethyl.</li><li>xxiv) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xvii), wherein n represents the integer 1.</li><li>xxv) Another embodiment of the invention relates to pyrimidine derivatives according to any one of the embodiments i) to xvi), wherein <b>k</b> represents the integer 1 or 2.</li><li>xxvi) A further embodiment of the invention relates to pyrimidine derivatives according to embodiment i), wherein
<ul><li><b>A</b> represents
<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="45" he="22" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisk indicates the bond that is linked to the pyrimidine group of formula (I);<!-- EPO <DP n="9"> -->
<ul><li><b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylamino, or N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino;</li><li><b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl;</li><li><b>R<sup>3</sup></b> represents hydrogen;</li><li><b>R<sup>4</sup></b> represents C<sub>1-2</sub>-alkyl;</li><li><b>R<sup>5</sup></b> represents 2,3-dihydroxy-propoxy or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>;</li><li><b>R<sup>54</sup></b> represents hydroxy-C<sub>1-2</sub>-alkyl; and</li><li><b>R<sup>6</sup></b> represents C<sub>1-3</sub>-alkyl.</li></ul></li></ul></li><li>xxvii) A further embodiment of the invention relates to pyrimidine derivatives according to embodiment xxvi), wherein <b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkylamino or N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino.</li><li>xxviii) A further embodiment of the invention relates to novel pyrimidine derivatives according to any one of embodiments i) to v) and viii) to xxvi), wherein <b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy.</li><li>xxix) A further embodiment of the invention relates to novel pyrimidine derivatives according to embodiment i), wherein <b>A</b> represents
<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="133" he="21" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="105" he="20" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisks indicate the bond that is linked to the pyrimidine group of formula (I);
<ul><li><b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylamino, N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino, C<sub>3-5</sub>-cycloalkylamino, C<sub>3-5</sub>-cycloalkylmethylamino, or pyrrolidine (such as pyrrolidin-1-yl);</li><li><b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl or C<sub>3-4</sub>-alkyl;</li><li><b>R<sup>3</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;<!-- EPO <DP n="10"> --></li><li><b>R<sup>4</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;</li><li><b>R<sup>5</sup></b> represents 2,3-dihydroxypropyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, 1-(3-carboxy-azetidinyl)-2-acetyl, 1-(2-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy (such as preferably (S)-2,3-dihydroxy-propoxy), 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(azetidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 3-[(azetidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> (wherein the carbon atom to which the hydroxy group is attached is preferably in the S-configuration);</li><li><b>R<sup>51</sup></b> represents hydrogen, C<sub>1-3</sub>-alkyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxypropyl, 2-carboxyethyl, 2-(C<sub>1-5</sub>-alkylcarboxy)ethyl, or 2-aminoethyl;</li><li><b>R<sup>52</sup></b> represents hydrogen;</li><li><b>R<sup>53</sup></b> represents C<sub>1-3</sub>-alkyl or dimethylamino;</li><li><b>R<sup>54</sup></b> represents hydroxy-C<sub>1-2</sub>-alkyl or R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyl;</li><li><b>R<sup>55</sup></b> and <b>R<sup>56</sup></b> both represent hydrogen;</li><li>k and m represent the integer 1;</li><li>n represents 0 or 1; and</li><li><b>R<sup>6</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or halogen.</li></ul></li><li>xxx) A further embodiment of the invention relates to novel pyrimidine derivatives according to embodiment i), wherein <b>A</b> represents<!-- EPO <DP n="11"> -->
<chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="38" he="20" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisk indicates the bond that is linked to the pyrimidine group of formula (I);
<ul><li><b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy;</li><li><b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl or C<sub>3-4</sub>-alkyl;</li><li><b>R<sup>3</sup></b> represents hydrogen;</li><li><b>R<sup>4</sup></b> represents C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;</li><li><b>R<sup>5</sup></b> represents -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>;</li><li><b>R<sup>51</sup></b> represents hydrogen, C<sub>1-3</sub>-alkyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxypropyl, carboxymethyl, (C<sub>1-5</sub>-alkylcarboxy)methyl, 2-carboxyethyl, 2-(C<sub>1-5</sub>-alkylcarboxy)ethyl, or 2-aminoethyl;</li><li><b>R<sup>52</sup></b> represents hydrogen, methyl, or ethyl;</li><li><b>R<sup>53</sup></b> represents C<sub>1-3</sub>-alkyl, methylamino, ethylamino, or dimethylamino;</li><li><b>R<sup>54</sup></b> represents hydroxy-C<sub>1-2</sub>-alkyl or R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyl;</li><li><b>R<sup>55</sup></b> and <b>R<sup>56</sup></b> independently represent hydrogen or methyl;</li><li>m represents the integer 1 or 2;</li><li>n represents 0, 1, or 2; and</li><li><b>R<sup>6</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or halogen.</li></ul></li></ul></p><p id="p0009" num="0009">The compounds of formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the Z- or E-configuration unless indicated otherwise. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.</p><p id="p0010" num="0010">Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.<!-- EPO <DP n="12"> --> Any reference hereinbefore or hereinafter to a compound of formula (I) is to be understood as referring also to salts, especially pharmaceutically acceptable salts, of a compound of formula (I), as appropriate and expedient.</p><p id="p0011" num="0011">Salts are preferably the pharmaceutically acceptable salts of the compounds of formula (I).</p><p id="p0012" num="0012">The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "<nplcit id="ncit0002" npl-type="s"><text>Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217</text></nplcit>.</p><p id="p0013" num="0013">Examples of preferred compounds are selected from the group consisting of:
<ul><li>N-(3-{2,6-dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;<!-- EPO <DP n="13"> --></li><li>3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol; and</li><li>3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol.</li></ul></p><p id="p0014" num="0014">Examples of preferred compounds are further selected from the group consisting of:
<ul><li>N-((S)-3-{2,6-dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-aceta mid e;</li><li>N-((R)-3-{2,6-dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;<!-- EPO <DP n="14"> --></li><li>N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-aceta mide;</li><li>N-((S)-3-{4-[5-(2-dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((R)-3-{4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>(S)-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(R)-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol;</li><li>(R)-3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(R)-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(R)-3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2.6-dimethyl-phenoxy}-propane-1,2-diol;<!-- EPO <DP n="15"> --></li><li>(R)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol; and</li><li>(R)-3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol.</li></ul></p><p id="p0015" num="0015">Further Examples of preferred compounds are selected from the group consisting of:
<ul><li>N-(3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-[3-(2-ethyl-4-{5-[2-(isobutyl-methyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-[3-(4-{5-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-2-ethyl-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide;</li><li>N-(3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{2-ethyl-6-methyl-4-[5-(2-methylamino-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{2-ethyl-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{2-ethyl-4-[5-(2-isobutoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{4-[5-(2-ethoxy-6-ethyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-aceta mid e;</li><li>N-(3-{2-ethyl-4-[5-(2-methoxy-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-(3-{2-chloro-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>2-hydroxy-N-(2-hydroxy-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propyl)-acetamide;<!-- EPO <DP n="16"> --></li><li>N-(3-{2-chloro-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{2-ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(2-cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{2-ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>3-{2-chloro-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propane-1,2-diol;</li><li>3-{2-chloro-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>N-((S)-3-{2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>3-(3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionic acid; and</li><li>3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-N-(2-hydroxy-ethyl)-propionamide.</li></ul></p><p id="p0016" num="0016">Further Examples of preferred compounds are further selected from the group consisting of:
<ul><li>N-((S)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;<!-- EPO <DP n="17"> --></li><li>N-[(S)-3-(2-ethy)-4-{5-[2-(isobuty)-methyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazo)-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-[(S)-3-(4-{5-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-2-ethyl-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-6-methyl-4-[5-(2-methylamino-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-isobutoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{4-[5-(2-ethoxy-6-ethyl-pyrimidin-4-y)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(2-methoxy-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>N-((S)-3-{2-chloro-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>2-hydroxy-N-((S)-2-hydroxy-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propyl)-acetamide;</li><li>N-((S)-3-{2-chloro-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>(S)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{2-ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(2-cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;<!-- EPO <DP n="18"> --></li><li>(R)-3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(R)-3-{4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{2-chloro-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propane-1,2-diol;</li><li>(S)-3-{2-chloro-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</li><li>N-((S)-3-{2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</li><li>3-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionic acid; and</li><li>3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-N-(2-hydroxy-ethyl)-propionamide.</li></ul></p><p id="p0017" num="0017">The compounds of formula (I) and their pharmaceutically acceptable salts, can be used as a medicament, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration, and are suitable for decreasing the number of circulating lymphocytes and for the prevention and/or treatment of diseases or disorders associated with an activated immune system.</p><p id="p0018" num="0018">The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example <nplcit id="ncit0003" npl-type="b"><text>Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams &amp; Wilkins</text></nplcit>]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.<!-- EPO <DP n="19"> --></p><p id="p0019" num="0019">Diseases or disorders associated with an activated immune system which can be treated and/or prevented with the compounds of formula (I) include rejection of transplanted organs, tissue or cells; graft-versus-host diseases brought about by transplantation; autoimmune syndromes including rheumatoid arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Hashimoto's thyroiditis; lymphocytic thyroiditis; multiple sclerosis; myasthenia gravis; type I diabetes; uveitis; episcleritis; scleritis; Kawasaki's disease, uveo-retinitis; posterior uveitis; uveitis associated with Behcet's disease; uveomeningitis syndrome; allergic encephalomyelitis; chronic allograft vasculopathy; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; inflammatory and hyperproliferative skin diseases; psoriasis; psoriatic arthritis; atopic dermatitis; myopathy; myositis; osteomyelitis; contact dermatitis; eczematous dermatitis; seborrhoeic dermatitis; lichen planus; pemphigus; bullous pemphigoid; epidermolysis bullosa; urticaria; angioedema; vasculitis; erythema; cutaneous eosinophilia; acne; scleroderma; alopecia areata; keratoconjunctivitis; vernal conjunctivitis; keratitis; herpetic keratitis; dystrophia epithelialis corneae; corneal leukoma; ocular pemphigus; Mooren's ulcer; ulcerative keratitis; scleritis; Graves' ophthalmopathy; Vogt-Koyanagi-Harada syndrome; sarcoidosis; pollen allergies; reversible obstructive airway disease; bronchial asthma; allergic asthma; intrinsic asthma; extrinsic asthma; dust asthma; chronic or inveterate asthma; late asthma and airway hyper-responsiveness; bronchiolitis; bronchitis; endometriosis; orchitis; gastric ulcers; ischemic bowel diseases; inflammatory bowel diseases; necrotizing enterocolitis; intestinal lesions associated with thermal burns; coeliac disease; proctitis; eosinophilic gastroenteritis; mastocytosis; Crohn's disease; ulcerative colitis; vascular damage caused by ischemic diseases and thrombosis; atherosclerosis; fatty heart; myocarditis; cardiac infarction; aortitis syndrome; cachexia due to viral disease; vascular thrombosis; migraine; rhinitis; eczema; interstitial nephritis; IgA-induced nephropathy; Goodpasture's syndrome; hemolytic-uremic syndrome; diabetic nephropathy; glomerulosclerosis; glomerulonephritis; tubulointerstitial nephritis; interstitial cystitis; multiple myositis; Guillain-Barré syndrome; Meniere's disease; polyneuritis; multiple neuritis; myelitis; mononeuritis; radiculopathy; hyperthyroidism; Basedow's disease; thyrotoxicosis; pure red cell aplasia; aplastic anemia; hypoplastic anemia; idiopathic thrombocytopenic purpura; autoimmune hemolytic anemia; autoimmune thrombocytopenia; agranulocytosis; pernicious anemia; megaloblastic anemia; anerythroplasia; osteoporosis; fibroid lung; idiopathic interstitial pneumonia; dermatomyositis; leukoderma vulgaris; ichthyosis vulgaris; photoallergic sensitivity; cutaneous T cell lymphoma; polyarteritis nodosa; Huntington's chorea; Sydenham's chorea; myocardosis; myocarditis; scleroderma; Wegener's granuloma; Sjogren's syndrome; adiposis; eosinophilic fascitis; lesions of<!-- EPO <DP n="20"> --> gingiva, periodontium, alveolar bone, substantia ossea dentis; male pattern alopecia or alopecia senilis; muscular dystrophy; pyoderma; Sezary's syndrome; hypophysitis; chronic adrenal insufficiency; Addison's disease; ischemia-reperfusion injury of organs which occurs upon preservation; endotoxin shock; pseudomembranous colitis; colitis caused by drug or radiation; ischemic acute renal insufficiency; chronic renal insufficiency; lung cancer; malignancy of lymphoid origin; acute or chronic lymphocytic leukemias; lymphoma; pulmonary emphysema; cataracta; siderosis; retinitis pigmentosa; senile macular degeneration; vitreal scarring; corneal alkali burn; dermatitis erythema; ballous dermatitis; cement dermatitis; gingivitis; periodontitis; sepsis; pancreatitis; peripheral artery disease; carcinogenesis; solid cancer tumors; metastasis of carcinoma; hypobaropathy; autoimmune hepatitis; primary biliary cirrhosis; sclerosing cholangitis; partial liver resection; acute liver necrosis; cirrhosis; alcoholic cirrhosis; hepatic failure; fulminant hepatic failure; late-onset hepatic failure; and "acute-on-chronic" liver failure.</p><p id="p0020" num="0020">Preferred diseases or disorders to be treated and/or prevented with the compounds of formula (I) are selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumor metastasis.</p><p id="p0021" num="0021">Particularly preferred diseases or disorders to be treated and/or prevented with the compounds of formula (I) are selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis. Very preferably the diseases or disorders to be treated and/or prevented with the compounds of formula (I) are selected from multiple sclerosis and psoriasis.</p><p id="p0022" num="0022">The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I).<!-- EPO <DP n="21"> --></p><p id="p0023" num="0023">Furthermore, compounds of the formula (I) are also useful in combination with one or several immunomodulating agents for the prevention and/or treatment of the diseases and disorders mentioned herein. According to a preferred embodiment of the invention, said agents are selected from the group consisting of immunosuppressants, corticosteroids, NSAID's, cytotoxic drugs, adhesion molecule inhibitors, cytokines, cytokine inhibitors, cytokine receptor antagonists and recombinant cytokine receptors.</p><p id="p0024" num="0024">The present invention also relates to the use of a compound of formula (I) for the preparation of a pharmaceutical composition, optionally for use in combination with one or several immunomodulating agents, for the prevention or treatment of the diseases and disorders mentioned herein.</p><p id="p0025" num="0025">The compounds of formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.</p><p id="p0026" num="0026">Compounds of the formula (I) of the present invention can be prepared according to the general sequence of reactions outlined below. Only a few of the synthetic possibilities leading to compounds of formula (I) are described.
<chemistry id="chem0014" num="0014"><img id="ib0014" file="imgb0014.tif" wi="91" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0027" num="0027">Compounds of formula (I) which represent a 5-pyrimidin-4-yl-[1,2,4]oxadiazole derivative, are prepared by reacting a compound of Structure 1 in a solvent such as dioxane, THF, dimethoxyethane, xylene, toluene, benzene, pyridine, DMF, dichloromethane, acetic acid, trifluoroacetic acid, etc. at rt or elevated temperatures in the presence or absence of auxiliaries such as acids (e.g. TFA, acetic acid, HCl, etc.), bases (e.g. NaH, NaOAc, Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, triethylamine, etc.), tetraalkylammonium salts, or water removing agents<!-- EPO <DP n="22"> --> (e.g. oxalyl chloride, a carboxylic acid anhydride, POCl<sub>3</sub>, PCl<sub>5</sub>, P<sub>4</sub>O<sub>10</sub>, molecular sieves, methoxycarbonylsulfamoyl triethylammonium hydroxide (Burgess reagent), etc.) (Lit.: e.g. <nplcit id="ncit0004" npl-type="s"><text>A. R. Gangloff, J. Litvak, E. J. Shelton, D. Sperandio, V. R. Wang, K. D. Rice, Tetrahedron Lett. 42 (2001), 1441-1443</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>T. Suzuki, K. Iwaoka, N. Imanishi, Y. Nagakura, K. Miyta, H. Nakahara, M. Ohta, T. Mase, Chem. Pharm. Bull. 47 (1999), 120-122</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>R. F. Poulain, A. L. Tartar, B. P. Déprez, Tetrahedron Lett. 42 (2001), 1495-1498</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>R. M. Srivastava, F. J. S. Oliveira, D. S. Machado, R. M. Souto-Maior, Synthetic Commun. 29 (1999), 1437-1450</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>E. O. John, J. M. Shreeve, Inorganic Chemistry 27 (1988), 3100-3104</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>B. Kaboudin, K. Navaee, Heterocycles 60 (2003), 2287-2292</text></nplcit>).
<chemistry id="chem0015" num="0015"><img id="ib0015" file="imgb0015.tif" wi="100" he="48" img-content="chem" img-format="tif"/></chemistry></p><p id="p0028" num="0028">Compounds of Structure 1 may be prepared by reacting a compound of Structure 2 with a compound of Structure 3 in a solvent such as DMF, THF, DCM, etc. in the presence or absence of one or more coupling agents such as TBTU, DCC, EDC, HBTU, HOBt, CDI, PyBOP, etc. and in the presence or absence of a base such as triethylamine, DIPEA, NaH, K<sub>2</sub>CO<sub>3</sub>, etc. (Lit.: e.g. <nplcit id="ncit0010" npl-type="s"><text>A. Hamze, J.-F. Hernandez, P. Fulcrand, J. Martinez, J. Org. Chem. 68 (2003) 7316-7321</text></nplcit>; and the literature cited above).
<chemistry id="chem0016" num="0016"><img id="ib0016" file="imgb0016.tif" wi="100" he="48" img-content="chem" img-format="tif"/></chemistry></p><p id="p0029" num="0029">Compounds of formula (I) which represent a 3-pyrimidin-4-yl-[1,2,4]oxadiazole derivative are prepared in an analogous fashion (Lit.: e.g. <nplcit id="ncit0011" npl-type="s"><text>C. T. Brain, J. M. Paul, Y. Loong, P. J. Oakley, Tetrahedron Lett. 40 (1999) 3275-3278</text></nplcit>) by reacting a compound of Structure 4 with a compound of Structure 5 and subsequent cyclisation of the corresponding<!-- EPO <DP n="23"> --> hydroxyamidine ester intermediate. Compounds of Structure 5 are either commercially available or are prepared according to procedures described herein or according to procedures known to a person skilled in the art.
<chemistry id="chem0017" num="0017"><img id="ib0017" file="imgb0017.tif" wi="97" he="46" img-content="chem" img-format="tif"/></chemistry></p><p id="p0030" num="0030">Compounds of Structure 3 and 4 may be prepared by reacting a compound of Structure 6 and 7, respectively, with hydroxylamine or one of its salts in a solvent such as methanol, ethanol, pyridine, etc. in the presence or absence of a base such as Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, triethylamine, KOtBu, etc. (Lit.: e.g. <nplcit id="ncit0012" npl-type="s"><text>T. Suzuki, K. Iwaoka, N. Imanishi, Y. Nagakura, K. Miyta, H. Nakahara, M. Ohta, T. Mase, Chem. Pharm. Bull. 47 (1999), 120-122</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>J. Cui, D. Crich, D. Wink, M. Lam, A. L. Rheingold, D. A. Case, W. T. Fu, Y. Zhou, M. Rao, A. J. Olson, M. E. Johnson, Bioorg. Med. Chem. 11 (2003), 3379-3392</text></nplcit>; <patcit id="pcit0003" dnum="WO2004035538A"><text>R. Miller, F. Lang, Z. J. Song, D. Zewge, WO 2004/035538</text></patcit> (Merck &amp; Co., Inc., USA); <nplcit id="ncit0014" npl-type="s"><text>B. Kaboudin, K. Navaee, Heterocycles 60 (2003), 2287-2292</text></nplcit>). Compounds of Structure 6 are either commercially available or are prepared according to procedures described herein or according to procedures known to a person skilled in the art.</p><p id="p0031" num="0031">Methods that effect the transformation of a compound of Structure 2 into a compound of Structure 7, or the opposite, are known to a person skilled in the art.
<chemistry id="chem0018" num="0018"><img id="ib0018" file="imgb0018.tif" wi="140" he="46" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="24"> --></p><p id="p0032" num="0032">Compounds of formula (I) which represent a 2-pyrimidin-4-yl-[1,3,4]oxadiazole or a 2-pyrimidin-4-yl-[1,3,4]thiadiazole derivative are prepared similarly by reacting a compound of Structure 2 with hydrazine (by using a coupling reagent such as TBTU, DCC, EDC, HBTU, PyBOP, HOBt, CDI, etc.) to form a compound of Structure 8 which is then coupled with a compound of Structure 5 to give a compound of Structure 9. A compound of Structure 9 can also be prepared by following the reverse reaction order, i.e. by first coupling a compound of Stucture 5 with hydrazine followed by reacting the corresponding hydrazide intermediate with a compound of Structure 2. Dehydration of a compound of Structure 9 to form the desired 2-pyrimidin-4-yl-[1,3,4]oxadiazole derivative is affected by treating a compound of Structure 9 with a reagent such as POCl<sub>3</sub>, CCl<sub>4</sub> or CBr<sub>4</sub> in combination with triphenylphosphine, P<sub>2</sub>O<sub>5</sub>, Burgess reagent, etc. in a solvent such as toluene, acetonitrile, dioxane, THF, CHCl<sub>3</sub>, etc. at temperatures between 20 and 120°C in the presence or absence of microwave irradiation. (Lit.: e.g. <nplcit id="ncit0015" npl-type="s"><text>M. A. Garcia, S. Martin-Santamaria, M. Cacho, F. Moreno de la Llave, M. Julian, A. Martinez, B. De Pascual-Teresa, A. Ramos, J. Med. Chem. 48 (2005) 4068-4075</text></nplcit>; <nplcit id="ncit0016" npl-type="s"><text>C. T. Brain, J. M. Paul, Y. Loong, P. J. Oakley, Tetrahedron Lett. 40 (1999) 3275-3278</text></nplcit>). Likewise, 2-pyrimidin-4-yl-[1,3,4]thiadiazole derivatives are obtained by cyclising a compound of Structure 9 with Lawesson's reagent optionally in combination with P<sub>2</sub>S<sub>5</sub> in the presence or absence of a solvent such as pyridine, toluene, THF, acetonitrile, etc. at elevated temperatures with or without microwave irradiation (Lit.: e.g. <nplcit id="ncit0017" npl-type="s"><text>A. A. Kiryanov, P. Sampson, A. J. Seed, J. Org. Chem. 66 (2001) 7925-7929</text></nplcit>).
<chemistry id="chem0019" num="0019"><img id="ib0019" file="imgb0019.tif" wi="92" he="48" img-content="chem" img-format="tif"/></chemistry></p><p id="p0033" num="0033">Compounds of formula (I) which represent a 5-pyrimidin-4-yl-oxazole or a 5-pyrimidin-4-yl-thiazole derivative are prepared by treating a compound of Structure 10 either with POCl<sub>3</sub>, PCl<sub>5</sub>, I<sub>2</sub> in combination with triphenylphosphine and triethylamine, trifluoroacetic anhydride, Burgess reagent, etc. in a solvent such as toluene, benzene, dioxane, THF, etc. at temperatures between 20 and 120°C, or with Lawesson's reagent, optionally in combination with P<sub>2</sub>S<sub>5</sub>, in the presence or absence of a solvent such as pyridine, toluene,<!-- EPO <DP n="25"> --> THF, acetonitrile, etc. at elevated temperatures with or without microwave irradiation as mentioned above (Lit.: e.g. <nplcit id="ncit0018" npl-type="s"><text>N. Sato, T. Shibata, M. Jitsuoka, T. Ohno, T. Takahashi, T. Hirohashi, T. Kanno, H. Iwaasa, A. Kanatani, T. Fukami, Takehiro, Bioorg. &amp; Med. Chem. Lett. 14 (2004) 1761-1764</text></nplcit>). The compounds of Structure 10 are prepared by reacting a compound of Structure 11 with a compound of Structure 5. The aminoketone of Structure 11 can be prepared from a compound of Structure 2 by procedures given in the literature (e.g. <nplcit id="ncit0019" npl-type="s"><text>J. L. LaMattina, J. Heterocyclic Chem. 20 (1983) 533-538</text></nplcit>; <nplcit id="ncit0020" npl-type="s"><text>M. Pesson, M. Antoine, P. Girard, J. L. Benichon, S. Chabassier, P. De Lajudie, S. Patte, F. Roquet, G. Montay, Eur. J. Med. Chem. 15 (1980) 263-268</text></nplcit>). Compounds of formula (I) which represent a 2-pyrimidin-4-yl-oxazole or a 2-pyrimidin-4-yl-thiazole derivative are prepared in an analogous fashion from a compound of Structure 12 and a compound of Structure 2. The compounds of Structure 12 are prepared in analogy to literature procedures (e.g. <nplcit id="ncit0021" npl-type="s"><text>W. A. Loughlin, L. C. Henderson, K. E. Elson, M. E. Murphy, Synthesis 2006, 1975-1980</text></nplcit>; <nplcit id="ncit0022" npl-type="s"><text>L. Widler, J. Green, M. Missbach, M. Susa, E. Altmann, Bioorganic &amp; Medicinal Chemistry Letters 11 (2001) 849-852</text></nplcit>; <nplcit id="ncit0023" npl-type="s"><text>J. M. Holub et al., Molecules 9 (2004) 135-157</text></nplcit>).
<chemistry id="chem0020" num="0020"><img id="ib0020" file="imgb0020.tif" wi="110" he="46" img-content="chem" img-format="tif"/></chemistry></p><p id="p0034" num="0034">Depending on the nature of the functionalities present in the residues <b>R<sup>3</sup></b> to <b>R<sup>6</sup></b> in Structures 1, 3, 5, 6, 9, 10, and 12, these functionalities may require temporary protection. Appropriate protecting groups are known to a person skilled in the art and include e.g. a benzyl or a trialkylsilyl group to protect an alcohol, a ketal to protect a diol, etc. These protecting groups may be employed according to standard methodology (e.g. <nplcit id="ncit0024" npl-type="b"><text>T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Edition, Wiley New York, 1999</text></nplcit>; <nplcit id="ncit0025" npl-type="b"><text>P. J. Kocienski, Protecting Groups, Thieme Stuttgart, 1994</text></nplcit>). Alternatively, the desired residues <b>R<sup>3</sup></b> to <b>R<sup>6</sup></b>, in particular <b>R<sup>5</sup></b>, may also be introduced in later steps that follow the A-ring formation between the pyrimidine and the phenyl rings according to procedures described herein or according to procedures known to a person skilled in the art.<!-- EPO <DP n="26"> --></p><p id="p0035" num="0035">Alternatively, the bonds between the pyrimidine or the phenyl ring and the central 5-membered heteroaromatic ring can also be formed by applying palladium catalysed cross coupling reactions.
<chemistry id="chem0021" num="0021"><img id="ib0021" file="imgb0021.tif" wi="93" he="46" img-content="chem" img-format="tif"/></chemistry></p><p id="p0036" num="0036">Compounds of Structure 2 may be prepared by reacting a 2,4-dioxo-alkanoic ester (Structure 13, wherein R<sup>2</sup> represents preferably a methyl or an ethyl) with urea in acidic medium in the presence or absence of an additional solvent such as methanol, ethanol, dioxane, etc., preferably at temperatures above 50°C to give a compound of Structure 14. The compounds of Structure 14 can then be reacted with POCl<sub>3</sub> (Lit.: e.g.<nplcit id="ncit0026" npl-type="s"><text> Palanki, M. S. S., Erdman, P. E., Gayo-Fung, L. M., Shelvin, G. I., Sullivan, R. W., Suto, M. J., Goldman, M. E., Ransone, L. J., Bennett, B. L., Manning, A. M., J. Med. Chem. 43 (2000) 3995-4004</text></nplcit>) to give a compound of Structure 15, which can be hydrolysed to a compound of Structure 16. The compounds of Structure 16 can be reacted with the appropriate amine or alcohol in combination with a base such as Hünig's base, in the presence or absence of an additional solvent such as THF, dioxane etc., preferably at temperatures above 50°C to give a compound of Structure 2.</p><p id="p0037" num="0037">Compounds of Structure 13 are either commercially available or are prepared according to procedures known to a person skilled in the art.
<chemistry id="chem0022" num="0022"><img id="ib0022" file="imgb0022.tif" wi="99" he="47" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="27"> --></p><p id="p0038" num="0038">Alternatively, the compounds of Structure 2 may also be prepared by reacting a compound of Structure 17 with an alkenyl boron derivative (e.g. 2,4,6-trivinyl-cyclotriboroxane) under Suzuki conditions (Lit.: e.g.<nplcit id="ncit0027" npl-type="s"><text> F. Kerins, D. F. O'Shea, J. Org. Chem. 67 (2002) 4968-4971</text></nplcit>). The obtained 2-chloro-6-alkenyl-pyrimidine carboxylate derivative is reacted with the appropriate amine or alcohol, then hydrogenated and finally hydrolyzed to the corresponding compound of Structure 2.
<chemistry id="chem0023" num="0023"><img id="ib0023" file="imgb0023.tif" wi="41" he="45" img-content="chem" img-format="tif"/></chemistry></p><p id="p0039" num="0039">Compounds of Structure 17 are either commercially available or may be prepared by reacting the methyl ester of orotic acid with POCl<sub>3</sub> (Lit.: e.g. <nplcit id="ncit0028" npl-type="s"><text>S. Miltschitzky, V. Michlova, S. Stadbauer, B. Koenig, Heterocycles 67 (2006) 135-160</text></nplcit>).</p><p id="p0040" num="0040">In case R<sup>1</sup> represents a monoalkylamino group, the corresponding monoalkylaminopyrimidine derivatives that may occur in the course of the synthesis of compounds of formula (I), may require temporary protection at the secondary amine function.
<chemistry id="chem0024" num="0024"><img id="ib0024" file="imgb0024.tif" wi="74" he="48" img-content="chem" img-format="tif"/></chemistry></p><p id="p0041" num="0041">The above described reaction sequences that allow the introduction of the two residues R<sup>1</sup> and R<sup>2</sup> may also be applied to a compound in which the scaffold has already been further elaborated. For instance, the desired residue R<sup>1</sup> may also be introduced in a later step from a compound of Structure 18 which can be synthesised by methods analogous to those<!-- EPO <DP n="28"> --> described herein, e.g. by the coupling-cyclisation sequence of the pyrimidine compounds of Structure 16 with the phenyl compounds of Structure 3.</p><p id="p0042" num="0042">Alternatively, the compounds of Structure 2 may also be prepared by reacting a compound of Structure 13 with S-methylisothiourea sulphate in the presence or absence of an additional solvent such as methanol, ethanol, dioxane, etc., preferably at temperatures above 50°C to give a compound of Structure 19. The compounds of Structure 19 can then be hydrolysed under basic conditions to the corresponding carboxylic acid derivatives which are reacted with oxidative agent such as mCPBA to give the compounds of Structure 20 (Lit.: e.g.<nplcit id="ncit0029" npl-type="s"><text> Z. Budesinsky, F. Roubinek, Collection Czechoslov. Chem. Commun. 26 (1961), 2871-2885</text></nplcit>). The compounds of Structure 20 can be reacted with the appropriate amine or alcohol in combination with a base such as Hünig's base or NaOH, in the presence or absence of an additional solvent such as THF, dioxane etc., preferably at temperatures above 50°C to give a compound of Structure 2. Compounds of Structure 2 with R<sup>1</sup> = C<sub>1-4</sub> alkoxy can also be accessible by reacting compounds of Structure 19 with mCPBA followed by nucleophilic displacement with the appropriate alkoholate.
<chemistry id="chem0025" num="0025"><img id="ib0025" file="imgb0025.tif" wi="98" he="53" img-content="chem" img-format="tif"/></chemistry></p><heading id="h0004"><b><u>Examples</u></b></heading><p id="p0043" num="0043">The following examples illustrate the invention but do not at all limit the scope thereof.</p><p id="p0044" num="0044">All temperatures are stated in °C. Compounds are characterized by <sup>1</sup>H-NMR (400 MHz) or <sup>13</sup>C-NMR (100 MHz) (Bruker; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quadruplet, quint = quintuplet, hex = hexet, hept = heptet, m = multiplet, br = broad, coupling constants are given in Hz); by LC-MS (Finnigan Navigator with HP 1100 Binary Pump and DAD, column: 4.6x50 mm, Zorbax SB-AQ, 5 µm, 120 A, gradient: 5-95% acetonitrile in water, 1 min, with 0.04% trifluoroacetic acid, flow: 4.5 mL/min), t<sub>R</sub> is given in min; retention times or LC-MS marked with * refer to<!-- EPO <DP n="29"> --> an LC run under basic conditions, i.e. eluting with a gradient of MeCN in water containing 13 mM of ammonium hydroxide, otherwise identical conditions; by TLC (TLC-plates from Merck, Silica gel 60 F<sub>254</sub>); or by melting point. Compounds are purified by preparative HPLC (column: X-Bridge PrepC18, 30x75 mm, 5 µm; gradient: 10-95% acetonitrile in water containing 0.5 % of formic acid) or by MPLC (Labomatic MD-80-100 pump, Linear UVIS-201 detector, column: 350x18 mm, Labogel-RP-18-5s-100, gradient: 10% methanol in water to 100% methanol). Racemates can be separated into their enantiomers by preparative HPLC (column: ChiraIPaK AD 20x250 mm, 5 µm, 15% ethanol in hexane).</p><heading id="h0005"><u>Abbreviations</u> (as used herein):</heading><p id="p0045" num="0045"><dl id="dl0001" compact="compact"><dt>AcOH</dt><dd>acetic acid</dd><dt>aq.</dt><dd>aqueous</dd><dt>Boc</dt><dd><i>tert</i>-butoxycarbonyl</dd><dt>BSA</dt><dd>bovine serum albumin</dd><dt>CC</dt><dd>column chromatography</dd><dt>CDI</dt><dd>carbonyl diimidazole</dd><dt>DCC</dt><dd>dicyclohexyl carbodiimide</dd><dt>DCM</dt><dd>dichloromethane</dd><dt>DEAD</dt><dd>diethyl azodicarboxylate</dd><dt>DIPEA</dt><dd>diisopropyl-ethylamine, Hünig's base, ethyl-diisopropylamine</dd><dt>DMF</dt><dd>dimethylformamide</dd><dt>DMSO</dt><dd>dimethylsulfoxide</dd><dt>EA</dt><dd>ethyl acetate</dd><dt>EDC</dt><dd>N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide</dd><dt>eq.</dt><dd>equivalent(s)</dd><dt>Et</dt><dd>ethyl</dd><dt>EtOAc</dt><dd>ethyl acetate</dd><dt>Ex.</dt><dd>Example(s)</dd><dt>h</dt><dd>hour(s)</dd><dt>HBTU</dt><dd>O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate</dd><dt>HOBt</dt><dd>1-hydroxybenzotriazole</dd><dt>HPLC</dt><dd>high performance liquid chromatography</dd><dt>iBu</dt><dd>isobutyl</dd><dt>iPr</dt><dd>isopropyl</dd><dt>KOtBu</dt><dd>potassium tert-butoxide<!-- EPO <DP n="30"> --></dd><dt>LC-MS</dt><dd>liquid chromatography - mass spectrometry</dd><dt>Lit.</dt><dd>Literature</dd><dt>mCPBA</dt><dd>meta-chloroperbenzoic acid</dd><dt>Me</dt><dd>methyl</dd><dt>MeOH</dt><dd>methanol</dd><dt>min</dt><dd>minute(s)</dd><dt>MPLC</dt><dd>medium pressure liquid chromatography</dd><dt>NaOAc</dt><dd>sodium acetate</dd><dt>nPr</dt><dd>n-propyl</dd><dt>org.</dt><dd>organic</dd><dt>Ph</dt><dd>phenyl</dd><dt>prep.</dt><dd>preparative</dd><dt>PyBOP</dt><dd>benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium-hexafluoro-phosphate</dd><dt>rt</dt><dd>room temperature</dd><dt>sat.</dt><dd>saturated</dd><dt>S1P</dt><dd>sphingosine 1-phosphate</dd><dt>TBTU</dt><dd>2-(1H-benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate</dd><dt>TFA</dt><dd>trifluoroacetic acid</dd><dt>TFFA</dt><dd>trifluoroacetic anhydride</dd><dt>THF</dt><dd>tetrahydrofuran</dd><dt>TLC</dt><dd>thin layer chromatography</dd><dt>t<sub>R</sub></dt><dd>retention time</dd></dl></p><heading id="h0006"><b>6-Methyl-2-propylamino-pyrimidine-4-carboxylic acid</b></heading><p id="p0046" num="0046"><ul><li>a) To a solution of commercially available methyl-2-chloro-6-methylpyrimidine-4-carboxylate (6.00 g, 32.15 mmol) in acetonitrile (500 mL), 1 M aq. solution of NaOH (48.2 mL) is added at 0°C. The mixture is stirred at 0°C for 1 h then acidified with 25% aq. HCl (7 mL). Volatiles are evaporated and the aq. solution is extracted with ethylacetate, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give 2-chloro-6-methylpyrimidine-4-carboxylic acid (4.22 g) as a yellow crystalline solid; LC-MS: t<sub>R</sub> = 0.42 min, [M+H]<sup>+</sup> = 172.96; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 2.58 (s, 3 H), 7.95 (s, 1 H), 14.1 (s br, 1 H).<!-- EPO <DP n="31"> --></li><li>b) A solution of 2-chloro-6-methylpyrimidine-4-carboxylic acid (100 mg, 0.58 mmol) and propylamine (0.48 mL) in dioxane (1 mL) is stirred at 70°C for 18 h. The reaction mixture is concentrated and purified by prep. HPLC (X-Bridge) to give 6-methyl-2-propylaminopyrimidine-4-carboxylic acid (81 mg) as a yellow crystalline solid; LC-MS: t<sub>R</sub> = 0.56 min, [M+H]<sup>+</sup> = 196.08; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 0.89 (t, J = 7.3Hz, 3 H), 1.53 (m, 2 H), 2.32 (s, 3 H), 3.25 (m, 2 H), 6.92 (s, 1 H), 7.36 (s br, 1 H), 13.2 (s br, 1 H).</li></ul></p><heading id="h0007"><b>6-Methyl-2-methylamino-pyrimidine-4-carboxylic acid</b></heading><p id="p0047" num="0047">The title compound is obtained as a yellow solid (230 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and 41% methylamine in water; LC-MS: t<sub>R</sub> = 0.32 min, [M+H]<sup>+</sup> = 168.04.</p><heading id="h0008"><b>2-Ethylamino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0048" num="0048">The title compound is obtained as a yellow solid (233 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and 2M ethylamine in THF; LC-MS: t<sub>R</sub> = 0.47 min, [M+H]<sup>+</sup> = 182.05.</p><heading id="h0009"><b>2-Isopropylamino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0049" num="0049">The title compound is obtained as a yellow solid (244 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and isopropylamine; LC-MS: t<sub>R</sub> = 0.55 min, [M+H]<sup>+</sup> = 196.05.</p><heading id="h0010"><b>2-Isobutylamino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0050" num="0050">The title compound is obtained as a yellow solid (271 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and isobutylamine; LC-MS: t<sub>R</sub> = 0.64 min, [M+H]<sup>+</sup> = 210.08.</p><heading id="h0011"><b>2-Dimethylamino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0051" num="0051">The title compound is obtained as a yellow solid (238 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and 2M dimethylamine in THF; LC-MS: t<sub>R</sub> = 0.44 min, [M+H]<sup>+</sup> = 182.08.<!-- EPO <DP n="32"> --></p><heading id="h0012"><b>2-Diethylamino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0052" num="0052">The title compound is obtained as a yellow solid (192 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and diethylamine; LC-MS: t<sub>R</sub> = 0.64 min, [M+H]<sup>+</sup> = 210.07.</p><heading id="h0013"><b>2-(Ethyl-methyl)amino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0053" num="0053">The title compound is obtained as a yellow solid (235 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and N-ethylmethylamine; LC-MS: t<sub>R</sub> = 0.54 min, [M+H]<sup>+</sup> = 196.08.</p><heading id="h0014"><b>2-N-isobutyl-N-methyl-amino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0054" num="0054">The title compound is obtained as a yellow solid (235 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (300 mg, 1.74 mmol) and N-isobutylmethylamine; LC-MS: t<sub>R</sub> = 0.80 min, [M+H]<sup>+</sup> = 224.21.</p><heading id="h0015"><b>6-Methyl-2-pyrrolidin-1-yl-pyrimidine-4-carboxylic acid</b></heading><p id="p0055" num="0055">The title compound is obtained as a yellow solid (200 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (200 mg, 1.16 mmol) and pyrrolidine; LC-MS: t<sub>R</sub> = 0.50 min, [M+H]<sup>+</sup> = 208.00.</p><heading id="h0016"><b>2-Cyclopropylamino-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0056" num="0056">The title compound is obtained as a yellow solid (336 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (500 mg, 2.90 mmol) and cyclopropylamine; LC-MS: t<sub>R</sub> = 0.44 min, [M+H]<sup>+</sup> = 193.98. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO) δ 0.47 (m, 2 H), 0.66 (m, 2 H), 2.35 (s, 3 H), 2.79 (m, 1 H), 6.99 (s, 1 H), 7.55 (s br, 1 H).</p><heading id="h0017"><b>2-(Cyclopropylmethyl-amino)-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0057" num="0057">The title compound is obtained as a yellow oil (230 mg) in analogy to 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic<!-- EPO <DP n="33"> --> acid (250 mg, 1.45 mmol) and cyclopropylmethylamine; LC-MS: t<sub>R</sub> = 0.57 min, [M+H]<sup>+</sup> = 208.00.</p><heading id="h0018"><b>2-Methoxy-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0058" num="0058">A suspension of methyl-2-chloro-6-methylpyrimidine-4-carboxylate (5.0 g) in 2N aq. NaOH (67 mL) and methanol (67 mL) is stirred at rt for 24 h. Methanol is evaporated and the aq. phase is acidified with 25% aq. HCl at 0°C. A beige crystalline solid crushes out. It is filtered, rinsed with water and heptane and dried (3.0 g); LC-MS: t<sub>R</sub> = 0.55 min, [M+H]<sup>+</sup> = 169.01; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 2.50 (s, 3 H), 3.94 (s, 3 H), 7.52 (s, 1 H), 13.7 (s br, 1 H).</p><heading id="h0019"><b>2-Ethoxy-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0059" num="0059">A solution of 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and Hünig's base (0.8 mL) in ethanol (1.79 mL) is stirred at 70°C for 24 h. Ethanol is evaporated and the aq. phase is acidified with 25% aq. HCl at 0°C, concentrated and purified by prep. HPLC (X-Bridge) to give 2-ethoxy-6-methyl-pyrimidine-4-carboxylic acid (201 mg) as a yellow solid; LC-MS: t<sub>R</sub> = 0.63 min, [M+H]<sup>+</sup> = 183.04.</p><heading id="h0020"><b>6-Methyl-2-propoxy-pyrimidine-4-carboxylic acid</b></heading><p id="p0060" num="0060">The title compound is obtained as a yellow solid (174 mg) in analogy to 2-ethoxy-6-methyl-amino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and n-propanol; LC-MS: t<sub>R</sub> = 0.72 min, [M+H]<sup>+</sup> = 197.06.</p><heading id="h0021"><b>2-Isopropoxy-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0061" num="0061">The title compound is obtained as a yellow solid (47 mg) in analogy to 2-ethoxy-6-methyl-amino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and isopropanol; LC-MS: t<sub>R</sub> = 0.71 min, [M+H]<sup>+</sup> = 197.07.</p><heading id="h0022"><b>2-Isobutoxy-6-methyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0062" num="0062">The title compound is obtained as a yellow solid (16 mg) in analogy to 2-ethoxy-6-methyl-amino-pyrimidine-4-carboxylic acid starting from 2-chloro-6-methylpyrimidine-4-carboxylic acid (265 mg, 1.54 mmol) and isobutanol; LC-MS: t<sub>R</sub> = 0.80 min, [M+H]<sup>+</sup> = 211.03.</p><heading id="h0023"><b>6-Ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester</b></heading><p id="p0063" num="0063">A solution of S-methylisothiourea sulphate (874 mg, 4.65 mmol) and 2,4-dioxohexanoic acid ethyl ester (800 mg, 4.65 mmol) in ethanol (4 mL) is heated to 80°C for 48 h. The reaction mixture is then filtered, evaporated and purified by prep. TLC (using heptane/EA<!-- EPO <DP n="34"> --> 1/1 as eluent) to give 590 mg of 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester as a yellow oil; LC-MS: t<sub>R</sub> = 0.91 min, [M+H]<sup>+</sup> = 227.22. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.24 (t, <i>J</i> = 7.5Hz, 3H), 1.34 (t, <i>J</i> = 7.0 Hz, 3 H), 2.56 (s, 3H), 2.81 (q, <i>J</i> = 7.5 Hz, 2 H), 4.37 (q, <i>J</i> = 7.0 Hz, 2 H), 7.58 (s, 1 H).</p><heading id="h0024"><b>6-Ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester</b></heading><p id="p0064" num="0064">To a solution of 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester (600 mg, 2.65 mmol) in DCM (20 mL) at 0°C, mCPBA (1.37 g, 5.57 mmol) is added. The reaction mixture is stirred for 12 h at rt, then quenched with 10% aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and extracted with DCM (3 x 40 mL). The combined org. layers are washed with sat. aq. NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure. The crude material is then purified by CC (EA/Heptane 1/9) to give 333 mg of the title compound as a yellow oil; LC-MS: t<sub>R</sub> = 0.80 min, [M+H]<sup>+</sup> = 259.07.</p><heading id="h0025"><b>6-Ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0065" num="0065"><ul><li>a) To a solution of 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester (590 mg, 2.61 mmol) in ethanol (12 mL) and THF (12 mL), 2M aq. LiOH (4 mL) is added. The mixture is stirred for 12 h at rt before neutralizing with 1 N aq. HCl. The aq. solution is extracted 3 times with ethylacetate and the combined org. layers are evaporated to dryness to give 510 mg of 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid as a white solid; LC-MS: t<sub>R</sub> = 0.75 min, [M+H]<sup>+</sup> = 199.02.</li><li>b) To a solution of 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid (510 mg, 2.57 mmol) in DCM (15 mL) at 0°C, mCPBA (1.33 g, 5.40 mmol) is added. The reaction mixture is stirred for 12 h at rt, then quenched with 10% aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and extracted with DCM (3 x 20 mL). The combined org. layers are washed with sat. aq. NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure. The crude material is then purified by prep. TLC (DCM/MeOH 4/1) to give 325 mg of the title compound as a yellow oil; LC-MS: t<sub>R</sub> = 0.54 min, [M+H]<sup>+</sup> = 231.05.</li></ul></p><heading id="h0026"><b>2-Methylsulfanyl-6-propyl-pyrimidine-4-carboxylic acid ethyl ester</b></heading><p id="p0066" num="0066">The title compound is obtained as a yellow oil (3.35 g) in analogy to 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester starting from 2,4-dioxo-heptanoic acid ethyl ester (4.0 g) and S-methyl-isothiourea sulfate; LC-MS: t<sub>R</sub> = 0.99 min, [M+H]<sup>+</sup> = 240.97. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.00 (m, 3 H), 1.44 (m, 3 H), 1.82 (m, 2 H), 2.64 (s, 3 H), 2.77 (m, 2 H), 4.47 (q, <i>J</i> = 7.3 Hz, 2 H), 7.47 (s, 1 H).<!-- EPO <DP n="35"> --></p><heading id="h0027"><b>2-Methanesulfonyl-6-propyl-pyrimidine-4-carboxylic acid ethyl ester</b></heading><p id="p0067" num="0067">The title compound is obtained as a yellow solid (107 mg) in analogy to 6-ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester starting from 2-methylsulfanyl-6-propyl-pyrimidine-4-carboxylic acid ethyl ester; LC-MS: t<sub>R</sub> = 0.85 min, [M+H]<sup>+</sup> = 272.96.</p><heading id="h0028"><b>2-Methanesulfonyl-6-propyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0068" num="0068">The title compound is obtained as a yellow solid (371 mg) in analogy to 6-ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid starting from 2-methylsulfanyl-6-propyl-pyrimidine-4-carboxylic acid ethyl ester; LC-MS: t<sub>R</sub> = 0.65 min, [M+H]<sup>+</sup> = 244.95.</p><heading id="h0029"><b>6-lsobutyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester</b></heading><p id="p0069" num="0069">The title compound is obtained as a yellow oil (2.31 g) in analogy to 6-ethyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester starting from 6-methyl-2,4-dioxo-heptanoic acid ethyl ester (3.5 g) and S-methyl-isothiourea sulfate; LC-MS: t<sub>R</sub> = 1.03 min, [M+H]<sup>+</sup> = 254.98. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.98 (d, <i>J</i> = 6.8 Hz, 6 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H), 2.20 (m, 1 H), 2.64 (s, 3 H), 2.67 (d, <i>J</i> = 7.0 Hz, 2 H), 4.48 (q, <i>J</i> = 7.0 Hz, 2 H), 7.44 (s, 1 H).</p><heading id="h0030"><b>6-Isobutyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester</b></heading><p id="p0070" num="0070">The title compound is obtained as a yellow solid (107 mg) in analogy to 6-ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester starting from 6-isobutyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester; LC-MS: t<sub>R</sub> = 0.91 min, [M+H]<sup>+</sup> = 286.97.</p><heading id="h0031"><b>6-Isobutyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0071" num="0071">The title compound is obtained as a beige solid (610 mg) in analogy to 6-ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid starting from 6-isobutyl-2-methylsulfanyl-pyrimidine-4-carboxylic acid ethyl ester; LC-MS: t<sub>R</sub> = 0.72 min, [M+H]<sup>+</sup> = 258.93.</p><heading id="h0032"><b>6-Ethyl-2-ethylamino-pyrimidine-4-carboxylic acid</b></heading><p id="p0072" num="0072">To a solution of 6-ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid (325 mg, 1.41 mmol) in THF (5 mL) is added 70% ethylamine in water (2.0 mL). The mixture is stirred at 70°C overnight. It is then evaporated to dryness and purified by prep. TLC (DCM/ 7N NH<sub>3</sub> in MeOH 4/1) to give 6-ethyl-2-ethylamino-pyrimidine-4-carboxylic acid as a yellow oil (200 mg); LC-MS: t<sub>R</sub> = 0.58 min, [M+H]<sup>+</sup> = 194.07. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.34 (m, 6 H), 2.84 (d, <i>J</i> = 7.5 Hz, 2H), 3.64 (m, 2H), 7.26 (s, 1 H), 11.0 (s br, 1 H).<!-- EPO <DP n="36"> --></p><heading id="h0033"><b>2-Methylamino-6-propyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0073" num="0073">A solution of 40% aq. methylamine (5 mL) and 2-methanesulfonyl-6-propyl-pyrimidine-4-carboxylic acid (150 mg, 0.614 mmol) is heated to 70°C for 2 h. The reaction mixture is then evaporated and the crude compound is dissolved in 3N NaOH solution (10 mL). The aq. solution is washed with EtOAc (5 mL), is then adjusted to pH 3 with 25% aq. HCl and finally extracted with DCM (3 x 15 mL). The combined DCM extracts are dried over MgSO<sub>4</sub>, filtered and evaporated to give 2-methylamino-6-propyl-pyrimidine-4-carboxylic acid as a beige powder (128 mg); LC-MS: t<sub>R</sub> = 0.56 min, [M+H]<sup>+</sup> = 196.00.</p><heading id="h0034"><b>6-Isobutyl-2-methylamino-pyrimidine-4-carboxylic acid</b></heading><p id="p0074" num="0074">The title compound is obtained as a beige solid (84 mg) in analogy to 2-methylamino-6-propyl-pyrimidine-4-carboxylic acid starting from 6-isobutyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.63 min, [M+H]<sup>+</sup> = 209.99.</p><heading id="h0035"><b>2-Dimethylamino-6-isobutyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0075" num="0075">The title compound is obtained as a beige solid (132 mg) in analogy to 2-methylamino-6-propyl-pyrimidine-4-carboxylic acid starting from 6-isobutyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid and 40% aq. dimethylamine; LC-MS: t<sub>R</sub> = 0.78 min, [M+H]<sup>+</sup> = 224.03.</p><heading id="h0036"><b>6-Isobutyl-2-isopropylamino-pyrimidine-4-carboxylic acid</b></heading><p id="p0076" num="0076">The title compound is obtained as a beige solid (103 mg) in analogy to 2-methylamino-6-propyl-pyrimidine-4-carboxylic acid starting from 6-isobutyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid and isopropylamine; LC-MS: t<sub>R</sub> = 0.77 min, [M+H]<sup>+</sup> = 238.04.</p><heading id="h0037"><b>2-Ethoxy-6-ethyl-pyrimidine-4-carboxylic acid</b></heading><p id="p0077" num="0077">To a solution of 6-ethyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester (100 mg, 0.39 mmol) in ethanol (4 mL), sodium ethylate (134 mg, 1.94 mmol) is added. The reaction mixture is stirred for 2 h, ethanol is evaporated and the residue is dissolved in EtOAc (25 mL). The org. solution is washed with 1M aq. KHSO<sub>4</sub>, followed by brine, dried over MgSO<sub>4</sub>, filtered and evaporated give 2-ethoxy-6-ethyl-pyrimidine-4-carboxylic acid as a yellow oil (35 mg); LC-MS: t<sub>R</sub> = 0.72 min, [M+H]<sup>+</sup> = 197.07.</p><heading id="h0038"><b>2-Methoxy-6-propyl-pyrimidine-4-carboxylic acid</b></heading><!-- EPO <DP n="37"> --><p id="p0078" num="0078">The title compound is obtained as a beige solid (84 mg) in analogy to 2-ethoxy-6-ethyl-pyrimidine-4-carboxylic acid starting from 2-methanesulfonyl-6-propyl-pyrimidine-4-carboxylic acid ethyl ester, KOtBu and methanol; LC-MS: t<sub>R</sub> = 0.71 min, [M+H]<sup>+</sup> = 196.96.</p><heading id="h0039"><b>6-Isobutyl-2-methoxy-pyrimidine-4-carboxylic acid</b></heading><p id="p0079" num="0079">The title compound is obtained as a yellow oil (82 mg) in analogy to 2-ethoxy-6-ethyl-pyrimidine-4-carboxylic acid starting from 6-isobutyl-2-methanesulfonyl-pyrimidine-4-carboxylic acid ethyl ester, KOtBu and methanol; LC-MS: t<sub>R</sub> = 0.77 min, [M+H]<sup>+</sup> = 210.96.</p><heading id="h0040"><b>3-Ethyl-4-hydroxy-5-methyl-benzaldehyde</b></heading><p id="p0080" num="0080">3-Ethyl-4-hydroxy-5-methyl-benzaldehyde is prepared from commercially available 2-ethyl-6-methyl-phenol following literature procedures (<nplcit id="ncit0030" npl-type="s"><text>G. Trapani, A. Latrofa, M. Franco, C. Altomare, E. Sanna, M. Usala, G. Biggio, G. Liso, J. Med. Chem. 41 (1998) 1846-1854</text></nplcit>; <nplcit id="ncit0031" npl-type="s"><text>A. K. Chakraborti, G. Kaur, Tetrahedron 55 (1999) 13265-13268</text></nplcit>; <nplcit id="ncit0032" npl-type="s"><text>E. Meyer, A. C. Joussef, H. Gallardo, Synthesis 2003, 899-905</text></nplcit>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.28 (t, <i>J</i> = 7.6 Hz, 3 H), 2.32 (s, 3 H), 2.69 (q, <i>J</i> = 7.6 Hz, 2 H), 5.30 (s br, 1 H), 7.58-7.53 (m, 2 H), 9.83 (s, 1 H).</p><heading id="h0041"><b>4-Benzyloxy-3-ethyl-5-methyl-benzaldehyde</b></heading><p id="p0081" num="0081">Potassium carbonate (4.38 g, 32 mmol) is added to a stirred solution of 3-ethyl-4-hydroxy-5-methyl-benzaldehyde (2.6 g, 16 mmol) in acetone (70 mL). Benzylbromide (2.07 mL, 17 mmol) is then added dropwise and the reaction mixture is heated to 60°C for 3 h. The suspension is filtered, the filtrate is evaporated and the crude product is purified by CC on silica gel eluting with heptane:EA 9:1 to give 4-benzyloxy-3-ethyl-5-methyl-benzaldehyde (3.66 g) as a colorless oil; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.28 (t, <i>J</i> = 7.5 Hz, 3H), 2.40 (s, 3H), 2.76 (q, <i>J</i> = 7.5 Hz, 2H), 4.90 (s, 2H), 7.50-7.35 (m, 5H), 7.62 (s, 1 H), 7.65 (s, 1 H), 9.94 (s, 1 H).</p><heading id="h0042"><b>4-Benzyloxy-3-ethyl-5-methyl-benzoic acid</b></heading><p id="p0082" num="0082">4-Benzyloxy-3-ethyl-5-methyl-benzaldehyde (1.4 g, 5.5 mmol) is dissolved in acetone (20 mL) and is slowly added to a cold solution of KMnO<sub>4</sub> (1.74 g, 11 mmol) in 20% aq. acetone (25 mL). The reaction mixture is stirred at rt for 3 h, and then acetone is evaporated. The remaining aq. phase is acidified with 10% citric acid (60 mL) and is extracted with DCM (80 mL, 60 mL, 60 mL). The combined org. extracts are washed with brine, dried over MgSO<sub>4</sub>, filtered and evaporated. The crude product is purified by CC on silica gel eluting with heptane:EA (5:1 to 2:1) to give 4-benzyloxy-3-ethyl-5-methyl-benzoic acid (1.16 g) as an off-white solid; LC-MS: t<sub>R</sub> = 0.56 min*; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.29 (t, <i>J</i> = 7.5 Hz, 3H), 2.39 (s,<!-- EPO <DP n="38"> --> 3H), 2.75 (q, <i>J</i> = 7.5 Hz, 2H), 4.90 (s, 2H), 7.53-7.36 (m, 5H), 7.86 (s, 1 H), 7.89 (s, 1 H), 12.0 (s br, 1H).</p><heading id="h0043"><b>3-Ethyl-4-hydroxy-5-methyl-benzonitrile</b></heading><p id="p0083" num="0083">The title compound is prepared from 3-ethyl-4-hydroxy-5-methyl-benzaldehyde following literature procedures (<nplcit id="ncit0033" npl-type="s"><text>A. K. Chakraborti, G. Kaur, Tetrahedron 55 (1999) 13265-13268</text></nplcit>); LC-MS: t<sub>R</sub> = 0.90 min; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.24 (t, <i>J</i> = 7.6 Hz, 3 H), 2.26 (s, 3 H), 2.63 (q, <i>J</i> = 7.6 Hz, 2 H), 5.19 (s, 1 H), 7.30 (s, 2 H).</p><heading id="h0044"><b>(S)-4-(3-Amino-2-hydroxypropoxy)-3-ethyl-5-methylbenzonitrile</b></heading><p id="p0084" num="0084"><ul><li>a) To a solution of 3-ethyl-4-hydroxy-5-methyl-benzonitrile (5.06 g, 31.4 mmol) in THF (80 mL), PPh<sub>3</sub> (9.06 g, 34.5 mmol) and (R)-glycidol (2.29 mL, 34.5 mmol) are added. The mixture is cooled to 0°C before DEAD in toluene (15.8 mL, 34.5 mmol) is added. The mixture is stirred for 18 h while warming up to rt. The solvent is evaporated and the crude product is purified by CC on silica gel eluting with heptane:EA 7:3 to give 3-ethyl-5-methyl-4-oxiranylmethoxy-benzonitrile (5.85 g) as a yellow oil; LC-MS: t<sub>R</sub> = 0.96 min; [M+42]<sup>+</sup> - 259.08.</li><li>b) The above epoxide is dissolved in 7 N NH<sub>3</sub> in methanol (250 mL) and the solution is stirred at 65°C for 18 h. The solvent is evaporated to give crude (S)-4-(3-amino-2-hydroxypropoxy)-3-ethyl-5-methylbenzonitrile (6.23 g) as a yellow oil; LC-MS: t<sub>R</sub> = 0.66 min; [M+H]<sup>+</sup> = 235.11.</li></ul></p><heading id="h0045"><b>Ng(S)-3-[2-Ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0085" num="0085"><ul><li>a) To a solution of (S)-4-(3-amino-2-hydroxypropoxy)-3-ethyl-5-methylbenzonitrile (6.23 g, 26.59 mmol), glycolic acid (2.43 g, 31.9 mmol), HOBt (4.31 g, 31.9 mmol) and EDC hydrochloride (6.12 g, 31.9 mmol) are added. The mixture is stirred at rt for 18 h before it is diluted with sat. aq. NaHCO<sub>3</sub> and extracted twice with EA. The combined org. extracts are dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product is purified by CC with DCM containing 8% of methanol to give (S)-N-[3-(4-cyano-2-ethyl-6-methyl-phenoxy)-2-hydroxypropyl]-2-hydroxy-acetamide (7.03 g) as a yellow oil; LC-MS: t<sub>R</sub> = 0.74 min; [M+H]<sup>+</sup> = 293.10; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25 (t, <i>J</i> = 7.5 Hz, 3 H), 2.32 (s, 3 H), 2.69 (q, <i>J</i> = 7.5 Hz, 2 H), 3.48-3.56 (m, 3 H), 3.70-3.90 (m, 3 H), 4.19 (s, br, 3 H), 7.06 (m, 1 H), 7.36 (s, 1 H), 7.38 (s, 1 H).<!-- EPO <DP n="39"> --></li><li>b) The above nitrile is converted to the N-hydroxy-benzamidine according to literature procedures (e.g. E. Meyer, A. C. Joussef, H. Gallardo, <i>Synthesis</i> <b>2003,</b> 899-905); LC-MS: t<sub>R</sub> = 0.51 min; [M+ H]<sup>+</sup> = 326.13; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.17 (t, <i>J</i> = 7.4Hz, 3 H), 2.24 (s, 3H), 2.62 (q, <i>J</i> = 7.4Hz, 2 H), 3.23 (m, 1 H), 3.43 (m, 1 H), 3.67 (m, 2 H), 3.83 (s, 2 H), 3.93 (m, 1 H), 5.27 (s br, 1 H), 5.58 (s br, 1 H), 5.70 (s, 2 H), 7.34 (s, 1 H), 7.36 (s, 1 H), 7.67 (m, 1 H), 9.46 (s br, 1H).</li></ul></p><heading id="h0046"><b>rac-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine</b></heading><p id="p0086" num="0086">The title compound is prepared by O-alkylating commercially available 4-hydroxy-3,5-dimethyl-benzonitrile with D,L-alpha-beta-isopropyliden glycerol under Mitsunobu conditions in the presence of PPh<sub>3</sub> and DEAD in THF. The nitrile is then transformed to the hydroxyamidine according to literature procedures (e.g. E. Meyer, A. C. Joussef, H. Gallardo, <i>Synthesis</i> <b>2003,</b> 899-905); LC-MS: t<sub>R</sub> = 0.67 min; [M+H]<sup>+</sup> = 295.06; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.32 (s, 3 H), 1.36 (s, 3H), 2.27 (s, 6H), 3.75-3.85 (m, 2H), 3.89 (m, 1 H), 4.10 (m, 1H), 4.41 (m, 1 H), 7.54 (s, 2H).</p><heading id="h0047"><b>4-Bromo-2-ethyl-6-methyl-aniline</b></heading><p id="p0087" num="0087">The title compound is prepared from commercially available 2-ethyl-6-methyl-aniline following literature procedures (<nplcit id="ncit0034" npl-type="s"><text>R. A. Benkeser, R. A. Hickner, D. I. Hoke, O. H. Thomas J. Am. Chem. Soc. 80 (1958) 5289-5293</text></nplcit>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.27 (t, <i>J</i>= 7.3 Hz, 3 H), 2.18 (s, 3H), 2.51 (q, <i>J</i> = 7.3 Hz, 2 H), 3.61 (s br, 2 H), 7.09 (s, 2 H).</p><heading id="h0048"><b>4-Amino-3-ethyl-5-methyl-benzonitrile</b></heading><p id="p0088" num="0088">The title compound is prepared from 4-bromo-2-ethyl-6-methyl-aniline following literature procedures (<nplcit id="ncit0035" npl-type="s"><text>J. Zanon, A. Klapars, S. Buchwald J. Am. Chem. Soc. 125 (2003) 2890-2891</text></nplcit>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.29 (t, <i>J</i> = 7.5 Hz, 3 H), 2.19 (s, 3H), 2.52 (q, <i>J</i> = 7.5 Hz, 2 H), 4.10 (s br, 2H), 7.25 (s br, 2 H).</p><heading id="h0049"><b>4-Bromo-3-ethyl-5-methyl-benzonitrile</b></heading><p id="p0089" num="0089">The title compound is prepared from 4-amino-3-ethyl-5-methyl-benzonitrile and copper(II) bromide following literature procedures (<nplcit id="ncit0036" npl-type="s"><text>M. P. Doyle, B. Siegfried, J. F. Dellaria Jr., J. Org. Chem. 42 (1977) 2426-2429</text></nplcit>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.26 (t, <i>J</i> = 7.5 Hz, 3 H), 2.47 (s, 3 H), 2.83 (q, <i>J</i> = 7.5 Hz, 2 H), 7.36 (s, 1 H), 7.37 (s, 1 H).</p><heading id="h0050"><b>3-(4-Cyano-2-ethyl-6-methyl-phenyl)-propionic acid ethyl ester</b></heading><!-- EPO <DP n="40"> --><p id="p0090" num="0090">The title compound is prepared from 4-bromo-3-ethyl-5-methyl-benzonitrile and commercially available acrolein diethyl acetal following literature procedures (<nplcit id="ncit0037" npl-type="s"><text>G. Battistuzzi, S. Cacchi, G. Fabrizi, R. Bernini, Synlett 8 (2003) 1133-1136</text></nplcit>); LC-MS: t<sub>R</sub> = 0.91 min; <sup>1</sup>H NMR (CDCl<sub>3</sub>):δ 1.2 (m, 6 H), 2.38 (s, 3 H), 2.44 (m, 2 H), 2.70 (q, <i>J</i> = 7.5 Hz, 2 H), 3.03 (m, 2 H), 4.18 (q, <i>J</i> = 7.3 Hz, 2 H), 7.30 (s, 1 H), 7.34 (s, 1 H).</p><heading id="h0051"><b>3-[2-Ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenyl]-propionic acid ethyl ester</b></heading><p id="p0091" num="0091">3-(4-Cyano-2-ethyl-6-methyl-phenyl)-propionic acid ethyl ester is transformed to the corresponding hydroxyamidine according to literature procedures using triethylamine as base (e.g. <nplcit id="ncit0038" npl-type="s"><text>E. Meyer, A. C. Joussef, H. Gallardo, Synthesis 2003, 899-905</text></nplcit>); LC-MS: t<sub>R</sub> = 0.77 min; [M+H]<sup>+</sup> = 279.52; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.19 (m, 6 H), 2.29 (s, 3 H), 2.41 (m, 2 H), 2.62 (q, <i>J</i> = 7.5 Hz, 2 H), 2.88 (m, 2H), 4.09 (q, <i>J</i> = 7.0 Hz, 2 H), 5.68 (s br, 2 H), 7.31 (s, 1 H), 7.33 (s, 1 H), 9.47 (s, 1 H).</p><heading id="h0052"><b>4-Hydroxy-3-methoxy-5-methyl-benzonitrile</b></heading><p id="p0092" num="0092">The title compound is prepared from commercially available 2-hydroxy-3-methoxy-toluene in analogy to literature procedures (see 3-ethyl-4-hydroxy-5-methyl-benzonitrile); LC-MS: t<sub>R</sub> = 0.84 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.27 (s, 3 H), 3.93 (s, 3 H), 6.24 (s, 1 H), 6.97 (d, <i>J</i> = 1.3 Hz, 1 H), 7.12 (s, 1 H).</p><heading id="h0053"><b>3-Chloro-4-hydroxy-5-methyl-benzonitrile</b></heading><p id="p0093" num="0093">The title compound is prepared from commercially available 2-chloro-6-methyl-phenol in analogy to literature procedures (see 3-ethyl-4-hydroxy-5-methyl-benzonitrile); LC-MS: t<sub>R</sub> = 0.85 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.33 (s, 3 H), 6.10 (s, 1 H), 7.38 (s, 1 H), 7.53 (d, <i>J</i> = 1.8 Hz, 1 H).</p><heading id="h0054"><b>4-Hydroxy-2-methoxy-benzonitrile</b></heading><p id="p0094" num="0094">The title compound is prepared from commercially available 4-hydroxy-2-methoxy-benzaldehyde in analogy to literature procedures (see 3-ethyl-4-hydroxy-5-methyl-benzonitrile); LC-MS: t<sub>R</sub> = 0.74 min. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 3.84 (s, 3 H), 6.47 (d, <i>J</i> = 8.5 Hz, 1 H), 6.54 (s, 1 H), 7.49 (d, <i>J</i> = 8.5 Hz, 1 H), 10.6 (s, 1 H).</p><heading id="h0055"><b>4-Hydroxy-2-methyl-benzonitrile</b></heading><p id="p0095" num="0095">A solution of 4-methoxy-2-methylbenzonitrile (5.0 g, 33.97 mmol) in DCM (150 mL) is cooled down to 0°C before adding dropwise a 1M BBr<sub>3</sub> in DCM solution (136 mL, 136 mmol). The reaction mixture is allowed to reach rt and stirring is then continued at 45°C for<!-- EPO <DP n="41"> --> 5 days. Ice water (500 mL) is then added and the reaction mixture is stirred for 1 h before sat. aq. NaHCO<sub>3</sub> (250 mL) is added. The mixture is extracted wit DCM (200 mL then 4 x 100 mL) and the combined org. extracts are dried over MgSO<sub>4</sub>, filtered and evaporated to give the title compound as a brown solid (4.7 g); LC-MS: t<sub>R</sub> = 0.76 min. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 2.38 (s, 3 H), 6.73 (dd, <i>J</i> = 8.5, 2.0 Hz, 1 H), 6.79 (d, <i>J</i> = 2.0 Hz, 1 H), 7.55 (d, <i>J</i> = 8.5 Hz, 1 H), 10.49 (s, 1 H).</p><heading id="h0056"><b>N-((R)-3-[2-Ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0096" num="0096">The title compound is obtained as a yellow oil (1.36 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from 3-ethyl-4-hydroxy-5-methyl-benzonitrile and (S)-glycidol; LC-MS: t<sub>R</sub> = 0.51 min, [M+H]<sup>+</sup> = 326.00.</p><heading id="h0057"><b>(S)-2-Hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide</b></heading><p id="p0097" num="0097">The title compound is obtained as a white solid (0.90 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from 4-hydroxy-3,5-methyl-benzonitrile and (R)-glycidol; LC-MS: t<sub>R</sub> = 0.47 min, [M+H]<sup>+</sup> = 311.98.</p><heading id="h0058"><b>(R)-2-Hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide</b></heading><p id="p0098" num="0098">The title compound is obtained as a yellow oil (0.60 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from from 4-hydroxy-3,5-methyl-benzonitrile and (S)-glycidol; LC-MS: t<sub>R</sub> = 0.47 min, [M+H]<sup>+</sup> = 311.99.</p><heading id="h0059"><b>(S)-2-Hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2-methoxy-6-methyl-phenoxy]-propyl)-acetamide</b></heading><p id="p0099" num="0099">The title compound is obtained as a reddish oil (1.3 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from 4-hydroxy-3-methoxy-5-methyl-benzonitrile; LC-MS: t<sub>R</sub> = 0.49 min, [M+H]<sup>+</sup> = 327.98.</p><heading id="h0060"><b>(S)-N-(-3-[2-Chloro-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><!-- EPO <DP n="42"> --><p id="p0100" num="0100">The title compound is obtained as a beige wax (1.1 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from 3-chloro-4-hydroxy-5-methyl-benzonitrile; LC-MS: t<sub>R</sub> = 0.48 min, [M+H]<sup>+</sup> = 331.94.</p><heading id="h0061"><b>(S)-2-Hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-3-methoxy-phenoxy]-propyl)-acetamide</b></heading><p id="p0101" num="0101">The title compound is obtained as a beige wax (0.52 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from 4-hydroxy-2-methoxy-benzonitrile; LC-MS: t<sub>R</sub> = 0.45 min, [M+H]<sup>+</sup> = 313.91.</p><heading id="h0062"><b>(S)-2-Hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-3-methyl-phenoxy]-propyl)-acetamide</b></heading><p id="p0102" num="0102">The title compound is obtained as a beige oil (1.0 g) in analogy to N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide starting from 4-hydroxy-2-methyl-benzonitrile; LC-MS: t<sub>R</sub> = 0.35 min, [M+H]<sup>+</sup> = 297.99.</p><heading id="h0063"><b>(<i>R</i>)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine</b></heading><p id="p0103" num="0103">The title compound is obtained as a white solid (0.81 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine using L-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.66 min, [M+H]<sup>+</sup> = 295.00.</p><heading id="h0064"><b>(<i>R</i>)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine</b></heading><p id="p0104" num="0104">The title compound is obtained as a yellow foam (0.34 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine using D-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.67 min, [M+H]<sup>+</sup> = 295.01.</p><heading id="h0065"><b>(<i>R</i>)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-ethyl-N-hydroxy-5-methyl-benzamidine</b></heading><p id="p0105" num="0105">The title compound is obtained as a beige oil (0.86 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine starting from 3-ethyl-4-hydroxy-5-methyl-benzonitrile and L-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.67 min, [M+H]<sup>+</sup> = 308.99.</p><heading id="h0066"><b>(<i>S</i>)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-ethyl-N-hydroxy-5-methyl-benzamidine</b></heading><!-- EPO <DP n="43"> --><p id="p0106" num="0106">The title compound is obtained as a yellow oil (0.77 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine starting from 3-ethyl-4-hydroxy-5-methyl-benzonitrile and D-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.68 min, [M+H]<sup>+</sup> = 308.99.</p><heading id="h0067"><b>(R)-3-Chloro-4-(2,2-dimethyl-[1,3]dioxotan-4-ylmethoxy)-N-hydroxy-5-methyl-benzamidine</b></heading><p id="p0107" num="0107">The title compound is obtained as a colorless oil (1.39 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine starting from 3-chloro-4-hydroxy-5-methyl-benzonitrile and L-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.66 min, [M+H]<sup>+</sup> = 314.96.</p><heading id="h0068"><b>(R)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3-methoxy-5-methyl-benzamidine</b></heading><p id="p0108" num="0108">The title compound is obtained as a beige oil (1.16 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine starting from 4-hydroxy-3-methoxy-5-methyl-benzonitrile and L-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.65 min, [M+H]<sup>+</sup> = 311.0.</p><heading id="h0069"><b>(R)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-2-methoxy-benzamidine</b></heading><p id="p0109" num="0109">The title compound is obtained as a beige oil (2.46 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine starting from 4-hydroxy-2-methoxy-benzonitrile and L-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.62 min, [M+H]<sup>+</sup> = 296.97.</p><heading id="h0070"><b>(R)-4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-2-methyl-benzamidine</b></heading><p id="p0110" num="0110">The title compound is obtained as a beige oil (0.65 g) in analogy to rac-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine starting from 4-hydroxy-2-methyl-benzonitrile and L-alpha-beta-isopropyliden glycerol; LC-MS: t<sub>R</sub> = 0.62 min, [M+H]<sup>+</sup> = 281.0.</p><heading id="h0071"><b>4-Benzyloxy-3-ethyl-N-hydroxy-5-methyl-benzamidine</b></heading><p id="p0111" num="0111"><ul><li>a) 3-Ethyl-4-hydroxy-5-methyl-benzonitrile (6.0 g, 37 mmol) is dissolved in acetonitrile (80 mL) and K<sub>2</sub>CO<sub>3</sub> (10.1 g, 73 mmol) and benzyl bromide (6.56 g, 38 mmol) are added. The resulting suspension is stirred at 60°C for 18 h, then water is added (100 mL) and the org. phase is collected. The aq. phase is extracted with EtOAc (100 mL) and the combined org.<!-- EPO <DP n="44"> --> extracts are washed with water followed by brine, dried over MgSO<sub>4</sub>, filtered, evaporated and purified by CC (eluting with Heptane/EtOAc 9:1) to give 4-benzyloxy-3-ethyl-5-methyl-benzonitrile as a yellow oil (7.02 g); LC-MS: t<sub>R</sub> = 1.11 min, [M+H]<sup>+</sup> = 293.16.</li><li>b) To a solution of the above benzonitrile intermediate (540 mg, 2.15 mmol) in MeOH (120 mL), hydroxylamine hydrochloride (448 mg, 6.45 mmol) and NaHCO<sub>3</sub> (632 mg, 7.52 mmol) are added. The reaction mixture is stirred at 60°C for 18 h and then then cooled down to rt prior to filtration. The filtrate is evaporated and dissolved in DCM, washed with water followed by brine, dried over MgSO<sub>4</sub>, filtered and evaporated to give the title compound (420 mg) as a yellow oil; LC-MS: t<sub>R</sub> = 0.79 min, [M+H]<sup>+</sup> = 285.14.</li></ul></p><heading id="h0072"><b>4-Benzyloxy-3-ethyl-5-methyl-benzoic acid hydrazide</b></heading><p id="p0112" num="0112">To a solution of 4-benzyloxy-3-ethyl-3-methyl-benzoic acid (8.3 g, 30.7 mmol) in DCM (300 mL) is added DIPEA (10.7 mL) and the mixture is cooled to 0°C before PyBOP (14.5 g, 33.8 mmol) is added. After 10 min, a solution of 1 M hydrazine in THF (100 mL) is added dropwise and the mixture is slowly warmed to rt during 2 h. The reaction mixture is then washed with sat. aq. NaHCO<sub>3</sub> followed by brine. The org. phase is collected, dried over MgSO<sub>4</sub>, filtered and evaporated to give the title compound (24 g, 40% purity) as a yellow wax; LC-MS: t<sub>R</sub> = 0.82 min; [M+H]<sup>+</sup> = 285.10.</p><heading id="h0073"><b>N-Hydroxy-4-vinyl-benzamidine</b></heading><p id="p0113" num="0113">4-Cyanostyrene is transformed to the corresponding hydroxyamidine according to literature procedures using hydroxylamine hydrochloride and NaHCO<sub>3</sub> as base (e.g. <nplcit id="ncit0039" npl-type="s"><text>E. Meyer, A. C. Joussef, H. Gallardo, Synthesis 2003, 899-905</text></nplcit>); LC-MS: t<sub>R</sub> = 0.55 min; [M+H]<sup>+</sup> = 163.04; <sup>1</sup>H NMR (D<sub>4</sub>-methanol): δ 4.86 (s br, 3H), 5.30 (d, <i>J</i> = 11.0 Hz, 1 H), 5.85 (d, <i>J</i> = 17.6 Hz, 1 H), 6.77 (dd, <i>J</i> = 17.6, 10.8 Hz, 1 H), 7.48 (d, <i>J</i> = 8.3 Hz, 2 H), 7.63 (d, <i>J</i> = 8.0 Hz, 2 H).</p><heading id="h0074"><b>4-Allyl-N-hydroxy-benzamidine</b></heading><p id="p0114" num="0114">The title compound is obtained in analogy to N-hydroxy-4-vinyl-benzamidine starting from 3-(4-cyanophenyl)-1-propene; LC-MS: t<sub>R</sub> = 0.59 min, [M+H]<sup>+</sup> = 177.03.</p><heading id="h0075"><b>N-Hydroxy-4-(2-hydroxy-ethyl)-benzamidine</b></heading><p id="p0115" num="0115">The title compound is obtained in analogy to N-hydroxy-4-vinyl-benzamidine starting from 4-(2-hydroxyethyl)-benzonitrile; LC-MS: t<sub>R</sub> = 0.51 min, [M+H]<sup>+</sup> = 181.27.</p><heading id="h0076"><b>[4-(N-Hydroxycarbamimidoyl)-phenyl]-acetic acid methyl ester</b></heading><!-- EPO <DP n="45"> --><p id="p0116" num="0116">The title compound is obtained in analogy to N-hydroxy-4-vinyl-benzamidine starting from methyl-4-(cyanophenyl)acetate; LC-MS: t<sub>R</sub> = 0.59 min, [M+H]<sup>+</sup> = 209.07.</p><heading id="h0077"><b>2,2-Dimethyl-[1,3]dioxan-5-yl)-methanol</b></heading><p id="p0117" num="0117">The title compound is prepared following the procedure given in <nplcit id="ncit0040" npl-type="s"><text>B. Xu, A. Stephens, G. Kirschenheuter, A.F. Crealin, X. Cheng, J. Sennelo, M: Cattaneo, M.L. Zighetti, A. Chen, S.-A. Kim, H.S. Kim, N. Bischofberger, G. Cook, K.A. Jacobson, J. Med. Chem 45 (2002), 5694-5709</text></nplcit>.</p><heading id="h0078"><b>4-(2,2-Dimethyl-[1,3]dioxan-5-ylmethoxy)-3-ethyl-N-hydroxy-5-methyl-benzamidine</b></heading><p id="p0118" num="0118">The title compound is prepared in analog to 4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine by O-alkylating 3-ethyl-4-hydroxy-5-methyl-benzonitrile with 2,2-dimethyl-[1,3]dioxan-5-yl)-methanol under Mitsunobu conditions; LC-MS: t<sub>R</sub> = 0.71 min; [M+H]<sup>+</sup> = 323.03.</p><heading id="h0079"><b>N-Hydroxy-2-isopropylamino-6-methyl-pyrimidine-4-carboxamidine</b></heading><p id="p0119" num="0119"><ul><li>a) To a solution of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid (1.27 g, 6.53 mmol) in ethanol (20 mL), concentrated H<sub>2</sub>SO<sub>4</sub> (4 mL) is added. The reaction mixture is stirred at 80°C for 18 h and is then evaporated. The residue is dissolved in EtOAc, washed with sat. aq. NaHCO<sub>3</sub> and water, dried over MgSO<sub>4</sub>, filtered and evaporated. The crude compound is purified by CC on silica gel (eluting with Heptane/EtOAc 4:1) to give 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid ethyl ester as a yellow oil (1.46 g); LC-MS: t<sub>R</sub> = 0.97; [M+H]<sup>+</sup> = 224.49.</li><li>b) A solution of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid ethyl ester (1.46 g, 6.54 mmol) in 3M NH<sub>3</sub> in MeOH (50 mL) is stirred at 60°C for 1 day. Volatiles are evaporated to give the crude 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid amide as a pale yellow solid (1.24 g); LC-MS: t<sub>R</sub> = 0.59; [M+H]<sup>+</sup> = 195.0.</li><li>c) To a suspension of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid amide (1.24 g, 6.4 mmol) in DCM (20 mL), pyridine (2.53 mL, 25.6 mmol) is added followed by TFFA (2.7 mL, 19.2 mmol). The reaction mixture is stirred for 4 h, and then is quenched with water. The mixture is extracted with DCM. The org. phase is washed with sat. aq. NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>, filtered and evaporated. Purification by CC on silica gel (eluting with Heptane/EtOAc 4:1) affords the 2-isopropylamino-6-methyl-pyrimidine-4-carbonitrile as a yellow oil (2.81 g); LC-MS: t<sub>R</sub> = 0.89; [M<sup>+</sup>H]<sup>+</sup> = 177.04.<!-- EPO <DP n="46"> --></li><li>d) 2-Isopropylamino-6-methyl-pyrimidine-4-carbonitrile (2.8 g, 16.0 mmol) is added to a suspension of NaHCO<sub>3</sub> (4.71 g, 56.1 mmol) and hydroxylamine hydrochloride (3.34 g, 48.1 mmol) in MeOH (20 mL). The reaction mixture is stirred at rt for 1 day and is filtered and evaporated. The residue is dissolved in DCM, washed with water followed by brine and dried to give N-hydroxy-2-isopropylamino-6-methyl-pyrimidine-4-carboxamidine as a yellow oil (1.38 g); LC-MS: t<sub>R</sub> = 0.55; [M+H]<sup>+</sup> = 209.96.</li></ul></p><heading id="h0080"><b>2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 1)</heading><p id="p0120" num="0120"><ul><li>a) To a solution of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid (200 mg, 1.02 mmol) and DIPEA (0.43 mL) in DMF (100 mL) is added TBTU (395 mg, 1.23 mmol). The reaction mixture is stirred at 0°C for 15 min before adding 4-benzyloxy-3-ethyl-5-methylbenzoic acid hydrazide. Stirring is continued for 1 h and the reaction mixture is then diluted with EtOAc and washed with sat. aq. NaHCO<sub>3</sub>. The aq. phase is extracted with EtOAc and the combined org. phases are dried over MgSO<sub>4</sub>, filtered and evaporated to give a brown oil. The oil is dissolved in THF (5.0 mL) and Burgess reagent (155 mg, 0.65 mmol) is added. The reaction mixture is heated to 110°C for 15 min under microwave conditions. The reaction mixture is evaporated and purified by prep. TLC (eluting with Heptane/EA 9:1) to afford {4-[5-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-[1,3,4]oxadiazol-2-yl]-6-methyl-pyrimidin-2-yl}-isopropyl-amine as a yellow oil (125 mg, 56%); LC-MS: t<sub>R</sub> = 1.16; [M+H]<sup>+</sup> = 444.08.</li><li>b) The above benzyloxy derivative (360 mg, 0.813 mmol) is dissolved in EtOAc (3.0 mL) and a solution of 33% HBr in AcOH (1 mL) is added. The reaction mixture is stirred at rt for 18 h, and is then diluted with EtOAc and neutralized with sat. aq. NaHCO<sub>3</sub>. The org. phase is collected and washed with sat. aq. NaHCO<sub>3</sub> again, dried over MgSO<sub>4</sub>, filtered and evaporated to give a residue that is purified by prep. HPLC to give the title compound (140 mg) as a beige solid; LC-MS: t<sub>R</sub> = 1.00; [M+H]<sup>+</sup> = 354.42.</li></ul></p><heading id="h0081"><b>2-Ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 2)</heading><p id="p0121" num="0121">The title compound is obtained in analogy to 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol starting from 2-isobutylamino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.05 min, [M+H]<sup>+</sup> = 368.24.<!-- EPO <DP n="47"> --></p><heading id="h0082"><b>2-Ethyl-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 3)</heading><p id="p0122" num="0122">The title compound is obtained in analogy to 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol starting from 2-isopropoxy-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.03 min, [M+H]<sup>+</sup> = 355.05.</p><heading id="h0083"><b>2-Ethyl-4-[5-(2-isobutoxy-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 4)</heading><p id="p0123" num="0123">The title compound is obtained in analogy to 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol starting from 2-isobutoxy-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.08 min, [M+H]<sup>+</sup> = 369.08.</p><heading id="h0084"><b>2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]thiadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 5)</heading><p id="p0124" num="0124">The title compound is obtained in analogy to 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenol (Intermediate 1) using the Lawesson reagent (1.3 eq.) in place of the Burgess reagent for the cyclization under microwave conditions (30 min, 110°C); LC-MS: t<sub>R</sub> = 1.03 min, [M+H]<sup>+</sup> = 370.31.</p><heading id="h0085"><b>2-Ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]thiadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 6)</heading><p id="p0125" num="0125">The title compound is obtained in analogy to 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]thiadiazol-2-yl]-6-methyl-phenol (Intermediate 5) starting from 2-isobutylamino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.06 min, [M+H]<sup>+</sup> = 383.85.</p><heading id="h0086"><b>2-Ethyl-4-[5-(2-isobutoxy-6-methyl-pyrimidin-4-yl)-[1,3,4]thiadiazol-2-yl]-6-methyl-phenol</b> (Intermediate 7)</heading><p id="p0126" num="0126">The title compound is obtained in analogy to 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,3,4]thiadiazol-2-yl]-6-methyl-phenol (Intermediate 5) starting from 2-isobutoxy-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.14 min, [M+H]<sup>+</sup> = 385.00.</p><heading id="h0087"><b>Isopropyl-{4-methyl-6-[3-(4-vinyl-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrimidin-2-yl}-amine</b> (Intermediate 8)</heading><p id="p0127" num="0127">To a suspension of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid (1.9 g, 11.8 mmol) in DMF (25 mL) is added HOBt (1.8 g, 13.4 mmol) followed by EDC (2.6 g, 13.4<!-- EPO <DP n="48"> --> mmol). The reaction mixture is stirred for 40 min until a clear solution is obtained and a solution of N-hydroxy-4-vinyl-benzamidine (2.09 g, 10.7 mmol) in DMF (20 mL) is added. After 2 h, EtOAc (320 mL) is added to the reaction mixture and the solution is then washed with sat. aq. NaHCO<sub>3</sub> (3 x 100 mL), with brine, dried over MgSO<sub>4</sub>, filtered and evaporated to give a red oil. The oil is dissolved in dioxane (50 mL) and the solution is heated to 95°C for 2 h. The reaction mixture is evaporated and purification by CC on silica gel affords the title compound as a yellow oil (2.79 g) ; LC-MS: t<sub>R</sub> = 1.12; [M+H]<sup>+</sup> = 321.95.</p><heading id="h0088"><b>{4-[3-(4-Allyl-phenyl)-[1,2,4]oxadiazol-5-yl]-6-methyl-pyrimidin-2-yl}-isopropyl-amine</b> (Intermediate 9)</heading><p id="p0128" num="0128">The title compound is obtained in analogy to isopropyl-{4-methyl-6-[3-(4-vinyl-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrimidin-2-yl}-amine starting from 4-allyl-N-hydroxy-benzamidine; LC-MS: t<sub>R</sub> = 1.14 min, [M+H]<sup>+</sup> = 336.04.</p><heading id="h0089"><b>3-{2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionic acid hydrochloride</b> (Intermediate 10)</heading><p id="p0129" num="0129"><ul><li>a) 2-Isopropylamino-6-methyl-pyrimidine-4-carboxylic acid (500 mg, 2.56 mmol) dissolved in DMF (10 mL) is coupled to 3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenyl]-propionic acid ethyl ester (786 mg, 2.79 mmol) under standard conditions using EDC (1.5 eq.), HOBt (1.5 eq.) and DIPEA (2.0 eq.) to give the hydroxyamidine ester intermediate. This material is dissolved in dioxane (20 mL) and the resulting solution is stirred at 85°C for 18 h. The solvent is removed in vacuo and the crude product is purified by CC on silica gel to give the desired 3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionic acid ethyl ester (0.87 g).</li><li>b) The above ethyl ester is hydrolyzed with 6N aq. HCl (69 mL) to give 3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionic acid hydrochloride as a yellow powder (825 mg); LC-MS: t<sub>R</sub> = 1.05 min; [M+H]<sup>+</sup> = 410.02.</li></ul></p><heading id="h0090"><b>4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenol</b> (Intermediate 11)</heading><p id="p0130" num="0130"><ul><li>a) To a solution of 2-diethylamino-6-methyl-pyrimidine-4-carboxylic acid (5.56 g, 27.0 mmol mmol) and 4-benzyloxy-3-ethyl-N-hydroxy-5-methyl-benzamidine (7.69 g, 27 mmol) in DMF (80 mL), EDC (6.74 g, 35.2 mmol) and HOBt (4.75 g, 35.2 mmol) are added at 0°C. Stirring is continued at rt for 2 h and the reaction mixture is then diluted with EtOAc and washed with sat. aq. NaHCO<sub>3</sub>. The aq. phase is extracted with EtOAc and the combined org.<!-- EPO <DP n="49"> --> extracts are dried over MgSO<sub>4</sub>, filtered and evaporated to give a brown oil. The oil is dissolved in dioxane (30 mL) and the solution is heated to 85°C for 18 h. The reaction mixture is evaporated and purified by CC (eluting with Heptane/EA 9:1) to afford {4-[3-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-[1,2,4]oxadiazol-5-yl]-6-methyl-pyrimidin-2-yl}-diethyl-amine as a yellow oil (4.3 g, 35%); LC-MS: t<sub>R</sub> = 1.35; [M+H]<sup>+</sup> = 458.48.</li><li>b) The above benzyloxy derivative (4.3 g, 9.4 mmol) is dissolved in THF (300 mL) and Pd/C (600 mg) is added followed by AcOH (5 mL). The reaction mixture is stirred for 1 h under H<sub>2</sub> atmosphere, then filtered and evaporated. The residue is purified by CC (eluting with Heptane/EtOAc 9:1) to give the title compound (2.61 g) as a yellow crystalline solid; LC-MS: t<sub>R</sub> = 1.17; [M+H]<sup>+</sup> = 368.10. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO) δ 1.19 (m, 9 H), 2.28 (s, 3 H), 2.44 (s, 3 H), 2.68 (q, <i>J</i> = 7.5 Hz, 2 H), 3.67 (q, <i>J</i> = 7.0 Hz, 4 H), 7.29 (s, 1 H), 7.68 (s, 2 H), 8.96 (s br, 1H).</li></ul></p><heading id="h0091"><b>(S)-Diethyl-{4-[3-(3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-6-methyl-pyrimidin-2-yl}-amine</b> (Intermediate 12)</heading><p id="p0131" num="0131">To a solution of 4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenol (700 mg, 1.90 mmol) in isopropanol (12 mL), are added 3M aq. NaOH (4 mL) and <i>R</i>-epichlorhydrine (1.49 mL, 19.0 mmol). The reaction mixture is stirred at rt for 15 h, then is diluted with EtOAc and washed with 1 M aq. NaOH followed by brine. The org. phase is dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, evaporated and purified by CC (eluting with Heptane/EtOAc 4:1) to give the title compound as a yellow oil (882 mg); LC-MS: t<sub>R</sub> = 1.23; [M+H]<sup>+</sup> = 424.04. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.25 (t, <i>J</i> = 7.0 Hz, 6 H), 1.33 (t, <i>J</i> = 7.5 Hz, 3 H), 2.41 (s, 3 H), 2.47 (s, 3 H), 2.79 (m, 3 H), 2.94 (t, <i>J</i> = 4.5 Hz, 1 H), 3.42 (m, 1 H), 3.76 (q, <i>J</i> = 7.0 Hz, 4 H), 3.83 (dd, <i>J</i> = 11.0, 5.8 Hz, 1 H), 4.13 (dd, <i>J</i> = 11.0, 3.0 Hz, 1 H), 7.23 (s, 1 H), 7.89 (d, <i>J</i> = 5.5 Hz, 2 H).</p><heading id="h0092"><b>2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol</b> (Intermediate 13)</heading><p id="p0132" num="0132">To a suspension of 2-diethylamino-6-methylpyrimidine-4-carboxylic acid (1.31 g, 6.28 mmol) in DMF (20 mL) is added DIPEA (3.23 mL, 18.8 mmol) followed by TBTU (2.62 g, 8.17 mmol). The mixture is stirred at rt for 10 min before N-hydroxy-4-(2-hydroxy-ethyl)-benzamidine (1.24 g, 6.91 mmol) is added. After stirring for 1 h, the reaction mixture is diluted with EtOAc and the solution is washed with sat. aq. NaHCO<sub>3</sub>. The aq. phase is extracted with EtOAc and the combined org. extracts are dried over MgSO<sub>4</sub>, filtered and concentrated to give the crude hydroxyamidine ester intermediate (3.56 g). This material is<!-- EPO <DP n="50"> --> dissolved in dioxane (50 mL) and the resulting solution is stirred at 85°C for 16 h. The solvent is evaporated and the crude product is purified by CC (eluting with EtOAc/Heptane 1:4) to give 2-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol as a yellow solid (1.30 g); LC-MS: t<sub>R</sub> = 1.07 min; [M+H]<sup>+</sup> = 354.07. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25 (t, <i>J</i> = 7.0 Hz, 6H), 1.45 (m, 1 H), 2.47 (s, 3 H), 2.98 (t, <i>J</i> = 6.5 Hz, 2 H), 3.75 (q, <i>J</i> = 7.0 Hz, 4 H), 3.95 (m, 2 H), 7.23 (s, 1 H), 7.41 (d, <i>J</i> = 7.8 Hz, 2 H), 8.15 (d, <i>J</i> = 7.5 Hz, 2 H).</p><heading id="h0093"><b>(4-{3-[4-(2-Amino-ethyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-6-methyl-pyrimidin-2-yl)-diethyl-amine</b> (Intermediate 14)</heading><p id="p0133" num="0133"><ul><li>a) To a solution of 2-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol (1.2 g, 3.40 mmol) in DCM (20 mL) is added DIPEA (5.09 mmol) followed by methanesulfonylchlorid (466 mg, 4.07 mmol). The reaction mixture is stirred for 1 h, then diluted with EtOAc and washed with sat. aq. NaHCO<sub>3</sub>. The aq. phase is extracted with EtOAc and the combined org. phases are dried over MgSO<sub>4</sub>, filtered and evaporated to give the mesylate intermediate as a light brown solid (1.46 g); LC-MS: t<sub>R</sub> = 1.13 min; [M+H]<sup>+</sup> = 432.00.</li><li>b) The mesylate intermediate (1.46 g, 3.40 mmol) is dissolved in DMF (10 mL) and NaN<sub>3</sub> is added (1.13 g, 16.97 mmol). The reaction mixture is stirred at rt for 24 h and is then diluted with EtOAc and washed with water and brine. The org. phase is dried over MgSO<sub>4</sub>, filtered and evaporated to give the azide intermediate as a yellow oil (1.45 g); LC-MS: t<sub>R</sub> = 1.20 min; [M+H]<sup>+</sup> = 379.07.</li><li>c) Triphenylphosphine (1.33 g, 5.09 mmol) is added to a solution of the azide derivative (1.28 g) in THF (30 mL). The reaction mixture is stirred at rt for 4 days, is then evaporated and the residue is purified by prep. HLPC to give (4-{3-[4-(2-amino-ethyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-6-methyl-pyrimidin-2-yl)-diethyl-amine as a yellow oil (435 mg); LC-MS: t<sub>R</sub> = 0.80 min; [M+H]<sup>+</sup> = 353.1. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.25 (t, <i>J</i> = 7.0 Hz, 6 H), 2.88 (t, <i>J</i> = 6.8 Hz, 2 H), 3.07 (t, <i>J</i> = 7.0 Hz, 2 H), 3.75 (q, <i>J</i> = 7.0 Hz, 4 H), 7.22 (s, 1 H), 7.37 (d, <i>J</i> = 8.3 Hz, 2 H), 8.13 (d, <i>J</i> = 8.3 Hz, 2 H).</li></ul></p><heading id="h0094"><b>{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-acetic acid</b> (Intermediate 15)</heading><p id="p0134" num="0134">The title compound is obtained in analogy to 3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionic acid hydrochloride<!-- EPO <DP n="51"> --> (Intermediate 10) starting from 2-diethylamino-6-methyl-pyrimidine-4-carboxylic acid and [4-(N-hydroxycarbamimidoyl)-phenyl]-acetic acid ethyl ester; LC-MS: t<sub>R</sub> = 1.05 min, [M+H]<sup>+</sup> = 368.04.</p><heading id="h0095"><b>Example 1</b></heading><heading id="h0096"><b>N-((S)-3-{2-Ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0135" num="0135">To a solution of 2-ethylamino-6-methyl-pyrimidine-4-carboxylic acid (40 mg, 0.221 mmol) in DMF (3.0 mL), HOBt (36 mg, 0.266 mmol) and EDC·HCl (47 mg, 0.243 mmol) are added. The reaction mixture is stirred for 5 min before adding (S)-N-(3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide (72 mg, 0.221 mmol). The mixture is stirred at rt for 1 h before it is diluted with ethylacetate, washed with sat. aq. NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give the hydroxyamidine ester intermediate. This material is dissolved in dioxane (3 mL) and the resulting solution is stirred at 85°C for 16 h. The solvent is evaporated and the crude product is purified by prep. HPLC (X-Bridge) to give N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide (31 mg) as a yellow crystalline solid; LC-MS: t<sub>R</sub> = 0.88 min; [M+H]<sup>+</sup> = 471.30. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.16 (t, <i>J</i> <b>=</b> 7.3 Hz, 3H), 1.22 (t, <i>J</i> = 7.5 Hz, 3 H), 2.34 (s, 3 H), 2.41 (s, 3 H), 2.73 (q, <i>J</i> = 7.5 Hz, 2 H), 3.25 (m, 1 H), 3.34-3.50 (m, 3 H), 3.75 (m, 2 H), 3.84 (d, <i>J</i> = 5.8 Hz, 2 H), 3.96 (m, 1 H), 5.31 (d, <i>J</i> = 5.8 Hz, 1 H), 5.55 (t, <i>J</i> = 5.8 Hz, 1 H), 7.29 (s, 1 H), 7.62 (s br, 1 H), 7.69 (t, <i>J</i> = 5.8 Hz, 1 H), 7.78 (s, 2 H).</p><heading id="h0097"><b>Example 2</b></heading><heading id="h0098"><b>N-((S)-3-{2-Ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0136" num="0136">N-((S)-3-{2-Ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxyl-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-isobutylamino-6-methylpyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.96 min; [M+H]<sup>+</sup> = 499.25. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 0.92 (d, <i>J</i> = 6.5 Hz, 6 H), 1.22 (t, <i>J</i> = 7.5 Hz, 3 H), 1.91 (m, 1 H), 2.35 (s, 3 H), 2.41 (s, 3 H), 2.73 (q, <i>J</i> = 7.5 Hz, 2 H), 3.15-3.28 (m, 3 H), 3.43 (m, 1 H), 3.70-3.80 (m, 2 H), 3.84 (d, <i>J</i> = 4.8 Hz, 2 H), 3.96 (m, 1 H), 5.30 (d, <i>J</i> = 5.0 Hz, 1 H), 5.55 (m, 1 H), 7.29 (s, 1 H), 7.69 (m, 2 H), 7.78 (s, 2 H).<!-- EPO <DP n="52"> --></p><heading id="h0099"><b>Example 3</b></heading><heading id="h0100"><b>N-((S)-3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0137" num="0137">N((S)-3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-diethylamino-6-methyl-pyrimidine -4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.03 min; [M+H]<sup>+</sup> = 499.23. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.18 (t, <i>J</i> = 7.0 Hz, 6 H), 1.22 (t, <i>J</i> = 7.3 Hz, 3 H), 2.35 (s, 3 H), 2.44 (s, 3 H), 2.73 (q, <i>J</i> = 7.3 Hz, 2 H), 3.25 (m, 1 H), 3.44 (m, 1 H), 3.67 (q, <i>J</i> = 7.0 Hz, 4 H), 3.76 (m, 2 H), 3.84 (d, <i>J</i> = 5.8 Hz, 2 H), 3.96 (m, 1 H), 5.31 (d, <i>J</i> = 5.0 Hz, 1 H), 5.55 (t, <i>J</i> = 5.5 Hz, 1 H), 7.30 (s, 1 H), 7.69 (t, <i>J</i> = 5.5 Hz, 1 H), 7.78 (s, 2 H).</p><heading id="h0101"><b>Example 4</b></heading><heading id="h0102"><b>rac-N-(3-{4-[5-(2-Ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0138" num="0138">rac-N-(3-{4-[5-(2-Ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-ethylamino-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.86 min; [M+H]<sup>+</sup> = 457.27. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.16 (t, <i>J</i> = 7.0 Hz, 3 H), 2.34 (s, 6 H), 2.41 (s, 3 H), 3.25 (m, 1 H), 3.35-3.50 (m, 3 H), 3.70-3.80 (m, 2 H), 3.84 (d, <i>J</i> = 5.3 Hz, 2 H), 3.96 (m, 1 H), 5.29 (d, <i>J</i> = 5.0 Hz, 1 H), 5.55 (t, <i>J</i> = 5.8 Hz, 1 H), 7.28 (s, 1 H), 7.63 (s br, 1 H), 7.69 (t, <i>J</i> = 5.3 Hz, 1 H), 7.76 (s, 2 H).</p><heading id="h0103"><b>Example 5</b></heading><heading id="h0104"><b>rac-N-(3-{2,6-Dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0139" num="0139">rac-N-(3-{2,6-Dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 6-methyl-2-methylamino-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.85 min; [M<sup>+</sup>H]<sup>+</sup> = 443.21.<!-- EPO <DP n="53"> --></p><heading id="h0105"><b>Example 6</b></heading><heading id="h0106"><b>rac-N-(3-{2,6-Dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0140" num="0140">rac-N-(3-{2,6-Dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.92 min, [M+H]<sup>+</sup> = 471.25.</p><heading id="h0107"><b>Example 7</b></heading><heading id="h0108"><b>rac-N-(3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0141" num="0141">rac-N-(3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.92 min, [M+H]<sup>+</sup> = 471.25.</p><heading id="h0109"><b>Example 8</b></heading><heading id="h0110"><b>rac-N-(3-{4-[5-(2-Isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0142" num="0142">rac-N-(3-{4-[5-(2-Isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-isobutylamino-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.96 min; [M+H]<sup>+</sup> = 485.31.</p><heading id="h0111"><b>Example 9</b></heading><heading id="h0112"><b>rac-N-(3-{4-[5-(2-(Ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0143" num="0143">rac-N-(3-{4-[5-(2-(Ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide<!-- EPO <DP n="54"> --> using 2-ethyl-methylamino-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.98 min; [M+H]<sup>+</sup> = 471.26.</p><heading id="h0113"><b>Example 10</b></heading><heading id="h0114"><b>rac-N-(3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0144" num="0144">rac-N-(3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-(5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-diethylamino-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 1.01 min; [M+H]<sup>+</sup> = 485.30. <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.18 (t, <i>J</i> = 6.8 Hz, 6 H), 2.34 (s, 6 H), 2.43 (s, 3 H), 3.25 (m, 1 H), 3.45 (m, 1 H), 3.67 (q, <i>J</i> = 6.8 Hz, 4 H), 3.70-3.82 (m, 2 H), 3.84 (d, <i>J</i> = 5.5 Hz, 2 H), 3.96 (m, 1 H), 5.29 (d, <i>J</i> = 5.3 Hz, 1 H), 5.55 (t, <i>J</i> = 5.5 Hz, 1 H), 7.27 (s, 1 H), 7.69 (t, <i>J</i> = 5.5 Hz, 1 H), 7.76 (s, 2 H).</p><heading id="h0115"><b>Example 11</b></heading><heading id="h0116"><b>rac-N-(3-{4-[5-(2-Dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0145" num="0145">rac-N-(3-{4-[5-(2-Dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 6-methyl-2-methylamino-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.94 min; [M+H]<sup>+</sup> = 457.31.</p><heading id="h0117"><b>Example 12</b></heading><heading id="h0118"><b>rac-N-(3-{4-[5-(2-Methoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0146" num="0146">rac-N-(3-{4-[5-(2-Methoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-methoxy-6-methyl-pyrimidine-4-carboxylic<!-- EPO <DP n="55"> --> acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.84 min; [M+H]<sup>+</sup> = 444.19.</p><heading id="h0119"><b>Example 13</b></heading><heading id="h0120"><b>rac-N-(3-{4-[5-(2-Ethoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-aceta mide</b></heading><p id="p0147" num="0147">rac-N-(3-{4-[5-(2-Ethoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-ethoxyl-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.92 min; [M+H]<sup>+</sup> = 458.20.</p><heading id="h0121"><b>Example 14</b></heading><heading id="h0122"><b>rac-N-(3-{4-[5-(6-Methyl-2-propoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0148" num="0148">rac-N-(3-{4-[5-(6-Methyl-2-propoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 6-methyl-2-propoxy-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.96 min; [M+H]<sup>+</sup> = 472.23.</p><heading id="h0123"><b>Example 15</b></heading><heading id="h0124"><b>rac-N-(3-{4-[5-(2-Isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0149" num="0149">rac-N-(3-{4-[5-(2-Isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide is prepared in analogy to N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide using 2-isopropoxy-6-methyl-pyrimidine-4-carboxylic acid and 2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimioyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; LC-MS: t<sub>R</sub> = 0.95 min; [M+H]<sup>+</sup> = 472.21.</p><heading id="h0125"><b>Example 16</b></heading><heading id="h0126"><b>rac-3-{4-[5-(2-Ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><!-- EPO <DP n="56"> --><heading id="h0127"><b>Method A</b></heading><p id="p0150" num="0150"><ul><li>a) 2-Ethylamino-6-methyl-pyrimidine-4-carboxylic acid and 4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine are coupled followed by cyclisation in analogy to Example 1 to give (4-{3-[4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3,5-dimethyl-phenyl]-[1,2,4]-oxadiazol-5-yl}-6-methyl-pyrimidin-2-yl)-ethyl-amine; LC-MS: t<sub>R</sub> = 1.12 min; [M+H]<sup>+</sup> = 440.21.</li><li>b) The above intermediate is dissolved in acetonitrile/methanol 1:1 before adding 5N HCl in propanol. The mixture is stirred at rt for 1 h, then basified with ammonium hydroxide, concentrated and purified by prep. HPLC (X-Bridge) to give rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol as a white crystalline solid; LC-MS: t<sub>R</sub> = 0.80 min*; [M+H]<sup>+</sup> = 400.06; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.17 (t, <i>J</i> = 7.0 Hz, 3 H), 2.35 (s, 6 H), 2.42 (s, 3 H), 3.37 (m, 2 H), 3.50 (t, <i>J</i> = 5.3 Hz, 2 H), 3.75 (dd, <i>J</i> = 5.5 and 8.8 Hz, 1 H), 3.80-3.90 (m, 2 H), 4.64 (t, <i>J</i> = 5.3 Hz, 1 H), 4.94 (d, <i>J</i> = 5.0 Hz, 1 H), 7.29 (s, 1 H), 7.65 (s br, 1 H), 7.76 (s, 2 H).</li></ul></p><heading id="h0128"><b>Method B</b></heading><p id="p0151" num="0151"><ul><li>a) To a solution of 2-chloro-6-methylpyrimidine-4-carboxylic acid (293 mg, 1.70 mmol) in DMF (10 mL), HOBt (275 mg, 2.04 mmol) and EDC·HCl (358 mg, 1.87 mmol) are added at 5°C. The reaction mixture is stirred for 5 min before adding 4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine (500 mg, 1.70 mmol). The mixture is stirred at rt for 1 h before it is diluted with ethylacetate, washed with sat. aq. NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give the hydroxyamidine ester intermediate. This material is dissolved in dioxane (3 mL) and the resulting solution is stirred at 85°C for 16 h. The solvent is evaporated and the crude product is purified by prep. HPLC (X-Bridge) to give 2-chloro-4-{3-[4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3,5-dimethyl-phenyl]-[1,2,4]oxadiazol-5-yl}-6-methyl-pyrimidine (93 mg) as a yellow solid.</li><li>b) To a solution of the above 2-chloro-6-methyl-pyrimidine intermediate (22 mg, 0.052 mmol) in dioxane (1 mL), ethylamine 70% in water (0.21 mL, 2.61 mmol) and 2M aq. NaOH (0.15 mL) are added. The mixture is stirred at 70°C for 18 h, then concentrated and purified by prep. HPLC (X-Bridge) to give (4-{3-[4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3,5-dimethyl-phenyl]-[1,2,4]-oxadiazol-5-yl}-6-methyl-pyrimidin-2-yl)-ethyl-amine (16 mg) as a pale yellow solid; LC-MS: t<sub>R</sub> = 1.12 min; [M+H]<sup>+</sup> = 440.21.<!-- EPO <DP n="57"> --></li><li>c) The above ispropylidenglycerol derivative is hydrolysed as described in Method A b) to give rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol.</li></ul></p><heading id="h0129"><b>Example 17</b></heading><heading id="h0130"><b>rac-3-{2,6-Dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol</b></heading><p id="p0152" num="0152">rac-3-{2,6-Dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxyl-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 6-methyl-2-methylamino-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.75 min*; [M+H]<sup>+</sup> = 386.15.</p><heading id="h0131"><b>Example 18</b></heading><heading id="h0132"><b>rac-3-{2,6-Dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol</b></heading><p id="p0153" num="0153">rac-3-{2,6-Dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 6-methyl-2-propylamino-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.85 min*; [M+H]<sup>+</sup> = 414.15.</p><heading id="h0133"><b>Example 19</b></heading><heading id="h0134"><b>rac-3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0154" num="0154">rac-3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 2-isopropyl-amino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.85 min*; [M+H]<sup>+</sup> = 414.12.</p><heading id="h0135"><b>Example 20</b></heading><heading id="h0136"><b>rac-3-{4-[5-(2-Isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0155" num="0155">rac-3-{4-[5-(2-Isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxyl-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol<!-- EPO <DP n="58"> --> using 2-isobutylamino-6-methyl-pyrimidine-4-carboxylic acid; white crystalline solid; LC-MS: t<sub>R</sub> = 0.90 min*; [M+H]<sup>+</sup> = 428.25; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 0.93 (d, <i>J</i> = 6.8 Hz, 6 H), 1.91 (m, 1 H), 2.35 (s, 6 H), 2.41 (s, 3 H), 3.18 (m, 2 H), 3.50 (t, <i>J</i> = 5.5 Hz, 2 H), 3.75 (dd, <i>J</i> = 5.5 and 8.8 Hz, 1 H), 3.79-3.91 (m, 2 H), 4.64 (t, <i>J</i> = 5.5 Hz, 1 H), 4.96 (d, <i>J</i> = 5.0 Hz, 1 H), 7.28 (s, 1 H), 7.65 (s br, 1 H), 7.76 (s, 2 H).</p><heading id="h0137"><b>Example 21</b></heading><heading id="h0138"><b>rac-3-{4-[5-(2-Dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0156" num="0156">rac-3-{4-[5-(2-Dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxyl-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 2-dimethyl-amino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.89 min*; [M+H]<sup>+</sup> = 400.11.</p><heading id="h0139"><b>Example 22</b></heading><heading id="h0140"><b>rac-3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0157" num="0157">rac-3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxyl-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 2-diethyl-amino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.02 min*; [M+H]<sup>+</sup> = 428.02.</p><heading id="h0141"><b>Example 23</b></heading><heading id="h0142"><b>rac-3-{4-[5-(2-(Ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0158" num="0158">rac-3-{4-[5-(2-(Ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 2-(ethyl-methyl)amino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.96 min*; [M+H]<sup>+</sup> = 414.10.</p><heading id="h0143"><b>Example 24</b></heading><!-- EPO <DP n="59"> --><heading id="h0144"><b>rac-3-{4-[5-(2-Ethoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0159" num="0159">rac-3-{4-[5-(2-Ethoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 2-ethoxy-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.81 min*; [M+H]<sup>+</sup> = 401.07.</p><heading id="h0145"><b>Example 25</b></heading><heading id="h0146"><b>rac-3-{2,6-Dimethyl-4-[5-(6-methyl-2-propoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol</b></heading><p id="p0160" num="0160">rac-3-{2,6-Dimethyl-4-[5-(6-methyl-2-propoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 6-methyl-2-propoxy-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.87 min*; [M+H]<sup>+</sup> = 415.08.</p><heading id="h0147"><b>Example 26</b></heading><heading id="h0148"><b>rac-3-{4-[5-(2-Isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0161" num="0161">rac-3-{4-[5-(2-Isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol is prepared in analogy to rac-3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol using 2-isopropoxy-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.86 min*; [M+H]<sup>+</sup> = 415.09.</p><heading id="h0149"><b>Examples 27 to 43</b></heading><p id="p0162" num="0162"><chemistry id="chem0026" num="0026"><img id="ib0026" file="imgb0026.tif" wi="92" he="53" img-content="chem" img-format="tif"/></chemistry></p><p id="p0163" num="0163">The following Examples are prepared starting from N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide and the appropriate pyrimidine-4-carboxylic acid in analogy to the procedure given in Example 1.<!-- EPO <DP n="60"> -->
<tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="33mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>2</sup></entry><entry namest="col4" nameend="col5" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle">Amount Form</entry></row></thead><tbody><row><entry align="center" valign="middle">27</entry><entry align="center" valign="middle">NHMe</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.80</entry><entry align="center" valign="middle">457.13</entry><entry align="center" valign="middle">28 mg white solid</entry></row><row><entry align="center" valign="middle">28</entry><entry align="center" valign="middle"><chemistry id="chem0027" num="0027"><img id="ib0027" file="imgb0027.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.91</entry><entry align="center" valign="middle">485.14</entry><entry align="center" valign="middle">86 mg yellow solid</entry></row><row><entry align="center" valign="middle">29</entry><entry align="center" valign="middle"><chemistry id="chem0028" num="0028"><img id="ib0028" file="imgb0028.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">1.05</entry><entry align="center" valign="middle">513.16</entry><entry align="center" valign="middle">47 mg yellow solid</entry></row><row><entry align="center" valign="middle">30</entry><entry align="center" valign="middle"><chemistry id="chem0029" num="0029"><img id="ib0029" file="imgb0029.tif" wi="16" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.95</entry><entry align="center" valign="middle">497.16</entry><entry align="center" valign="middle">11 mg white solid</entry></row><row><entry align="center" valign="middle">31</entry><entry align="center" valign="middle"><chemistry id="chem0030" num="0030"><img id="ib0030" file="imgb0030.tif" wi="18" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.87</entry><entry align="center" valign="middle">483.06</entry><entry align="center" valign="middle">8 mg white solid</entry></row><row><entry align="center" valign="middle">32</entry><entry align="center" valign="middle"><chemistry id="chem0031" num="0031"><img id="ib0031" file="imgb0031.tif" wi="23" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.92</entry><entry align="center" valign="middle">497.16</entry><entry align="center" valign="middle">37 mg yellow solid</entry></row><row><entry align="center" valign="middle">33</entry><entry align="center" valign="middle"><chemistry id="chem0032" num="0032"><img id="ib0032" file="imgb0032.tif" wi="17" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.93</entry><entry align="center" valign="middle">485.28</entry><entry align="center" valign="middle">72 mg yellow solid</entry></row><row><entry align="center" valign="middle">34</entry><entry align="center" valign="middle">NHMe</entry><entry align="center" valign="middle">nPr</entry><entry valign="middle" align="char" char=".">0.91</entry><entry align="center" valign="middle">485.09</entry><entry align="center" valign="middle">23 mg white solid</entry></row><row><entry align="center" valign="middle">35</entry><entry align="center" valign="middle">NHMe</entry><entry align="center" valign="middle">iBu</entry><entry valign="middle" align="char" char=".">0.93</entry><entry align="center" valign="middle">498.77</entry><entry align="center" valign="middle">23 mg yellow solid</entry></row><!-- EPO <DP n="61"> --><row><entry align="center" valign="middle">36</entry><entry align="center" valign="middle"><chemistry id="chem0033" num="0033"><img id="ib0033" file="imgb0033.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">iBu</entry><entry valign="middle" align="char" char=".">1.02</entry><entry align="center" valign="middle">527.2</entry><entry align="center" valign="middle">28 mg colorless wax</entry></row><row><entry align="center" valign="middle">37</entry><entry align="center" valign="middle"><chemistry id="chem0034" num="0034"><img id="ib0034" file="imgb0034.tif" wi="12" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">iBu</entry><entry valign="middle" align="char" char=".">1.06</entry><entry align="center" valign="middle">513.12</entry><entry align="center" valign="middle">40 mg yellow wax</entry></row><row><entry align="center" valign="middle">38</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.86</entry><entry align="center" valign="middle">458.05</entry><entry align="center" valign="middle">12 mg white solid</entry></row><row><entry align="center" valign="middle">39</entry><entry align="center" valign="middle"><chemistry id="chem0035" num="0035"><img id="ib0035" file="imgb0035.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.94</entry><entry align="center" valign="middle">486.31</entry><entry align="center" valign="middle">15 mg colorless wax</entry></row><row><entry align="center" valign="middle">40</entry><entry align="center" valign="middle"><chemistry id="chem0036" num="0036"><img id="ib0036" file="imgb0036.tif" wi="21" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.99</entry><entry align="center" valign="middle">500.33</entry><entry align="center" valign="middle">79 mg yellow solid</entry></row><row><entry align="center" valign="middle">41</entry><entry align="center" valign="middle">OEt</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.94</entry><entry align="center" valign="middle">486.10</entry><entry align="center" valign="middle">8 mg white solid</entry></row><row><entry align="center" valign="middle">42</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">nPr</entry><entry valign="middle" align="char" char=".">0.94</entry><entry align="center" valign="middle">486.13</entry><entry align="center" valign="middle">8 mg beige wax</entry></row><row><entry align="center" valign="middle">43</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">iBu</entry><entry valign="middle" align="char" char=".">0.97</entry><entry align="center" valign="middle">500.08</entry><entry align="center" valign="middle">47 mg colorless wax</entry></row></tbody></tgroup></table></tables></p><heading id="h0150"><b>Example 28:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.31 (m, 9 H), 2.38 (s, 3 H), 2.50 (s, 3 H), 2.56 (m, 1 H), 2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 3.34 (d, <i>J</i> = 2.8 Hz, 1 H), 3.55 (m, 1 H), 3.81 (m, 2 H), 3.91 (m, 1 H), 4.21 (m, 3 H), 4.32 (m, 1 H), 5.28 (m, 1 H), 6.99 (m, 1 H), 7.30 (s, 1 H), 7.91 (s, 1 H), 7.92 (s, 1 H).</heading><heading id="h0151"><b>Example 32:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.32 (m, 2 H), 0.57 (m, 2 H), 1.13 (m, 1 H), 1.31 (t, <i>J</i> = 7.5 Hz, 3 H), 2.38 (s, 3 H), 2.50 (s, 3 H), 2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 3.41 (t, <i>J</i> = 5.8 Hz, 2 H), 3.55<!-- EPO <DP n="62"> --> (m, 1 H), 3.81 (m, 2 H), 3.90 (m, 1 H), 4.20 (m, 3 H), 5.60 (m, 1 H), 7.04 (m, 1 H), 7.32 (s, 1 H), 7.89 (s, 1 H), 7.90 (s, 1 H).</heading><heading id="h0152"><b>Example 36:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.01 (d, <i>J</i> = 6.5 Hz, 6 H), 1.30 (m, 9 H), 2.22 (m, 1 H), 2.38 (m, 3 H), 2.59 (d, <i>J</i> = 7.3 Hz, 2 H), 2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 3.05 (s br, 1 H), 3.52 (m, 2 H), 3.81 (m, 2 H), 3.90 (m, 1 H), 4.20 (m, 3 H), 4.29 (m, 1 H), 5.31 (m, 1 H), 7.09 (s, 1 H), 7.29 (s, 1 H), 7.89 (s, 1 H), 7.90 (s, 1 H).</heading><heading id="h0153"><b>Example</b> 38: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.31 (t, <i>J</i> = 7.5 Hz, 3 H), 2.37 (m, 3 H), 2.64 (m, 3 H), 2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 3.55 (dd, <i>J</i> = 7.0, 5.5 Hz, 1 H), 3.81 (m, 2 H), 3.91 (m, 1 H), 4.16 (m, 3 H), 4.20 (m, 3 H), 7.13 (m, 1 H), 7.74 (s, 1 H), 7.88 (s, 1 H), 7.89 (s, 1 H).</heading><heading id="h0154"><b>Example 42:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.05 (t, <i>J</i> = 7.5 Hz, 3 H), 1.32 (t, <i>J</i> = 7.5 Hz, 3 H), 1.88 (m, 2 H), 2.39 (m, 3 H), 2.75 (m, 2 H), 2.85 (m, 2 H), 3.54 (m, 1 H), 3.82 (m, 2 H), 3.91 (m, 1 H), 4.17 (m, 3 H), 4.20 (m, 3 H), 7.03 (m, 1 H), 7.73 (s, 1 H), 7.90 (s, 1 H), 7.91 (s, 1 H).</heading><heading id="h0155"><b>Examples 44 to 45</b></heading><p id="p0164" num="0164"><chemistry id="chem0037" num="0037"><img id="ib0037" file="imgb0037.tif" wi="92" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0165" num="0165">The following Examples are prepared starting from N-((R)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide and the appropriate pyrimidine-4-carboxylic acid in analogy to the procedure given in Example 1.
<tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>2</sup></entry><entry namest="col4" nameend="col5" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">44</entry><entry align="center" valign="middle"><chemistry id="chem0038" num="0038"><img id="ib0038" file="imgb0038.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">1.02</entry><entry valign="middle" align="char" char="." charoff="31">500.49</entry><entry align="center" valign="middle">15 mg yellow solid</entry></row><!-- EPO <DP n="63"> --><row><entry align="center" valign="middle">45</entry><entry align="center" valign="middle"><chemistry id="chem0039" num="0039"><img id="ib0039" file="imgb0039.tif" wi="17" he="5" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.95</entry><entry valign="middle" align="char" char="." charoff="31">486.11</entry><entry align="center" valign="middle">7 mg yellow solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0156"><b>Examples 46 to 47</b></heading><p id="p0166" num="0166"><chemistry id="chem0040" num="0040"><img id="ib0040" file="imgb0040.tif" wi="92" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0167" num="0167">The following Examples are prepared starting from (S)-2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide and the appropriate pyrimidine-4-carboxylic acid in analogy to the procedure given in Example 1.
<tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>2</sup></entry><entry namest="col4" nameend="col5" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">46</entry><entry align="center" valign="middle"><chemistry id="chem0041" num="0041"><img id="ib0041" file="imgb0041.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.99</entry><entry valign="middle" align="char" char="." charoff="31">486.53</entry><entry align="center" valign="middle">12 mg yellow foam</entry></row><row><entry align="center" valign="middle">47</entry><entry align="center" valign="middle"><chemistry id="chem0042" num="0042"><img id="ib0042" file="imgb0042.tif" wi="17" he="5" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">472.11</entry><entry align="center" valign="middle">9 mg white solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0157"><b>Example 46:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.09 (d, <i>J</i> = 6.8 Hz, 6 H), 2.18 (m, 1 H), 2.33 (s, 6 H), 2.61 (s, 3 H), 3.54 (m, 1 H), 3.74 (m, 1 H), 3.85 (m, 2 H), 4.07 (s, 1 H), 4.17 (m, 4 H), 4.27 (d, <i>J</i> = 6.5 Hz, 2 H), 7.36 (t, <i>J</i> = 5.8 Hz, 1 H), 7.67 (s, 1 H), 7.81 (s, 2 H).</heading><!-- EPO <DP n="64"> --><heading id="h0158"><b>Examples 48 to 49</b></heading><p id="p0168" num="0168"><chemistry id="chem0043" num="0043"><img id="ib0043" file="imgb0043.tif" wi="92" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0169" num="0169">The following Examples are prepared starting from (R)-2-hydroxy-N-{2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2,6-dimethyl-phenoxy]-propyl}-acetamide and the appropriate pyrimidine-4-carboxylic acid in analogy to the procedure given in Example 1.
<tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>2</sup></entry><entry namest="col4" nameend="col5" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">48</entry><entry align="center" valign="middle"><chemistry id="chem0044" num="0044"><img id="ib0044" file="imgb0044.tif" wi="22" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.99</entry><entry valign="middle" align="char" char="." charoff="31">486.36</entry><entry align="center" valign="middle">9 mg yellow solid</entry></row><row><entry align="center" valign="middle">49</entry><entry align="center" valign="middle"><chemistry id="chem0045" num="0045"><img id="ib0045" file="imgb0045.tif" wi="17" he="5" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">472.09</entry><entry align="center" valign="middle">4 mg white solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0159"><b>Examples 50 to 57</b></heading><!-- EPO <DP n="65"> --><p id="p0170" num="0170"><chemistry id="chem0046" num="0046"><img id="ib0046" file="imgb0046.tif" wi="88" he="53" img-content="chem" img-format="tif"/></chemistry></p><p id="p0171" num="0171">The following Examples are prepared starting from (S)-N-(-3-[2-chloro-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide (Ex. 50 and 54) or (S)-2-hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2-methoxy-6-methyl-phenoxy]-propyl)-acetamide (Ex. 51 and 55) or (S)-2-hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-3-methyl-phenoxy]-propyl)-acetamide (Ex. 52 and 56) or (S)-2-hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-3-methoxy-phenoxy]-propyl)-acetamide (Ex. 53 and 57) and the appropriate pyrimidine-4-carboxylic acid in analogy to the procedure given in Example 1.
<tables id="tabl0005" num="0005"><table frame="all"><tgroup cols="8"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="14mm"/><colspec colnum="6" colname="col6" colwidth="17mm"/><colspec colnum="7" colname="col7" colwidth="19mm"/><colspec colnum="8" colname="col8" colwidth="33mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>3</sup></entry><entry align="center" valign="middle">R<sup>4</sup></entry><entry align="center" valign="middle">R<sup>6</sup></entry><entry namest="col6" nameend="col7" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">50</entry><entry align="center" valign="middle"><chemistry id="chem0047" num="0047"><img id="ib0047" file="imgb0047.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Cl</entry><entry valign="middle" align="char" char=".">0.92</entry><entry align="center" valign="middle">490.781</entry><entry align="center" valign="middle">188 mg yellow solid</entry></row><row><entry align="center" valign="middle">51</entry><entry align="center" valign="middle"><chemistry id="chem0048" num="0048"><img id="ib0048" file="imgb0048.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.88</entry><entry align="center" valign="middle">487.07</entry><entry align="center" valign="middle">13 mg beige solid</entry></row><row><entry align="center" valign="middle">52</entry><entry align="center" valign="middle"><chemistry id="chem0049" num="0049"><img id="ib0049" file="imgb0049.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.86</entry><entry align="center" valign="middle">457.02</entry><entry align="center" valign="middle">40 mg beige solid</entry></row><row><entry align="center" valign="middle">53</entry><entry align="center" valign="middle"><chemistry id="chem0050" num="0050"><img id="ib0050" file="imgb0050.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.80</entry><entry align="center" valign="middle">473.06</entry><entry align="center" valign="middle">9 mg beige solid</entry></row><!-- EPO <DP n="66"> --><row><entry align="center" valign="middle">54</entry><entry align="center" valign="middle"><chemistry id="chem0051" num="0051"><img id="ib0051" file="imgb0051.tif" wi="17" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Cl</entry><entry valign="middle" align="char" char=".">0.93</entry><entry align="center" valign="middle">492.01</entry><entry align="center" valign="middle">19 mg white solid</entry></row><row><entry align="center" valign="middle">55</entry><entry align="center" valign="middle"><chemistry id="chem0052" num="0052"><img id="ib0052" file="imgb0052.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.90</entry><entry align="center" valign="middle">488.11</entry><entry align="center" valign="middle">2.4 mg white solid</entry></row><row><entry align="center" valign="middle">56</entry><entry align="center" valign="middle"><chemistry id="chem0053" num="0053"><img id="ib0053" file="imgb0053.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.88</entry><entry align="center" valign="middle">457.95</entry><entry align="center" valign="middle">17 mg beige solid</entry></row><row><entry align="center" valign="middle">57</entry><entry align="center" valign="middle"><chemistry id="chem0054" num="0054"><img id="ib0054" file="imgb0054.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.82</entry><entry align="center" valign="middle">473.97</entry><entry align="center" valign="middle">7 mg yellow glass</entry></row></tbody></tgroup></table></tables></p><heading id="h0160"><b>Example 51:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.29 (d, <i>J</i> = 6.3 Hz, 6 H), 2.35 (s, 3 H), 2.48 (s, 3 H), 3.47 (m, 1 H), 3.73 (m, 1 H), 3.96 (m, 4 H), 4.09 (m, 2 H), 4.17 (m, 2 H), 4.30 (m, 1 H), 5.30 (m, 1 H), 7.17 (m, 1 H), 7.28 (s, 1 H), 7.56 (d, <i>J</i> = 1.5 Hz, 1 H), 7.67 (s, 1 H).</heading><heading id="h0161"><b>Example 54:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.47 (d, <i>J</i> = 6.3 Hz, 6 H), 2.43 (s, 3 H), 2.63 (s, 3 H), 2.82 (s br, 1H), 3.57 (m, 2 H), 3.81 (ddd, <i>J</i> = 14.1, 6.5, 3.3 Hz, 1 H), 4.00 (m, 1 H), 4.06 (m, 1 H), 4.23 (m, 3 H), 5.48 (m, 1 H), 7.08 (m, 1 H), 7.69 (s, 1 H), 7.95 (d, <i>J</i> = 1.5 Hz, 1 H), 8.09 (d, <i>J</i> = 2.3 Hz, 1 H).</heading><heading id="h0162"><b>Example 56:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.47 (d, <i>J</i> = 6.0 Hz, 6 H), 2.61 (s, 3 H), 2.68 (s, 3 H), 3.53 (m, 1 H), 3.72 (m, 1 H), 4.05 (d, <i>J</i> = 4.5 Hz, 2 H), 4.19 (m, 3 H), 5.48 (m, 1 H), 6.87 (m, 2 H), 7.15 (m, 1 H), 7.67 (s, 1 H), 8.06 (d, <i>J</i> = 8.8 Hz, 1 H).</heading><heading id="h0163"><b>Examples 58 to 73</b></heading><p id="p0172" num="0172"><chemistry id="chem0055" num="0055"><img id="ib0055" file="imgb0055.tif" wi="83" he="39" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="67"> --></p><p id="p0173" num="0173">The following Examples are prepared starting from (R)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-ethyl-N-hydroxy-5-methyl-benzamidine or (R)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine and the appropriate pyrimidine-4-carboxylic acid in analogy to Method A given in Example 16.
<tables id="tabl0006" num="0006"><table frame="all"><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="18mm"/><colspec colnum="7" colname="col7" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>2</sup></entry><entry align="center" valign="middle">R<sup>4</sup></entry><entry namest="col5" nameend="col6" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">58</entry><entry align="center" valign="middle">NHMe</entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.87</entry><entry valign="middle" align="char" char="." charoff="31">400.07</entry><entry align="center" valign="middle">6 mg white solid</entry></row><row><entry align="center" valign="middle">59</entry><entry align="center" valign="middle"><chemistry id="chem0056" num="0056"><img id="ib0056" file="imgb0056.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">428.09</entry><entry align="center" valign="middle">30 mg yellow solid</entry></row><row><entry align="center" valign="middle">60</entry><entry align="center" valign="middle"><chemistry id="chem0057" num="0057"><img id="ib0057" file="imgb0057.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">1.00</entry><entry valign="middle" align="char" char="." charoff="31">442.04</entry><entry align="center" valign="middle">23 mg yellow oil</entry></row><row><entry align="center" valign="middle">61</entry><entry align="center" valign="middle"><chemistry id="chem0058" num="0058"><img id="ib0058" file="imgb0058.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">1.11</entry><entry valign="middle" align="char" char="." charoff="31">456.10</entry><entry align="center" valign="middle">24 mg yellow oil</entry></row><row><entry align="center" valign="middle">62</entry><entry align="center" valign="middle"><chemistry id="chem0059" num="0059"><img id="ib0059" file="imgb0059.tif" wi="16" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">1.00</entry><entry valign="middle" align="char" char="." charoff="31">440.06</entry><entry align="center" valign="middle">23 mg yellow solid</entry></row><row><entry align="center" valign="middle">63</entry><entry align="center" valign="middle"><chemistry id="chem0060" num="0060"><img id="ib0060" file="imgb0060.tif" wi="18" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">425.99</entry><entry align="center" valign="middle">16 mg yellow wax</entry></row><row><entry align="center" valign="middle">64</entry><entry align="center" valign="middle"><chemistry id="chem0061" num="0061"><img id="ib0061" file="imgb0061.tif" wi="22" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">440.07</entry><entry align="center" valign="middle">18 mg white solid</entry></row><row><entry align="center" valign="middle">65</entry><entry align="center" valign="middle"><chemistry id="chem0062" num="0062"><img id="ib0062" file="imgb0062.tif" wi="17" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">428.09</entry><entry align="center" valign="middle">63 mg yellow solid</entry></row><!-- EPO <DP n="68"> --><row><entry align="center" valign="middle">66</entry><entry align="center" valign="middle">NHMe</entry><entry align="center" valign="middle">iBu</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.98</entry><entry valign="middle" align="char" char="." charoff="31">442.02</entry><entry align="center" valign="middle">11 mg yellow solid</entry></row><row><entry align="center" valign="middle">67</entry><entry align="center" valign="middle">NHMe</entry><entry align="center" valign="middle">nPr</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">428.11</entry><entry align="center" valign="middle">12 mg yellow solid</entry></row><row><entry align="center" valign="middle">68</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">401.02</entry><entry align="center" valign="middle">5 mg beige solid</entry></row><row><entry align="center" valign="middle">69</entry><entry align="center" valign="middle"><chemistry id="chem0063" num="0063"><img id="ib0063" file="imgb0063.tif" wi="17" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.98</entry><entry valign="middle" align="char" char="." charoff="31">429.05</entry><entry align="center" valign="middle">15 mg white solid</entry></row><row><entry align="center" valign="middle">70</entry><entry align="center" valign="middle"><chemistry id="chem0064" num="0064"><img id="ib0064" file="imgb0064.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">1.03</entry><entry valign="middle" align="char" char="." charoff="31">442.87</entry><entry align="center" valign="middle">61 mg yellow solid</entry></row><row><entry align="center" valign="middle">71</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">nPr</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.99</entry><entry valign="middle" align="char" char="." charoff="31">429.08</entry><entry align="center" valign="middle">18 mg beige wax</entry></row><row><entry align="center" valign="middle">72</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">iBu</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">1.02</entry><entry valign="middle" align="char" char="." charoff="31">442.91</entry><entry align="center" valign="middle">14 mg white solid</entry></row><row><entry align="center" valign="middle">73</entry><entry align="center" valign="middle"><chemistry id="chem0065" num="0065"><img id="ib0065" file="imgb0065.tif" wi="17" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.93</entry><entry valign="middle" align="char" char="." charoff="31">428.01</entry><entry align="center" valign="middle">4 mg yellow solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0164"><b>Example 60:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.09 (d, <i>J</i> = 6.5 Hz, 6 H), 1.31 (t, <i>J</i> = 7.5 Hz, 3 H), 2.07 (m, 1 H), 2.37 (s, 3 H), 2.73 (m, 5 H), 3.56 (t, <i>J</i> = 5.8 Hz, 2 H), 3.82 (m, 1 H), 3.89 (m, 3 H), 4.16 (m, 1 H), 7.40 (s, 1 H), 7.77 (s, 1 H), 7.79 (s, 1 H), 8.85 (s, 1 H).</heading><heading id="h0165"><b>Example 65:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.24-1.37 (m, 9 H), 2.37 (s, 3 H), 2.74 (m, 5 H), 3.20 (s br, 1H), 3.57 (quint, <i>J</i> = 6.8 Hz, 2 H), 3.83 (m, 1 H), 3.91 (m, 3 H), 4.17 (m, 1 H), 5.53 (s, 1 H), 7.30 (s, 1 H), 7.87 (s, 1 H), 7.89 (s, 1 H).</heading><!-- EPO <DP n="69"> --><heading id="h0166"><b>Example 69:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.32 (t, <i>J</i> = 7.5 Hz, 3 H), 1.47 (d, <i>J</i> = 6.3 Hz, 6 H), 2.18 (m, 1 H), 2.40 (s, 3 H), 2.62 (s, 3 H), 2.76 (q, <i>J</i> = 7.5 Hz, 2 H), 2.81 (s br, 1 H), 3.85 (m, 1 H), 3.94 (m, 3 H), 4.17 (m, 1 H), 5.49 (hept, <i>J</i> = 6.0 Hz, 1 H), 7.70 (s, 1 H), 7.89 (s, 1 H), 7.90 (s, 1 H).</heading><heading id="h0167"><b>Example 71:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.05 (t, <i>J</i> = 7.3 Hz, 3 H), 1.33 (t, <i>J</i> = 7.5 Hz, 3 H), 1.88 (h, <i>J</i> = 7.5 Hz, 2 H), 2.09 (m, 1 H), 2.41 (s, 3 H), 2.74 (s br, 1 H), 2.77 (q, <i>J</i> = 7.8 Hz, 2 H), 2.85 (m, 2 H), 3.85 (m, 1 H), 3.92 (m, 1 H), 3.96 (m, 2 H), 4.17 (s, 4 H), 7.74 (s, 1 H), 7.91 (s, 1 H), 7.92 (s, 1 H).</heading><heading id="h0168"><b>Example 74</b></heading><heading id="h0169"><b>rac-3-{4-[5-(2-Methoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0174" num="0174">The title compound is prepared in analogy to Example 16 (Method A) starting from 2-methoxy-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 0.88 min; [M+H]<sup>+</sup> = 387.11.</p><heading id="h0170"><b>Examples 75 to 76</b></heading><p id="p0175" num="0175"><chemistry id="chem0066" num="0066"><img id="ib0066" file="imgb0066.tif" wi="83" he="39" img-content="chem" img-format="tif"/></chemistry></p><p id="p0176" num="0176">The following Examples are prepared starting from (<i>S</i>)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-ethyl-N-hydroxy-5-methyl-benzamidine or (<i>S</i>)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3,5-dimethyl-benzamidine and 6-ethyl-2-ethylamino-pyrimidine-4-carboxylic acid in analogy to Method A given in Example 16.<!-- EPO <DP n="70"> -->
<tables id="tabl0007" num="0007"><table frame="all"><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="21mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="18mm"/><colspec colnum="7" colname="col7" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>2</sup></entry><entry align="center" valign="middle">R<sup>4</sup></entry><entry namest="col5" nameend="col6" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">75</entry><entry align="center" valign="middle"><chemistry id="chem0067" num="0067"><img id="ib0067" file="imgb0067.tif" wi="17" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry align="center" valign="middle">Et</entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">428.09</entry><entry align="center" valign="middle">11 mg yellow solid</entry></row><row><entry align="center" valign="middle">76</entry><entry align="center" valign="middle"><chemistry id="chem0068" num="0068"><img id="ib0068" file="imgb0068.tif" wi="17" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Et</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.93</entry><entry valign="middle" align="char" char="." charoff="31">414.07</entry><entry align="center" valign="middle">15 mg yellow solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0171"><b>Example 75</b>: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25-1.37 (m, 9 H), 2.39 (s, 3 H), 2.61 (s, 1 H), 2.75 (m, 4 H), 2.89 (s br, 1 H), 3.58 (quint, <i>J</i> = 7.0 Hz, 2 H), 3.87 (m, 2 H), 3.96 (m, 2 H), 4.17 (m, 1 H), 5.42 (s br, 1 H), 7.32 (s, 1 H), 7.90 (s, 1 H), 7.91 (s, 1 H).</heading><heading id="h0172"><b>Examples 77 to 84</b></heading><p id="p0177" num="0177"><chemistry id="chem0069" num="0069"><img id="ib0069" file="imgb0069.tif" wi="79" he="39" img-content="chem" img-format="tif"/></chemistry></p><p id="p0178" num="0178">The following Examples are prepared starting from (<i>R</i>)-3-chloro-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-5-methyl-benzamidine (Ex. 77 and 81) or (<i>R</i>)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3-methoxy-5-methyl-benzamidine (Ex. 78 and 82) or (<i>R</i>)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-2-methoxy-benzamidine (Ex. 79 and 83) or (<i>R</i>)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-2-methyl-benzamidine (Ex. 80 and 84) and the appropriate pyrimidine-4-carboxylic acid in analogy to Method A given in Example 16.
<tables id="tabl0008" num="0008"><table frame="all"><tgroup cols="8"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="21mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="14mm"/><colspec colnum="6" colname="col6" colwidth="18mm"/><colspec colnum="7" colname="col7" colwidth="18mm"/><colspec colnum="8" colname="col8" colwidth="33mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>3</sup></entry><entry align="center" valign="middle">R<sup>4</sup></entry><entry align="center" valign="middle">R<sup>6</sup></entry><entry namest="col6" nameend="col7" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">77</entry><entry align="center" valign="middle"><chemistry id="chem0070" num="0070"><img id="ib0070" file="imgb0070.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Cl</entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">433.94</entry><entry align="center" valign="middle">12 mg yellow solid</entry></row><!-- EPO <DP n="71"> --><row><entry align="center" valign="middle">78</entry><entry align="center" valign="middle"><chemistry id="chem0071" num="0071"><img id="ib0071" file="imgb0071.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">430.05</entry><entry align="center" valign="middle">16 mg white solid</entry></row><row><entry align="center" valign="middle">79</entry><entry align="center" valign="middle"><chemistry id="chem0072" num="0072"><img id="ib0072" file="imgb0072.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.90</entry><entry valign="middle" align="char" char="." charoff="31">400.06</entry><entry align="center" valign="middle">8 mg beige solid</entry></row><row><entry align="center" valign="middle">80</entry><entry align="center" valign="middle"><chemistry id="chem0073" num="0073"><img id="ib0073" file="imgb0073.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.83</entry><entry valign="middle" align="char" char="." charoff="31">415.99</entry><entry align="center" valign="middle">16 mg colorless wax</entry></row><row><entry align="center" valign="middle">81</entry><entry align="center" valign="middle"><chemistry id="chem0074" num="0074"><img id="ib0074" file="imgb0074.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">Cl</entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">434.91</entry><entry align="center" valign="middle">7.5 mg white solid</entry></row><row><entry align="center" valign="middle">82</entry><entry align="center" valign="middle"><chemistry id="chem0075" num="0075"><img id="ib0075" file="imgb0075.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">Me</entry><entry valign="middle" align="char" char=".">0.94</entry><entry valign="middle" align="char" char="." charoff="31">430.98</entry><entry align="center" valign="middle">14 mg white solid</entry></row><row><entry align="center" valign="middle">83</entry><entry align="center" valign="middle"><chemistry id="chem0076" num="0076"><img id="ib0076" file="imgb0076.tif" wi="17" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">Me</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">401.04</entry><entry align="center" valign="middle">15 mg beige solid</entry></row><row><entry align="center" valign="middle">84</entry><entry align="center" valign="middle"><chemistry id="chem0077" num="0077"><img id="ib0077" file="imgb0077.tif" wi="17" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle">OMe</entry><entry align="center" valign="middle">H</entry><entry align="center" valign="middle">H</entry><entry valign="middle" align="char" char=".">0.85</entry><entry valign="middle" align="char" char="." charoff="31">417.00</entry><entry align="center" valign="middle">15 mg yellow solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0173"><b>Example 78:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.30 (d, <i>J</i> = 6.5 Hz, 6 H), 2.29 (m, 1 H), 2.39 (s, 3 H), 2.50 (s, 3 H), 3.41 (d, <i>J</i> = 4.3 Hz, 1 H), 3.83 (m, 2 H), 3.99 (m, 3 H), 4.06 (m, 2 H), 4.16 (m, 1 H), 4.31 (m, 1 H), 5.27 (m, 1 H), 7.30 (s, 1 H), 7.60 (d, <i>J</i> = 1.5 Hz, 1 H), 7.71 (d, <i>J</i> = 1.3 Hz, 1 H).</heading><heading id="h0174"><b>Example 83:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.47 (d, <i>J</i> = 6.3 Hz, 6 H), 2.07 (t, <i>J</i> = 5.8 Hz, 1 H), 2.62 (s, 3 H), 2.65 (d, <i>J</i> = 4.0 Hz, 1 H), 2.70 (s, 3 H), 3.81 (m, 1 H), 3.90 (m, 1 H), 4.16 (m, 3 H), 5.48 (m, 1 H), 6.90 (s, 1 H), 7.69 (s, 2 H), 8.10 (d, <i>J</i> = 8.8 Hz, 1 H).</heading><heading id="h0175"><b>Example 85</b></heading><!-- EPO <DP n="72"> --><heading id="h0176"><b>(S)-N-(3-{2-Ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide</b></heading><p id="p0179" num="0179"><ul><li>a) To a solution of 4-benzyloxy-3-ethyl-5-methyl-benzoic acid (893 mg, 3.30 mmol) in DMF (20 mL), DIPEA (1.70 mL, 9.9 mmol) is added followed by TBTU (1.27 g, 3.96 mmol). The reaction mixture is stirred for 15 min before adding N-hydroxy-2-isopropylamino-6-methyl-pyrimidine-4-carboxamidine (691 mg, 3.30 mmol). After 3 h, the reaction mixture is diluted with EtOAc, and the org. solution is washed with sat. aq. NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered and evaporated to give the hydroxyamidine ester intermediate. This material is dissolved in dioxane (10 mL) and the resulting solution is stirred at 95°C for 7 days. The solvent is removed in vacuo and the crude compound is purified by CC on silica gel to give the desired {4-[5-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-6-methyl-pyrimidin-2-yl}-isopropyl-amine (322 mg) as a yellow oil; LC-MS: t<sub>R</sub> = 1.19 min; [M+H]<sup>+</sup> = 444.09.</li><li>b) The above benzyloxy derivative (321 mg, 0.72 mmol) is dissolved in EtOAc (3 mL) and a solution of 33% HBr in acetic acid (1 mL) is added. The reaction mixture is stirred at rt for 18 h, then is diluted with EtOAc and neutralized with sat. aq. NaHCO<sub>3</sub>. The org. phase is dried over MgSO<sub>4</sub>, filtered, and evaporated to give 2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenol (278 mg) as a yellow solid; LC-MS: t<sub>R</sub> = 0.99; [M+H]<sup>+</sup> = 354.05.</li><li>c) 2-Ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methylphenol is reacted with R-epichlorhydrine in analogy to Intermediate 1 to give (S)-{4-[5-(3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-6-methyl-pyrimidin-2-yl}-iso-propyl-amine as a yellow oil; LC-MS: t<sub>R</sub> = 1.10 min; [M+H]<sup>+</sup> = 410.55.</li><li>d) A solution of (S)-{4-[5-(3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-6-methyl-pyrimidin-2-yl}-iso-propyl-amine (48 mg, 0.12 mmol) in 7M NH<sub>3</sub> in MeOH (5 mL) is stirred at 65°C for 24 h. Volatiles are removed in vacuo to give the crude 1-amino-3-{2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-propan-2-ol as a yellow oil (43 mg); LC-MS: t<sub>R</sub> = 0.76 min; [M+H]<sup>+</sup> = 426.80.</li><li>e) To a solution of crude 1-amino-3-{2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-propan-2-ol (43 mg, 97 µmol) in DMF, glycolic acid (11 mg, 146 µmol), HOBt (20 mg, 146 µmol), and EDC hydrochloride (28 mg, 146 µmol) are added. The mixture is stirred at rt for 18 h before it is diluted with sat. aq.<!-- EPO <DP n="73"> --> NaHCO<sub>3</sub> and extracted twice with EtOAc. The combined org. extracts are dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product is purified by prep. TLC plates with DCM containing 10% of 7M NH<sub>3</sub> in MeOH to give (S)-N-(3-{2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide (21 mg) as a white solid; LC-MS: t<sub>R</sub> = 0.85 min; [M+H]<sup>+</sup> = 485.14; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.29 (m, 9 H), 2.35 (m, 3 H), 2.46 (s, 3 H), 2.72 (q, <i>J</i> = 7.5 Hz, 2 H), 3.52 (m, 1 H), 3.76 (m, 1 H), 3.87 (m, 3 H), 4.20 (m, 3 H), 4.31 (m, 1 H), 5.31 (m, 1 H), 7.22 (s, 1 H), 7.25 (t, <i>J</i> = 6.0 Hz, 1 H), 7.89 (s, 1 H), 7.91 (s, 1 H).</li></ul></p><heading id="h0177"><b>Example 86</b></heading><heading id="h0178"><b>(S)-N-[3-(2-Ethyl-4-{3-[2-(isobutyl-methyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide</b></heading><p id="p0180" num="0180">The title compound is prepared in analogy to Example 85 using 2-N-isobutyl-N-methylamino-6-methyl-pyrimidine-4-carboxylic acid; LC-MS: t<sub>R</sub> = 1.0 min; [M+1]<sup>+</sup> = 513.16.</p><heading id="h0179"><b>Examples 87 to 94</b></heading><p id="p0181" num="0181"><chemistry id="chem0078" num="0078"><img id="ib0078" file="imgb0078.tif" wi="61" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0182" num="0182">Examples 87, 88, 89 and 90 are prepared from Intermediate 1, 2, 3 and 4, respectively, following the procedures described for Example 85 (paragraph c) to e)).</p><p id="p0183" num="0183">Examples 91, 92, 93 and 94 are prepared from Intermediate 1, 2, 3 and 4, respectively, as described below:</p><p id="p0184" num="0184">To a solution of 1 eq. of Intermediate 1, 2, 3, or 4 (concentration: 0.02 mol/L) in iPrOH, 3M aq. NaOH followed by S-3-chloro-1,2-propanediol (10 eq.) is added. The reaction mixture is stirred at rt for 15-48 h (monitored by LC-MS), and is then diluted with EtOAc and washed with 1 M aq. NaOH followed by brine. The org. solution is dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude compound is purified by prep. HPLC or prep. TLC.<!-- EPO <DP n="74"> -->
<tables id="tabl0009" num="0009"><table frame="all"><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="37mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="18mm"/><colspec colnum="7" colname="col7" colwidth="27mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">Prepared from Intermediate</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>5</sup></entry><entry namest="col5" nameend="col6" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">87</entry><entry align="center" valign="middle">1</entry><entry align="center" valign="middle"><chemistry id="chem0079" num="0079"><img id="ib0079" file="imgb0079.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0080" num="0080"><img id="ib0080" file="imgb0080.tif" wi="33" he="24" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.83</entry><entry valign="middle" align="char" char="." charoff="31">485.2</entry><entry align="center" valign="middle">15 mg yellow solid</entry></row><row><entry align="center" valign="middle">88</entry><entry align="center" valign="middle">2</entry><entry align="center" valign="middle"><chemistry id="chem0081" num="0081"><img id="ib0081" file="imgb0081.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0082" num="0082"><img id="ib0082" file="imgb0082.tif" wi="33" he="25" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.87</entry><entry valign="middle" align="char" char="." charoff="31">498.83</entry><entry align="center" valign="middle">19 mg yellow solid</entry></row><row><entry align="center" valign="middle">89</entry><entry align="center" valign="middle">3</entry><entry align="center" valign="middle"><chemistry id="chem0083" num="0083"><img id="ib0083" file="imgb0083.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0084" num="0084"><img id="ib0084" file="imgb0084.tif" wi="33" he="25" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.88</entry><entry valign="middle" align="char" char="." charoff="31">486.14</entry><entry align="center" valign="middle">20 mg yellow solid</entry></row><row><entry align="center" valign="middle">90</entry><entry align="center" valign="middle">4</entry><entry align="center" valign="middle"><chemistry id="chem0085" num="0085"><img id="ib0085" file="imgb0085.tif" wi="22" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0086" num="0086"><img id="ib0086" file="imgb0086.tif" wi="33" he="25" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">500.32</entry><entry align="center" valign="middle">13 mg yellow solid</entry></row><row><entry align="center" valign="middle">91</entry><entry align="center" valign="middle">1</entry><entry align="center" valign="middle"><chemistry id="chem0087" num="0087"><img id="ib0087" file="imgb0087.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0088" num="0088"><img id="ib0088" file="imgb0088.tif" wi="26" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.87</entry><entry valign="middle" align="char" char="." charoff="31">428.11</entry><entry align="center" valign="middle">7 mg white solid</entry></row><row><entry align="center" valign="middle">92</entry><entry align="center" valign="middle">2</entry><entry align="center" valign="middle"><chemistry id="chem0089" num="0089"><img id="ib0089" file="imgb0089.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0090" num="0090"><img id="ib0090" file="imgb0090.tif" wi="27" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">442.04</entry><entry align="center" valign="middle">5 mg white solid</entry></row><row><entry align="center" valign="middle">93</entry><entry align="center" valign="middle">3</entry><entry align="center" valign="middle"><chemistry id="chem0091" num="0091"><img id="ib0091" file="imgb0091.tif" wi="17" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0092" num="0092"><img id="ib0092" file="imgb0092.tif" wi="27" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">429.09</entry><entry align="center" valign="middle">6 mg yellow solid</entry></row><!-- EPO <DP n="75"> --><row><entry align="center" valign="middle">94</entry><entry align="center" valign="middle">4</entry><entry align="center" valign="middle"><chemistry id="chem0093" num="0093"><img id="ib0093" file="imgb0093.tif" wi="22" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0094" num="0094"><img id="ib0094" file="imgb0094.tif" wi="26" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.01</entry><entry valign="middle" align="char" char="." charoff="31">443.21</entry><entry align="center" valign="middle">6 mg yellow oil</entry></row></tbody></tgroup></table></tables></p><heading id="h0180"><b>Example 89:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.29 (t, <i>J</i> = 7.3 Hz, 3 H), 1.47 (d, <i>J</i> = 6.3 Hz, 6 H), 2.38 (s, 3 H), 2.60 (s, 3 H), 2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 3.55 (m, 2 H), 3.77 (m, 1 H), 3.87 (m, 2 H), 4.18 (m, 3 H), 5.47 (m, 1 H), 5.70 (m, 1 H), 7.22 (m, 1 H), 7.69 (s, 1 H), 7.88 (s, 1 H), 7.89 (s, 1 H).</heading><heading id="h0181"><b>Example 91:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.31 (d, <i>J</i> = 6.5 Hz, 6 H), 1.33 (t, <i>J</i> = 7.0 Hz, 3 H), 2.41 (s, 3 H), 2.48 (s, 3 H), 2.72 (m, 1 H), 2.77 (q, <i>J</i> = 7.5 Hz, 2 H), 3.85 (m, 1 H), 3.91 (m, 1 H), 3.96 (m, 2 H), 4.18 (m, 1 H), 4.32 (m, 1 H), 5.21 (m, 1 H), 7.89 (s, 1 H), 7.91 (m, 1 H).</heading><heading id="h0182"><b>Examples 95 to 99</b></heading><p id="p0185" num="0185"><chemistry id="chem0095" num="0095"><img id="ib0095" file="imgb0095.tif" wi="61" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0186" num="0186">Examples 95 to 99 are prepared in analogy to Examples 87-94 starting from Intermediate 5, 6 and 7, respectively.
<tables id="tabl0010" num="0010"><table frame="all"><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="14mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="30mm"/><colspec colnum="4" colname="col4" colwidth="43mm"/><colspec colnum="5" colname="col5" colwidth="15mm"/><colspec colnum="6" colname="col6" colwidth="19mm"/><colspec colnum="7" colname="col7" colwidth="21mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">Prepared from Intermediate</entry><entry align="center" valign="middle">R<sup>1</sup></entry><entry align="center" valign="middle">R<sup>5</sup></entry><entry namest="col5" nameend="col6" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">95</entry><entry align="center" valign="middle">5</entry><entry align="center" valign="middle"><chemistry id="chem0096" num="0096"><img id="ib0096" file="imgb0096.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0097" num="0097"><img id="ib0097" file="imgb0097.tif" wi="34" he="26" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.85</entry><entry valign="middle" align="char" char="." charoff="30">501.13</entry><entry align="center" valign="middle">15 mg yellow solid</entry></row><!-- EPO <DP n="76"> --><row><entry align="center" valign="middle">96</entry><entry align="center" valign="middle">7</entry><entry align="center" valign="middle"><chemistry id="chem0098" num="0098"><img id="ib0098" file="imgb0098.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0099" num="0099"><img id="ib0099" file="imgb0099.tif" wi="34" he="26" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.02</entry><entry valign="middle" align="char" char="." charoff="30">516.30</entry><entry align="center" valign="middle">12 mg white solid</entry></row><row><entry align="center" valign="middle">97</entry><entry align="center" valign="middle">5</entry><entry align="center" valign="middle"><chemistry id="chem0100" num="0100"><img id="ib0100" file="imgb0100.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0101" num="0101"><img id="ib0101" file="imgb0101.tif" wi="27" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.89</entry><entry valign="middle" align="char" char="." charoff="30">444.08</entry><entry align="center" valign="middle">9 mg yellow solid</entry></row><row><entry align="center" valign="middle">98</entry><entry align="center" valign="middle">6</entry><entry align="center" valign="middle"><chemistry id="chem0102" num="0102"><img id="ib0102" file="imgb0102.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0103" num="0103"><img id="ib0103" file="imgb0103.tif" wi="27" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.93</entry><entry valign="middle" align="char" char="." charoff="30">458.03</entry><entry align="center" valign="middle">12 mg yellow solid</entry></row><row><entry align="center" valign="middle">99</entry><entry align="center" valign="middle">7</entry><entry align="center" valign="middle"><chemistry id="chem0104" num="0104"><img id="ib0104" file="imgb0104.tif" wi="22" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center" valign="middle"><chemistry id="chem0105" num="0105"><img id="ib0105" file="imgb0105.tif" wi="27" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.07</entry><entry valign="middle" align="char" char="." charoff="30">459.73</entry><entry align="center" valign="middle">7 mg yellow wax</entry></row></tbody></tgroup></table></tables></p><heading id="h0183"><b>Example 96: <sup>1</sup></b>H NMR (CDCl<sub>3</sub>): δ 1.10 (d, <i>J</i> = 6.8 Hz, 6 H), 1.30 (t, <i>J</i> = 7.5 Hz, 3 H), 2.20 (m, 1 H), 2.37 (s, 3 H), 2.59 (s, 3 H), 2.73 (q, <i>J</i> = 7.8 Hz, 2 H), 3.54 (m, 1 H), 3.77 (m, 1 H), 3.86 (m, 2 H), 4.21 (m, 5 H), 7.23 (t, <i>J</i> = 5.8 Hz, 1 H), 7.70 (d, <i>J</i> = 1.8 Hz, 1 H), 7.74 (d, <i>J</i> = 2.0 Hz, 1 H), 7.78 (s, 1 H).</heading><heading id="h0184"><b>Example 97:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.04 (d, <i>J</i> = 6.5 Hz, 6 H), 1.33 (t, <i>J</i> = 7.5 Hz, 3 H), 1.96 (m, 1 H), 2.07 (s br, 1 H), 2.41 (s, 3 H), 2.47 (s, 3 H), 2.72 (S br, 1 H), 2.77 (q, <i>J</i> = 7.3 Hz, 2 H), 3.35 (t, <i>J</i> = 6.3 Hz, 2 H), 3.84 (m, 1 H), 3.91 (m, 1 H), 3.96 (m, 2 H), 4.18 (m, 1 H), 5.26 (m, 1 H), 7.42 (s, 1 H), 7.75 (d, <i>J</i> = 2.0 Hz, 1 H), 7.78 (d, <i>J</i> = 2.0 Hz, 1 H).</heading><heading id="h0185"><b>Example 100</b></heading><heading id="h0186"><b>2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,3-diol</b></heading><p id="p0187" num="0187">To a solution of Intermediate 11 (150 mg, 0.41 mmol) in acetonitrile (10 mL) are added K<sub>2</sub>CO<sub>3</sub> (80 mg, 0.61 mmol) and dimethylchloromalonate (82 mg, 0.49 mmol). The reaction mixture is stirred at 65°C for 3 h, and is then diluted with EtOAc, washed with water, dried over MgSO<sub>4</sub>, filtered and evaporated. The residue is purified by prep. TLC (eluting with Heptane/EA 4:1) and is then dissolved in ethanol (10 mL). NaBH<sub>4</sub> (60 mg, 1.59 mmol) is added and the reaction mixture is stirred at rt for 3 h. After cooling to 5°C, water is added<!-- EPO <DP n="77"> --> and the compound is extracted twice with EtOAc. The org. phase is dried over MgSO<sub>4</sub>, filtered, concentrated and purified by prep. TLC (eluting with Heptane/EA 1:1) to give the title compound as a yellow wax (54 mg); LC-MS: t<sub>R</sub> = 1.06 min; [M+H]<sup>+</sup> = 442.0.</p><heading id="h0187"><b>Example 101</b></heading><heading id="h0188"><b>2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxymethyl}-propane-1,3-diol</b></heading><p id="p0188" num="0188">2-Diethylamino-6-methyl-pyrimidine-4-carboxylic acid (180 mg, 0.86 mmol) is reacted with 4-(2,2-dimethyl-[1,3]dioxan-5-ylmethoxy)-3-ethyl-N-hydroxy-5-methyl-benzamidine (277 mg, 0.86 mmol) in analogy to isopropyl-{4-methyl-6-[3-(4-vinyl-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrimidin-2-yl}-amine (Intermediate 8) using HOBt and EDC followed by cylization in dioxane to give the oxadiazole intermediate (150 mg). The acetal function is then hydrolyzed with 4M HCl in dioxane (5 mL) to give the title compound as a yellow solid (92 mg) after purification by prep. TLC (eluting with DCM/MeOH 9:1); LC-MS: t<sub>R</sub> = 1.10 min; [M+H]<sup>+</sup> = 456.14.</p><heading id="h0189"><b>Example 102</b></heading><heading id="h0190"><b>2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethanol</b></heading><p id="p0189" num="0189">To a solution of Intermediate 11 (1.5 g, 4.08 mmol) in isopropanol (20 mL) is added 3M aq. NaOH (5 mL) followed by bromoethanol (2.90 mL, 40.8 mmol). The reaction mixture is stirred at rt for 15 h, and is then diluted with EtOAc. The org. solution is washed with 1M aq. NaOH followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude compound is purified by CC (eluting with Heptane/EA 4:1) to give the title compound as a yellow oil (1.77 g); LC-MS: t<sub>R</sub> = 1.16 min; [M+H]<sup>+</sup> = 412.09. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ1.26 (t, <i>J</i> = 7.0 Hz, 6 H), 1.33 (t, <i>J</i> = 7.5 Hz, 3 H), 2.41 (s, 3 H), 2.47 (s, 3 H), 2.78 (q, <i>J</i> = 7.5 Hz, 2 H), 2.16 (t, <i>J</i> = 5.5 Hz, 1 H), 3.76 (q, <i>J</i> = 7.0 Hz, 4 H), 4.01 (m, 4 H), 7.23 (s, 1 H), 7.90 (d, <i>J</i> = 5.8 Hz, 2 H).</p><heading id="h0191"><b>Examples 103 to 110</b></heading><p id="p0190" num="0190"><chemistry id="chem0106" num="0106"><img id="ib0106" file="imgb0106.tif" wi="62" he="37" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="78"> --></p><p id="p0191" num="0191">Examples 103 to 110 are prepared from Example 102 according to the general method described below:
<br/>
a) To a solution of 2-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxyl-ethanol (895 mg, 2.44 mmol) in DCM (20 mL) is added Et<sub>3</sub>N (0.47 mL, 3.41 mmol). The reaction mixture is cooled down to 5°C before adding methanesulfonylchloride (0.23 mL, 2.92 mmol) and stirring is continued at rt for 2 h. The mixture is then diluted with EtOAc and the org. solution is washed with sat. aq. NaHCO<sub>3</sub> followed by brine, is dried over MgSO<sub>4</sub>, filtered and concentrated to give methanesulfonic acid 2-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl ester as a brown oil (1.07 g); LC-MS: t<sub>R</sub> = 1.19 min; [M+H]<sup>+</sup> = 489.89.<br/>
b) To a solution of the mesylate intermediate (1 eq.) in ethanol is added the appropriate nucleophile (4-5 eq.: ethanolamine or 3-azetidine carboxylic methylester, or S-proline methylester or 3-pyrrolidine carboxylic methylester or β-alanine). The reaction mixture is stirred at 80°C for 2 h to 72 h (monitored by LC-MS), is then diluted with DCM and washed with sat. aq. NaHCO<sub>3</sub>. The org. phase is dried, filtered and evaporated and the crude compound is purified by prep. TLC.<br/>
c) The amino acid derivatives 105, 107, and 109 are prepared by hydrolysis of their corresponding amino carboxylic esters 104, 106, and 108 using 20-30 eq. of 2M aq. LiOH in MeOH.
<tables id="tabl0011" num="0011"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="44mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="27mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R</entry><entry namest="col3" nameend="col4" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">103</entry><entry align="center" valign="middle"><chemistry id="chem0107" num="0107"><img id="ib0107" file="imgb0107.tif" wi="34" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">455.10</entry><entry align="center" valign="middle">49 mg yellow oil</entry></row><row><entry align="center" valign="middle">104</entry><entry align="center" valign="middle"><chemistry id="chem0108" num="0108"><img id="ib0108" file="imgb0108.tif" wi="39" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.98</entry><entry valign="middle" align="char" char="." charoff="31">509.19</entry><entry align="center" valign="middle">16 mg yellow oil</entry></row><!-- EPO <DP n="79"> --><row><entry align="center" valign="middle">105</entry><entry align="center" valign="middle"><chemistry id="chem0109" num="0109"><img id="ib0109" file="imgb0109.tif" wi="36" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.94</entry><entry valign="middle" align="char" char="." charoff="31">495.20</entry><entry align="center" valign="middle">5 mg yellow oil</entry></row><row><entry align="center" valign="middle">106</entry><entry align="center" valign="middle"><chemistry id="chem0110" num="0110"><img id="ib0110" file="imgb0110.tif" wi="25" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">522.84</entry><entry align="center" valign="middle">43 mg yellow oil</entry></row><row><entry align="center" valign="middle">107</entry><entry align="center" valign="middle"><chemistry id="chem0111" num="0111"><img id="ib0111" file="imgb0111.tif" wi="25" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.94</entry><entry valign="middle" align="char" char="." charoff="31">509.17</entry><entry align="center" valign="middle">25 mg yellow oil</entry></row><row><entry align="center" valign="middle">108</entry><entry align="center" valign="middle"><chemistry id="chem0112" num="0112"><img id="ib0112" file="imgb0112.tif" wi="36" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.99</entry><entry valign="middle" align="char" char="." charoff="31">522.86</entry><entry align="center" valign="middle">51 mg yellow oil</entry></row><row><entry align="center" valign="middle">109</entry><entry align="center" valign="middle"><chemistry id="chem0113" num="0113"><img id="ib0113" file="imgb0113.tif" wi="33" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.94</entry><entry valign="middle" align="char" char="." charoff="31">509.14</entry><entry align="center" valign="middle">35 mg yellow oil</entry></row><row><entry align="center" valign="middle">110</entry><entry align="center" valign="middle"><chemistry id="chem0114" num="0114"><img id="ib0114" file="imgb0114.tif" wi="39" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.68</entry><entry valign="middle" align="char" char="." charoff="31">483.00</entry><entry align="center" valign="middle">2 mg yellow wax</entry></row></tbody></tgroup></table></tables></p><heading id="h0192"><b>Example 103</b>: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25 (t, <i>J</i> = 7.0 Hz, 6 H), 1.32 (t, <i>J</i> = 7.5 Hz, 3 H), 2.39 (s, 3 H), 2.46 (s, 3 H), 2.76 (q, <i>J</i> = 7.5 Hz, 2 H), 2.93 (m, 2 H), 3.09 (t, <i>J</i> = 5.0 Hz, 2 H), 3.75 (m, 6 H), 3.96 (t, <i>J</i> = 5.3 Hz, 2 H), 7.22 (s, 1 H), 7.87 (s, 1 H), 7.88 (s, 1 H).</heading><heading id="h0193"><b>Example 105:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.24 (t, <i>J</i> = 7.0 Hz, 6 H), 1.30 (t, <i>J</i> = 7.8 Hz, 3 H), 2.37 (s, 3 H), 2.45 (s, 3 H), 2.72 (m, 2 H), 3.25 (s, 2 H), 3.39 (m, 1 H), 3.74 (q, <i>J</i> = 6.8 Hz, 4 H), 3.98 (m, 4 H), 4.13 (m, 2 H), 7.20 (s, 1 H), 7.83 (s, 1 H), 7.85 (s, 1 H).</heading><heading id="h0194"><b>Examples 111 to 113</b></heading><!-- EPO <DP n="80"> --><p id="p0192" num="0192"><chemistry id="chem0115" num="0115"><img id="ib0115" file="imgb0115.tif" wi="62" he="37" img-content="chem" img-format="tif"/></chemistry></p><p id="p0193" num="0193">Examples 111 to 113 are prepared from Example 102 according to the general method described below:
<br/>
a) A solution of methanesulfonic acid 2-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl ester (850 mg, 1.74 mmol), derived from Example 102, in 7M NH<sub>3</sub> in MeOH (20 mL) is stirred at 60°C for 18 h. Volatiles are then evaporated and the residue is purified by CC (eluting with EA/MeOH 10:1) to give (4-{3-[4-(2-amino-ethoxy)-3-ethyl-5-methyl-phenyl]-[1,2,4]oxadiazol-5-yl}-6-methyl-pyrimidin-2-yl)-diethyl-amine as a yellow solid (700 mg); LC-MS: t<sub>R</sub> = 0.92 min; [M+H]<sup>+</sup> = 410.95.<br/>
b) The above amino intermediate (1 eq.) is coupled to the appropriate carboxylic acid derivatives (1.2 eq.: glycolic acid or Boc-glycine or Boc-β-alanine) under standard conditions described before using DMF as solvent and EDC (1.5 eq.) and HOBt (1.5 eq.) as coupling agents. Completion of the reaction is monitored by LC-MS.<br/>
c) Examples 112 and 113 are obtained after a standard Boc cleavage in DCM using TFA.
<tables id="tabl0012" num="0012"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="45mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="31mm"/><thead><row><entry align="center" valign="middle">Ex. No.</entry><entry align="center" valign="middle">R</entry><entry namest="col3" nameend="col4" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">111</entry><entry align="center" valign="middle"><chemistry id="chem0116" num="0116"><img id="ib0116" file="imgb0116.tif" wi="35" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.10</entry><entry valign="middle" align="char" char="." charoff="31">469.11</entry><entry align="center" valign="middle">21 mg yellow oil</entry></row><row><entry align="center" valign="middle">112</entry><entry align="center" valign="middle"><chemistry id="chem0117" num="0117"><img id="ib0117" file="imgb0117.tif" wi="36" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">468.12</entry><entry align="center" valign="middle">26 mg yellow solid</entry></row><!-- EPO <DP n="81"> --><row><entry align="center" valign="middle">113</entry><entry align="center" valign="middle"><chemistry id="chem0118" num="0118"><img id="ib0118" file="imgb0118.tif" wi="41" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">482.09</entry><entry align="center" valign="middle">10 mg yellow solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0195"><b>Example 111:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25 (t, <i>J</i> = 7.0 Hz, 6 H), 1.32 (t, <i>J</i> = 7.5 Hz, 3 H), 2.38 (s, 3H),2.43(m,1 1 H), 2.47 (s, 3 H), 2.75 (m, 2 H), 3.77 (m, 6 H), 3.97 (t, <i>J</i> = 4.8 Hz, 2 H), 4.23 (d, <i>J</i> = 2.0 Hz, 2 H), 7.04 (m, 1 H), 7.23 (s, 1 H), 7.88 (s, 1 H), 7.89 (s, 1 H).</heading><heading id="h0196"><b>Example 114</b></heading><heading id="h0197"><b>N-(2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-ethyl)-N',N'-dimethyl-sulfamic acid amide</b></heading><p id="p0194" num="0194">To a solution of 4-{3-[4-(2-amino-ethoxy)-3-ethyl-5-methyl-phenyl]-[1,2,4]oxadiazol-5-yl}-6-methyl-pyrimidin-2-yl)-diethyl-amine (50 mg, 0.122 mmol) in DCM (5 mL) is added DIPEA (25 µL, 0.146 mmol) followed by N,N-dimethylsulfamoyl chloride (28 µL, 0.268 mmol). The reaction mixture is stirred at 40°C for 18 h, is then evaporated and purified by prep. HPLC to give the title compound (13 mg); LC-MS: t<sub>R</sub> = 1.2 min; [M+H]<sup>+</sup> = 518.13.</p><heading id="h0198"><b>Examples 115 to 126</b></heading><p id="p0195" num="0195"><chemistry id="chem0119" num="0119"><img id="ib0119" file="imgb0119.tif" wi="78" he="38" img-content="chem" img-format="tif"/></chemistry></p><p id="p0196" num="0196">Examples 115 to 126 are prepared from Intermediate 12 following the general method described below:
<br/>
a) To a solution of Intermediate 12 (1 eq.) in MeOH or DMF, the appropriate nucleophile is added (5 eq.: methanoate, or methylamine, or ethanolamine, or ethylsulfonamide, or amino acid carboxylic esters). The reaction mixture is stirred at 80°C for 1 day (completion of the reaction is monitored by LC-MS), then diluted with DCM. The org. solution is washed with sat aq. NaHCO<sub>3</sub>, followed by brine, dried over MgSO<sub>4</sub>, filtered and evaporated to give the crude compound which is purified by standard method such as prep. HPLC or prep. TLC.<!-- EPO <DP n="82"> --><br/>
b) The esters 118, 120, 122 and 125 are hydrolyzed using 2M aq. LiOH in MeOH to give the Examples 119, 121, 123 and 126.
<tables id="tabl0013" num="0013"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="35mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R</entry><entry namest="col3" nameend="col4" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">115</entry><entry align="center" valign="middle">OMe</entry><entry valign="middle" align="char" char=".">1.17</entry><entry valign="middle" align="char" char="." charoff="31">456.11</entry><entry align="center" valign="middle">31 mg yellow oil</entry></row><row><entry align="center" valign="middle">116</entry><entry align="center" valign="middle">NHMe</entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">455.15</entry><entry align="center" valign="middle">6.5 mg yellow oil</entry></row><row><entry align="center" valign="middle">117</entry><entry align="center" valign="middle"><chemistry id="chem0120" num="0120"><img id="ib0120" file="imgb0120.tif" wi="22" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.11</entry><entry valign="middle" align="char" char="." charoff="31">533.13</entry><entry align="center" valign="middle">20 mg yellow oil</entry></row><row><entry align="center" valign="middle">118</entry><entry align="center" valign="middle"><chemistry id="chem0121" num="0121"><img id="ib0121" file="imgb0121.tif" wi="30" he="13" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">538.83</entry><entry align="center" valign="middle">135 mg yellow oil</entry></row><row><entry align="center" valign="middle">119</entry><entry align="center" valign="middle"><chemistry id="chem0122" num="0122"><img id="ib0122" file="imgb0122.tif" wi="28" he="13" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.92</entry><entry valign="middle" align="char" char="." charoff="31">525.2</entry><entry align="center" valign="middle">22 mg yellow oil</entry></row><row><entry align="center" valign="middle">120</entry><entry align="center" valign="middle"><chemistry id="chem0123" num="0123"><img id="ib0123" file="imgb0123.tif" wi="25" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">553.21</entry><entry align="center" valign="middle">143 mg yellow oil</entry></row><row><entry align="center" valign="middle">121</entry><entry align="center" valign="middle"><chemistry id="chem0124" num="0124"><img id="ib0124" file="imgb0124.tif" wi="22" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">538.83</entry><entry align="center" valign="middle">42 mg yellow oil</entry></row><row><entry align="center" valign="middle">122</entry><entry align="center" valign="middle"><chemistry id="chem0125" num="0125"><img id="ib0125" file="imgb0125.tif" wi="27" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">553.20</entry><entry align="center" valign="middle">145 mg yellow oil</entry></row><!-- EPO <DP n="83"> --><row><entry align="center" valign="middle">123</entry><entry align="center" valign="middle"><chemistry id="chem0126" num="0126"><img id="ib0126" file="imgb0126.tif" wi="24" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.93</entry><entry valign="middle" align="char" char="." charoff="31">538.74</entry><entry align="center" valign="middle">88 mg yellow solid</entry></row><row><entry align="center" valign="middle">124</entry><entry align="center" valign="middle"><chemistry id="chem0127" num="0127"><img id="ib0127" file="imgb0127.tif" wi="26" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.89</entry><entry valign="middle" align="char" char="." charoff="31">485.15</entry><entry align="center" valign="middle">19 mg</entry></row><row><entry align="center" valign="middle">125</entry><entry align="center" valign="middle"><chemistry id="chem0128" num="0128"><img id="ib0128" file="imgb0128.tif" wi="31" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.95</entry><entry valign="middle" align="char" char="." charoff="31">527.18</entry><entry align="center" valign="middle">57 mg yellow oil</entry></row><row><entry align="center" valign="middle">126</entry><entry align="center" valign="middle"><chemistry id="chem0129" num="0129"><img id="ib0129" file="imgb0129.tif" wi="30" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.90</entry><entry valign="middle" align="char" char="." charoff="31">513.15</entry><entry align="center" valign="middle">19 mg yellow solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0199"><b>Example 115:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.26 (t, <i>J</i> = 7.0 Hz, 6 H), 1.32 (t, <i>J</i> = 7.5 Hz, 3 H), 2.40 (s, 3 H), 2.47 (s, 3 H), 2.59 (d, <i>J</i> = 4.0 Hz, 1 H), 2.77 (q, <i>J</i> = 7.3 Hz, 2 H), 3.47 (s, 3 H), 3.66 (m, 2 H), 3.76 (q, <i>J</i> = 6.5 Hz, 4 H), 3.92 (d, <i>J</i> = 5.3 Hz, 2 H), 4.23 (m, 1 H), 7.23 (s, 1 H), 7.88 (s, 1 H), 7.89 (s, 1 H).</heading><heading id="h0200"><b>Example 117:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.26 (t, <i>J</i> = 7.0 Hz, 6 H), 1.33 (t, <i>J</i> = 7.5 Hz, 3 H), 1.44 (t, <i>J</i> = 7.3 Hz, 3 H), 2.39 (s, 3 H), 2.48 (s, 3 H), 2.75 (m, 2 H), 3.14 (q, <i>J</i> = 7.5 Hz, 2 H), 3.35 (m, 1 H), 3.50 (m, 1 H), 3.76 (q, <i>J</i> = 7.0 Hz, 4 H), 3.91 (m, 2 H), 4.24 (m, 1 H), 4.78 (m, 1 H), 7.23 (s, 1 H), 7.89 (s, 1 H), 7.90 (s, 1 H).</heading><heading id="h0201"><b>Example 124:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.25 (t, <i>J</i> = 6.8 Hz, 6 H), 1.31 (t, <i>J</i> = 7.3 Hz, 3 H), 2.38 (m, 4 H), 2.46 (s, 3 H), 2.74 (m, 2 H), 3.06 (m, 2 H), 3.11 (m, 1 H), 3.75 (q, <i>J</i> = 6.8 Hz, 4 H), 3.86 (t, <i>J</i> = 4.5 Hz, 2 H), 3.90 (d, <i>J</i> = 4.5 Hz, 2 H), 4.33 (m, 1 H), 7.22 (s, 1 H), 7.86 (s, 1 H), 7.88 (s, 1 H).</heading><heading id="h0202"><b>Example 127</b></heading><heading id="h0203"><b>N-(2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-2-hydroxy-acetamide</b></heading><p id="p0197" num="0197">To a solution of glycolic acid (33 mg, 0.43 mmol) and DIPEA (146 µL, 0.85 mmol) in DMF (5 mL) is added EDC (82 mg, 0.43 mmol) followed by HOBt (58 mg, 0.43 mmol). The reaction mixture is stirred at rt for 10 min before adding Intermediate 12 (100 mg, 0.28<!-- EPO <DP n="84"> --> mmol). Stirring is continued for 18 h and the reaction mixture is then diluted with EtOAc, washed with sat. aq. NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered and evaporated. The residue is purified by prep. TLC (eluting with DCM/7M NH<sub>3</sub> in MeOH 10:1) to give the title compound (50 mg) as a yellow solid; t<sub>R</sub> = 1.05 min; [M+H]<sup>+</sup> = 411.75.</p><heading id="h0204"><b>Example 128</b></heading><heading id="h0205"><b>N-(2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-methanesulfonamide</b></heading><p id="p0198" num="0198">To a solution of Intermediate 12 (100 mg, 0.28 mmol) and DIPEA (97 µL, 0.57 mmol) in DCM (2 mL) at 0°C is added dropwise a solution of methanesulfonyl chloride (33 µL, 0.43 mmol) in DCM (2 mL). The reaction mixture is stirred at rt for 1 h and is then diluted with EtOAc, and washed with sat. aq. NaHCO<sub>3</sub>. The org. phase is dried over MgSO<sub>4</sub>, filtered, evaporated and purified by prep. TLC (eluting with Heptane/EtOAc 1:1) to give the title compound (71 mg) as a yellow solid; LC-MS: t<sub>R</sub> = 1.07 min; [M+H]<sup>+</sup> = 431.07.</p><heading id="h0206"><b>Example 129</b></heading><heading id="h0207"><b>N-(2-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-N',N'-dimethyl-sulfamic acid amide</b></heading><p id="p0199" num="0199">Example 129 is prepared in analogy to Example 128 using N,N-dimethylsulfamoylchloride; LC-MS: t<sub>R</sub> = 1.12 min; [M+H]<sup>+</sup> = 460.01.</p><heading id="h0208"><b>Examples 130 to 133</b></heading><p id="p0200" num="0200"><chemistry id="chem0130" num="0130"><img id="ib0130" file="imgb0130.tif" wi="71" he="30" img-content="chem" img-format="tif"/></chemistry></p><p id="p0201" num="0201">Examples 130 to 133 are prepared by coupling Intermediate 15 with the appropriate amino carboxylic esters or amine following the procedure described below.</p><p id="p0202" num="0202">To a suspension of {4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-acetic acid (Intermediate 15) in DMF are added TBTU (1.5 eq.) and DIPEA (3 eq.). The resulting solution is stirred for 5 min before adding the appropriate amine or amino carboxylic ester. The completion of the reaction is monitored by LC-MS. The reaction<!-- EPO <DP n="85"> --> mixture is then diluted with EtOAc, washed with sat. aq. NaHCO<sub>3</sub>, dried, filtered, concentrated and purified by prep. TLC.</p><p id="p0203" num="0203">The amino acid derivatives 131, 132 and 133 are prepared by hydrolysis of their corresponding amino carboxylic methyl esters using 20-30 eq. of 2M aq. LiOH in MeOH.
<tables id="tabl0014" num="0014"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R</entry><entry namest="col3" nameend="col4" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">130</entry><entry align="center" valign="middle"><chemistry id="chem0131" num="0131"><img id="ib0131" file="imgb0131.tif" wi="17" he="9" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.07</entry><entry valign="middle" align="char" char="." charoff="31">395.09</entry><entry align="center" valign="middle">35 mg yellow solid</entry></row><row><entry align="center" valign="middle">131</entry><entry align="center" valign="middle"><chemistry id="chem0132" num="0132"><img id="ib0132" file="imgb0132.tif" wi="28" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.98</entry><entry valign="middle" align="char" char="." charoff="31">450.91</entry><entry align="center" valign="middle">5 mg yellow solid</entry></row><row><entry align="center" valign="middle">132</entry><entry align="center" valign="middle"><chemistry id="chem0133" num="0133"><img id="ib0133" file="imgb0133.tif" wi="23" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.02</entry><entry valign="middle" align="char" char="." charoff="31">465.01</entry><entry align="center" valign="middle">47 mg yellow solid</entry></row><row><entry align="center" valign="middle">133</entry><entry align="center" valign="middle"><chemistry id="chem0134" num="0134"><img id="ib0134" file="imgb0134.tif" wi="24" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.01</entry><entry valign="middle" align="char" char="." charoff="31">465.05</entry><entry align="center" valign="middle">28 mg yellow oil</entry></row></tbody></tgroup></table></tables></p><heading id="h0209"><b>Example 130:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.11 (t, <i>J</i> = 7.3 Hz, 3 H), 1.26 (t, <i>J</i> = 6.8 Hz, 6 H), 2.48 (s, 3 H), 3.30 (m, 2 H), 3.65 (m, 2 H), 3.77 (m, 4 H), 5.36 (m, 1 H), 7.22 (s, 1 H), 7.43 (s, 1 H), 7.45 (s, 1 H), 8.18 (s, 1 H), 8.20 (s, 1 H).</heading><heading id="h0210"><b>Examples 134 to 140</b></heading><p id="p0204" num="0204"><chemistry id="chem0135" num="0135"><img id="ib0135" file="imgb0135.tif" wi="75" he="35" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="86"> --></p><p id="p0205" num="0205">Examples 134 to 140 are prepared by coupling 3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionic acid (Intermediate 10) with the appropriate amino carboxylic esters or aminoalcohols following the procedure described for Examples 130-133.
<tables id="tabl0015" num="0015"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="34mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">R</entry><entry namest="col3" nameend="col4" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">134</entry><entry align="center" valign="middle"><chemistry id="chem0136" num="0136"><img id="ib0136" file="imgb0136.tif" wi="30" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">481.08</entry><entry align="center" valign="middle">49 mg yellow solid</entry></row><row><entry align="center" valign="middle">135</entry><entry align="center" valign="middle"><chemistry id="chem0137" num="0137"><img id="ib0137" file="imgb0137.tif" wi="28" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.97</entry><entry valign="middle" align="char" char="." charoff="31">493.11</entry><entry align="center" valign="middle">10 mg yellow solid</entry></row><row><entry align="center" valign="middle">136</entry><entry align="center" valign="middle"><chemistry id="chem0138" num="0138"><img id="ib0138" file="imgb0138.tif" wi="22" he="14" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">1.01</entry><entry valign="middle" align="char" char="." charoff="31">506.76</entry><entry align="center" valign="middle">39 mg colorless wax</entry></row><row><entry align="center" valign="middle">137</entry><entry align="center" valign="middle"><chemistry id="chem0139" num="0139"><img id="ib0139" file="imgb0139.tif" wi="24" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.99</entry><entry valign="middle" align="char" char="." charoff="31">506.79</entry><entry align="center" valign="middle">38 mg yellow solid</entry></row><row><entry align="center" valign="middle">138</entry><entry align="center" valign="middle"><chemistry id="chem0140" num="0140"><img id="ib0140" file="imgb0140.tif" wi="25" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">453.15</entry><entry align="center" valign="middle">54 mg white solid</entry></row><row><entry align="center" valign="middle">139</entry><entry align="center" valign="middle"><chemistry id="chem0141" num="0141"><img id="ib0141" file="imgb0141.tif" wi="25" he="18" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">482.90</entry><entry align="center" valign="middle">60 mg white solid</entry></row><row><entry align="center" valign="middle">140</entry><entry align="center" valign="middle"><chemistry id="chem0142" num="0142"><img id="ib0142" file="imgb0142.tif" wi="30" he="10" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">482.93</entry><entry align="center" valign="middle">68 mg white solid</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="87"> --></p><heading id="h0211"><b>Example 137:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.30 (m, 9 H), 2.20 (m, 1 H), 2.27 (m, 1 H), 2.44 (d, <i>J</i> = 2.0 Hz, 4 H), 2.48 (m, 4 H), 2.76 (qd, <i>J</i> = 7.5, 1.5 Hz, 2 H), 3.13 (m, 3 H), 3.40 (m, 1 H), 3.55 (m, 2 H), 3.71 (m, 1 H), 3.82 (m, 1 H), 4.32 (m, 1 H), 7.27 (s, 1 H), 7.84 (s, 1 H), 7.86 (s, 1 H).</heading><heading id="h0212"><b>Example 139:</b><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.31 (m, 9 H), 2.43 (m, 5 H), 2.50 (s, 3 H), 2.77 (m, 3 H), 2.93 (s br, 1 H), 3.10 (m, 2 H), 3.45 (m, 2 H), 3.58 (m, 2 H), 3.79 (m, 1 H), 4.32 (m, 1 H), 5.28 (m, 1 H), 5.88 (m, 1 H), 7.31 (s, 1 H), 7.86 (s, 1 H), 7.88 (s, 1 H).</heading><heading id="h0213"><b>Example 141</b></heading><heading id="h0214"><b>N-(2-amino-ethyl)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionamide dihydrochloride</b></heading><p id="p0206" num="0206">To a suspension of Intermediate 10 (25 mg, 0.061 mmol) in DMF is added DIPEA (16 µL, 0.092 mmol) followed by TBTU (23.5 mg, 0.073 mmol). The reaction mixture is stirred for 5 min before adding <i>N</i>-Boc-ethylenediamine (12 µL, 0.073 mmol) and stirring is continued for 2 h. The reaction mixture is diluted with EtOAc (20 mL) and is washed with sat. aq. NaHCO<sub>3</sub> (15 mL). The org. phase is then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give a yellow oil that is purified by prep. TLC (eluting with DCM/MeOH 95:5) to afford [2-(3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionylamino)-ethyl]-carbamic acid tert-butyl ester (27 mg) as a white solid; LC-MS: t<sub>R</sub> = 1.09 min; [M+1]<sup>+</sup> = 552.30.</p><p id="p0207" num="0207">The above intermediate (23 mg, 0.042 mmol) is then dissolved in dioxane (0.5 mL) and 0.5 mL of 4N HCl in dioxane is added. The reaction mixture is stirred for 1.5 h and is evaporated to give a yellow solid which is sonicated in Et<sub>2</sub>O (2 mL), filtered and dried to give 20 mg of N-(2-amino-ethyl)-3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-propionamide dihydrochloride as a white solid; LC-MS: t<sub>R</sub> = 0.84 min; [M+H]<sup>+</sup> = 452.17.</p><heading id="h0215"><b>Example 142 (Reference Example)</b></heading><heading id="h0216"><b>rac-1-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethane-1,2-diol</b></heading><p id="p0208" num="0208">To a solution of isopropyl-{4-methyl-6-[3-(4-vinyl-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrimidin-2-yl}-amine (Intermediate 8: 2.78 g, 8.67 mmol) in acetone (45 mL) are added water (4 mL) and a 2.5% aq. solution of OsO<sub>4</sub> (136 µL), followed by N-methyl-morpholine-N-oxide monohydrate (1.4 g, 10.4 mmol). The reaction mixture is stirred at rt for 18 h. Another 68 µL of 2.5% aq. solution of OsO<sub>4</sub> is added and stirring is continued for another 3 h. The<!-- EPO <DP n="88"> --> mixture is then diluted with DCM (150 mL), and washed with water (3 x 50 mL), dried over MgSO<sub>4</sub>, filtered and evaporated to give 0.97 g of racemic 1-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyll-ethane-1,2-diol as a brown solid; LC-MS: t<sub>R</sub> = 0.84 min; [M+H]<sup>+</sup> = 356.04. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.30 (d, <i>J</i> = 6.5 Hz, 6 H), 2.16 (s br, 1 H), 2.49 (s, 3 H), 2.74 (s br, 1 H), 3.72 (dd, <i>J</i> = 11.0, 8.0 Hz, 1 H), 3.86 (dd, <i>J</i> = 11.0, 3.3 Hz, 0 H), 4.31 (m, 1 H), 4.94 (dd, <i>J</i> = 7.8, 3.3 Hz, 1 H), 5.28 (s br, 1 H), 7.30 (s, 1 H), 7.55 (d, <i>J</i> = 8.3 Hz, 2 H), 8.20 (d, <i>J</i> = 8.3 Hz, 2 H).</p><heading id="h0217"><b>Example 143</b></heading><heading id="h0218"><b>rac-2-(2-Hydroxy-ethylamino)-1-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol</b></heading><p id="p0209" num="0209"><ul><li>a) A solution of Example 142 (868 mg, 2.44 mmol) and DIPEA (0.84 mL, 4.88 mmol) in THF (30 mL) is cooled down to -5°C before adding a solution of methanesulfonyl chloride (152 µL, 1.95 mmol) in THF (1 mL). The reaction mixture is stirred at -5°C for 1 h, then at rt for another hour. After dilution with DCM (250 mL) the org. solution is washed with sat. aq. NaHCO<sub>3</sub> (3 x 50 mL), dried over MgSO<sub>4</sub>, filtered and evaportated to give the crude methanesulfonic acid 2-hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester as a grey oil (1.28 g); LC-MS: t<sub>R</sub> = 0.95 min; [M+H]<sup>+</sup> = 443.95.</li><li>b) Ethanolamine (3.0 mL, 49.85 mmol) is added to a solution of methanesulfonic acid 2-hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester (152 mg, 0.35 mmol) in dioxane (2.0 mL). The reaction mixture is stirred at 80°C for 18 h, is then evaporated and purified by prep. TLC (eluting with DCM/MeOH 10:1) to give 99 mg of the title compound as a yellow oil; LC-MS: t<sub>R</sub> = 0.74 min; [M+H]<sup>+</sup> = 399.07. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.29 (d, <i>J</i> = 6.5 Hz, 6 H), 2.48 (s, 3 H), 2.84 (m, 3 H), 2.97 (dd, <i>J</i> = 12.3, 3.5 Hz, 1 H), 3.73 (t, <i>J</i> = 5.0 Hz, 1 H), 4.31 (m, 1 H), 4.85 (dd, <i>J</i> = 8.8, 3.3 Hz, 1 H), 5.30 (s br, 1 H), 7.29 (s, 1 H), 7.53 (d, <i>J</i> = 8.3 Hz, 2 H), 8.17 (d, <i>J</i> = 8.0 Hz, 2 H).</li></ul></p><heading id="h0219"><b>Example 144</b></heading><heading id="h0220"><b>rac-2-Amino-1-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol</b></heading><p id="p0210" num="0210">A solution of 7M NH<sub>3</sub> in methanol (35 mL) is added to methanesulfonic acid 2-hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester (606 mg, 1.40 mmol, synthesis described for Example 143). The reaction mixture is stirred at 65°C for 18 h and is then evaporated to give 293 mg of rac-2-amino-1-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol<!-- EPO <DP n="89"> --> as a yellow oil; LC-MS: t<sub>R</sub> = 0.73 min; [M+H]<sup>+</sup> = 355.06.</p><heading id="h0221"><b>Example 145</b></heading><heading id="h0222"><b>rac-N-(2-Hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-methanesulfonamide</b></heading><p id="p0211" num="0211">To a solution of rac-2-amino-1-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol (39 mg, 0.11 mmol) and DIPEA (30 µL, 0.176 mmol) in DCM (6 mL) at 0°C is added dropwise a solution of mesylchloride (10 µL, 0.132 mmol) in DCM (2 mL). The reaction mixture is stirred at 0°C for 1 h, and then at rt for another hour. The reaction mixture is evaporated and purified by prep. TLC eluting with DCM/ 7M NH<sub>3</sub> in MeOH 10:1 to give rac-N-(2-hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-methanesulfonamide (19 mg) as a white solid; t<sub>R</sub> = 0.89 min; [M+H]<sup>+</sup> = 432.99.</p><heading id="h0223"><b>Example 146</b></heading><heading id="h0224"><b>rac-N-(2-Hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)- N',N'-dimethyl-sulfamic acid amide</b></heading><p id="p0212" num="0212">Example 146 is prepared in analogy to Example 145 using dimethylsulfamoyl chloride; LC-MS: t<sub>R</sub> = 0.94 min; [M+H]<sup>+</sup> = 461.99.</p><heading id="h0225"><b>Example 147</b></heading><heading id="h0226"><b>rac-2-Hydroxy-N-(2-hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-acetamide</b></heading><p id="p0213" num="0213">The title compound is prepared in analogy to Example 127 using rac-2-amino-1-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol (Example 144) and glycolic acid; LC-MS: t<sub>R</sub> = 0.81 min; [M+H]<sup>+</sup> = 413.03.</p><heading id="h0227"><b>Example 148</b></heading><heading id="h0228"><b>rac-2-Amino-N-(2-hydroxy-2-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl)-acetamide</b></heading><p id="p0214" num="0214">Example 148 is prepared in analogy to Example 147 using Boc-glycine followed by standard Boc cleavage using TFA in DCM; LC-MS: t<sub>R</sub> = 0.73 min; [M+H]<sup>+</sup> = 412.07.</p><heading id="h0229"><b>Example 149</b></heading><!-- EPO <DP n="90"> --><heading id="h0230"><b>rac-3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-propane-1,2-diol</b></heading><p id="p0215" num="0215">Example 149 is prepared in analogy to Example 142 using 3-(4-cyanophenyl)-1-propene (Intermediate 9); LC-MS: t<sub>R</sub> = 0.73 min; [M+H]<sup>+</sup> = 412.07; <sup>1</sup>H NMR (MeOH-D<sub>4</sub>) δ 1.29 (d, <i>J</i> = 6.5 Hz, 6 H), 2.47 (s, 3 H), 2.78 (dd, <i>J</i> = 13.6, 7.8 Hz, 1 H), 2.97 (dd, <i>J</i> = 13.6, 5.0 Hz, 1 H), 3.54 (m, 2 H), 3.89 (m, 1 H), 4.30 (m, 1 H), 7.33 (s, 1 H), 7.47 (d, <i>J</i> = 8.3 Hz, 2 H), 8.09 (d, <i>J</i> = 8.3 Hz, 2 H).</p><heading id="h0231"><b>Examples 150 to 155</b></heading><p id="p0216" num="0216"><chemistry id="chem0143" num="0143"><img id="ib0143" file="imgb0143.tif" wi="75" he="35" img-content="chem" img-format="tif"/></chemistry></p><p id="p0217" num="0217">The following Examples are prepared starting from Example 149 in analogy to previous Examples 143-148.
<tables id="tabl0016" num="0016"><table frame="all"><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="49mm"/><colspec colnum="3" colname="col3" colwidth="31mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="31mm"/><thead><row><entry valign="middle">Ex. No.</entry><entry align="center" valign="middle">prepared in analogy to Example</entry><entry align="center" valign="middle">R</entry><entry namest="col4" nameend="col5" align="center" valign="middle">LC-MS t<sub>R</sub> [min] [M+H]<sup>+</sup></entry><entry align="center" valign="middle"><b>Amount Form</b></entry></row></thead><tbody><row><entry align="center" valign="middle">150</entry><entry align="center" valign="middle">145</entry><entry align="center" valign="middle"><chemistry id="chem0144" num="0144"><img id="ib0144" file="imgb0144.tif" wi="16" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.91</entry><entry valign="middle" align="char" char="." charoff="31">446.92</entry><entry align="center" valign="middle">123 mg beige solid</entry></row><row><entry align="center" valign="middle">151</entry><entry align="center" valign="middle">146</entry><entry align="center" valign="middle"><chemistry id="chem0145" num="0145"><img id="ib0145" file="imgb0145.tif" wi="21" he="15" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.96</entry><entry valign="middle" align="char" char="." charoff="31">476.01</entry><entry align="center" valign="middle">129 mg white solid</entry></row><row><entry align="center" valign="middle">152</entry><entry align="center" valign="middle">147</entry><entry align="center" valign="middle"><chemistry id="chem0146" num="0146"><img id="ib0146" file="imgb0146.tif" wi="25" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.83</entry><entry valign="middle" align="char" char="." charoff="31">426.88</entry><entry align="center" valign="middle">109 mg beige solid</entry></row><!-- EPO <DP n="91"> --><row><entry align="center" valign="middle">153</entry><entry align="center" valign="middle">148</entry><entry align="center" valign="middle"><chemistry id="chem0147" num="0147"><img id="ib0147" file="imgb0147.tif" wi="27" he="16" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.76</entry><entry valign="middle" align="char" char="." charoff="31">425.99</entry><entry align="center" valign="middle">115 mg white solid</entry></row><row><entry align="center" valign="middle">154</entry><entry align="center" valign="middle">143</entry><entry align="center" valign="middle"><chemistry id="chem0148" num="0148"><img id="ib0148" file="imgb0148.tif" wi="25" he="11" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.77</entry><entry valign="middle" align="char" char="." charoff="31">412.96</entry><entry align="center" valign="middle">98 mg yellow solid</entry></row><row><entry align="center" valign="middle">155</entry><entry align="center" valign="middle">144</entry><entry align="center" valign="middle"><chemistry id="chem0149" num="0149"><img id="ib0149" file="imgb0149.tif" wi="13" he="5" img-content="chem" img-format="tif"/></chemistry></entry><entry valign="middle" align="char" char=".">0.76</entry><entry valign="middle" align="char" char="." charoff="31">369.06</entry><entry align="center" valign="middle">1.15 g white solid</entry></row></tbody></tgroup></table></tables></p><heading id="h0232"><b>Example 156</b></heading><heading id="h0233"><b>(S)-3-{2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-oxazol-2-yl]-6-methyl-phenoxy}-propane-1,2-diol</b></heading><p id="p0218" num="0218"><ul><li>a) To a solution of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid (2.0 g, 10.2 mmol) in DCM (45 mL), DIPEA (8.8 mL, 51.2 mmol) followed by TBTU (3.9 g, 12.3 mmol) is added. The mixture is stirred at rt for 30 min before N,O-dimethylhydroxylamine (1.20 g, 12.3 mmol) is added. The mixture is stirred at rt for 18 h before it is diluted with DCM, washed with sat. aq. NaHCO<sub>3</sub>, followed by water, dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product is purified by CC on silica gel eluting with heptane:EA 1:2 to give 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide (2.39 g) as a yellow oil; LC-MS: t<sub>R</sub> = 0.66 min, [M+H]<sup>+</sup> = 239.03; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.14 (d, <i>J</i> = 6.5 Hz, 6 H), 2.28 (s, 3 H), 3.23 (s, 3 H), 3.67 (s, 3 H), 4.05 (m, 1 H), 6.50 (s br, 1 H), 7.12 (s br, 1 H).</li><li>b) To a solution of 2-isopropylamino-6-methyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide (2.39 g, 10.0 mmol) in THF (50 mL), methyl magnesium bromide (7.0 mL of a 3 M solution in ether, 20.1 mmol) is added dropwise at 5°C. The mixture is stirred at 5°C for 1.5 h. The reaction is quenched by adding NH<sub>4</sub>Cl. The mixture is diluted with EtOAc (75 mL), washed with sat. aq. NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give 1-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethanone (1.71 g) as a yellow solid. LC-MS: t<sub>R</sub> = 0.75 min, [M+H]<sup>+</sup> = 194.01; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.29 (d, <i>J</i> = 6.5 Hz, 6 H), 2.41 (s, 3 H), 2.62 (s, 3 H), 4.22 (m, 1 H), 5.02 (m, 1 H), 6.97 (s, 1 H).<!-- EPO <DP n="92"> --></li><li>c) A solution of hydroxylamine hydrochloride (737 mg, 10.6 mmol) in water (3.0 mL) and 1 N aq. NaOH (11 mL) is added to 1-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethanone (1.71 g, 8.85 mmol). The solution is stirred at 80°C for 2 h and MeOH is added to maintain homogeneity of the mixture. The mixture is cooled to rt and the precipitate that forms is collected, washed with water and dried in vacuo to give 1-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethanone oxime (1.54 g) as a yellow solid; LC-MS: t<sub>R</sub> = 0.72 min, [M+H]<sup>+</sup> = 209.52; <sup>1</sup>H NMR (D<sub>6</sub>-DMSO): δ 1.15 (d, <i>J</i> = 6.5 Hz, 6 H), 2.10 (s, 3 H), 2.25 (s, 3 H), 4.07 (m, 1 H), 6.80 (s, 1 H), 6.86 (d, <i>J</i> = 7.5 Hz, 1 H), 11.62 (s, 1 H).</li><li>d) To a solution of 1-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethanone oxime (920 mg, 4.42 mmol) in pyridine (5 mL), p-toluenesulfonyl chloride (1.43 g, 7.5 mmol) is added at 5°C. The mixture is stirred at 5°C for 24 h. The solvent is evaporated and the remaining residue is partioned between water (40 mL) and EtOAc (100 mL). The org. phase is separated, washed with water, dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product is purified by CC on silica gel eluting with heptane:EA 0:1 to 1:1 to give 1-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethanone oxime p-toluenesulfonic ester (1.46 g) as a pale brown solid; LC-MS: t<sub>R</sub> = 0.99 min, [M+H]<sup>+</sup> = 363.0.</li><li>e) A solution of potassium ethanolate (24% in water, 0.18 mL) is added to a solution of 1-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethanone oxime p-toluenesulfonic ester (300 mg, 0.83 mmol) in ethanol (1.5 mL) at 5°C. The mixture is stirred at rt for 2 h. The mixture is diluted with ether and stirred for 30 min before it is filtered through celite. The filtrate is concentrated and dissolved in ether (20 mL). 2 N aq. HCl (10 mL) is added and the mixture is stirred at rt for 1 h. The org. phase is separated and extracted with 2 N aq. HCl (10 mL). The aq. extracts are combined and concentrated at 30°C to give crude [4-(2-amino-1,1-diethoxy-ethyl)-6-methyl-pyrimidin-2-yl]-isopropyl-amine dihydrochloride (174 mg) as a yellow oil; LC-MS: t<sub>R</sub> = 0.85 min, [M+H]<sup>+</sup> = 283.03.</li><li>f) To a solution of 4-benzyloxy-3-ethyl-5-methyl-benzoic acid (224 mg, 0.83 mmol) in DMF (5 mL), EDC (175 mg, 0.91 mmol) and HOBt (124 mg, 0.91 mmol) are added. The mixture is stirred at rt for 15 min before DIPEA (0.57 mL, 3.3 mmol) and a solution of crude [4-(2-amino-1,1-diethoxy-ethyl)-6-methyl-pyrimidin-2-yl]-isopropyl-amine dihydrochloride (174 mg, 0.83 mmol) in DMF (2.0 mL) is added. The mixture is stirred at rt for 4 h, diluted with EtOAc (30 mL), and washed with sat. aq. NaHCO<sub>3</sub> (15 mL) and brine (15 mL). The org. extract is dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product is purified on prep. TLC plates with Heptane/EtOAc 1:1 to give 4-benzyloxy-N-[2,2-diethoxy-2-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethyl]-3-ethyl-5-methyl-benzamide<!-- EPO <DP n="93"> --> (348 mg) as a yellow oil; LC-MS: t<sub>R</sub> = 1.02 min, [M+H]<sup>+</sup> = 535.22.</li><li>g) To a solution of 4-benzyloxy-N-[2,2-diethoxy-2-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-ethyl]-3-ethyl-5-methyl-benzamide (346 mg, 0.65 mmol) in THF (8 mL), 25% aq. HCl (500 µL) is added and the mixture is stirred at 65°C for 18 h. The mixture is cooled to 0°C, neutralized by adding 1 N aq. NaOH solution and extracted twice with EtOAc. The combined org. extracts are dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give crude 4-benzyloxy-3-ethyl-N-[2-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-2-oxo-ethyl]-5-methyl-benzamide (325 mg) as a yellow oil; LC-MS: t<sub>R</sub> = 0.94 min, [M+H]<sup>+</sup> = 461.13.</li><li>h) To a solution of crude 4-benzyloxy-3-ethyl-N-[2-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-2-oxo-ethyl]-5-methyl-benzamide (300 mg, 0.65 mmol) in THF (10 mL), Burgess reagent (775 mg, 3.3 mmol) is added. The mixture is stirred at 80°C for 18 h before it is concentrated. The crude product is purified on prep. TLC plates with Heptane/EA 1:1 to give {4-[2-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-oxazol-5-yl]-6-methyl-pyrimidin-2-yl}-isopropyl-amine (27 mg) as a yellow solid; LC-MS: t<sub>R</sub> = 1.05 min, [M+H]<sup>+</sup> = 442.81.</li><li>i) To a solution of {4-[2-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-oxazol-5-yl]-6-methyl-pyrimidin-2-yl}-isopropyl-amine (27 mg, 61 µmol) in THF (2 mL) and MeOH (2 mL), 10% Pd/C is added (50 mg). The reaction mixture is stirred under H<sub>2</sub> atmosphere for 18 h, and is filtered through celite. The filtrate is evaporated to give 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-oxazol-2-yl]-6-methyl-phenol (21 mg) as a yellow oil; LC-MS: t<sub>R</sub> = 0.88 min, [M+H]<sup>+</sup> = 353.03.</li><li>j) To a solution of 2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-oxazol-2-yl]-6-methyl-phenol (30 mg, 85 µmol) in iPrOH (4 mL), 3M aq. NaOH (1 mL) followed by (S)-3-chloro-propane-1,2-diol (67 µL, 0.85 mmol) is added. The reaction mixture is stirred at rt for 15 h, and is then diluted with EtOAc and washed with 1 M aq. NaOH followed by brine. The org. solution is dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give 3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-oxazol-2-yl]-6-methyl-phenoxy}-propane-1,2-diol (9 mg) as a yellow solid; LC-MS: t<sub>R</sub> = 0.79 min, [M+H]<sup>+</sup> = 426.80.</li></ul></p><heading id="h0234"><b>Example 157: GTPγS assay to determine EC<sub>50</sub> values</b></heading><!-- EPO <DP n="94"> --><p id="p0219" num="0219">GTPγS binding assays are performed in 96 well microtiter plates (Nunc, 442587) in a final volume of 200 µl, using membrane preparations of CHO cells expressing recombinant human S1 P1 receptor. Assay conditions are 20 mM Hepes (Fluka, 54461), 100 mM NaCl (Fluka, 71378), 5 mM MgCl<sub>2</sub> (Fluka, 63064), 0.1% BSA (Calbiochem, 126609), 1 µM GDP (Sigma, G-7127), 2.5% DMSO (Fluka, 41644), 50 pM <sup>35</sup>S-GTPγS (Amersham Biosciences, SJ1320). The pH is 7.4. Test compounds are dissolved and diluted in 100% DMSO and pre-incubated at room temperature for 30 min in 150 µl of the above assay buffer, in the absence of <sup>35</sup>S-GTPγS. After addition of 50 µl of <sup>35</sup>S-GTPγS, the assay is incubated for 1 h at rt. The assay is terminated by transfer of the reaction mixture to a Multiscreen plate (Millipore, MAHFC1H60) using a cell harvester from Packard Biosciences, and the plates are washed with ice-cold 10 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> (70%/30%), dried, sealed at the bottom and, after addition of 25 µl MicroScint20 (Packard Biosciences, order# 6013621), sealed on the top. Membrane-bound <sup>35</sup>S-GTPγS is measured with a TopCount from Packard Biosciences.</p><p id="p0220" num="0220">EC<sub>50</sub> is the concentration of agonist inducing 50 % of the maximal specific <sup>35</sup>S-GTPγS binding. Specific binding is determined by subtracting non-specific binding from maximal binding. Maximal binding is the amount of cpm bound to the Multiscreen plate in the presence of 10 µM of S1P. Non-specific binding is the amount of binding in the absence of an agonist in the assay.</p><p id="p0221" num="0221">The compound of Example 132 showed EC<sub>50</sub> values above 10 µM. EC<sub>50</sub> values of all other exemplified compounds are in the range of 0.17 to 9360 nM with an average of 260 nM. Agonistic activities of some compounds of formula (I), determined according to the method described above, are displayed in Table 1.
<tables id="tabl0017" num="0017"><table frame="all"><title><b>Table 1:</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="39mm"/><colspec colnum="2" colname="col2" colwidth="20mm"/><thead><row><entry align="center" valign="top"><b>Compound of Example</b></entry><entry align="center" valign="top"><b>EC<sub>50</sub> [nM]</b></entry></row></thead><tbody><row><entry align="center">1</entry><entry align="center">1.15</entry></row><row><entry align="center">2</entry><entry align="center">1.20</entry></row><row><entry align="center">4</entry><entry align="center">0.46</entry></row><row><entry align="center">7</entry><entry align="center">0.88</entry></row><!-- EPO <DP n="95"> --><row><entry align="center">14</entry><entry align="center">26</entry></row><row><entry align="center">19</entry><entry align="center">2.27</entry></row><row><entry align="center">31</entry><entry align="center">0.17</entry></row><row><entry align="center">35</entry><entry align="center">1.37</entry></row><row><entry align="center">41</entry><entry align="center">4.5</entry></row><row><entry align="center">43</entry><entry align="center">0.97</entry></row><row><entry align="center">46</entry><entry align="center">3.7</entry></row><row><entry align="center">54</entry><entry align="center">1.0</entry></row><row><entry align="center">63</entry><entry align="center">0.25</entry></row><row><entry align="center">78</entry><entry align="center">5.8</entry></row><row><entry align="center">81</entry><entry align="center">7.4</entry></row><row><entry align="center">86</entry><entry align="center">5.7</entry></row><row><entry align="center">89</entry><entry align="center">39.4</entry></row><row><entry align="center">99</entry><entry align="center">3730</entry></row><row><entry align="center">100</entry><entry align="center">5.1</entry></row><row><entry align="center">103</entry><entry align="center">72.1</entry></row><row><entry align="center">109</entry><entry align="center">8.4</entry></row><row><entry align="center">112</entry><entry align="center">12.5</entry></row><row><entry align="center">117</entry><entry align="center">22.3</entry></row><row><entry align="center">126</entry><entry align="center">1.4</entry></row><row><entry align="center">128</entry><entry align="center">74.4</entry></row><!-- EPO <DP n="96"> --><row><entry align="center">131</entry><entry align="center">44.6</entry></row><row><entry align="center">134</entry><entry align="center">2.0</entry></row><row><entry align="center">140</entry><entry align="center">12.6</entry></row><row><entry align="center">144</entry><entry align="center">80.3</entry></row><row><entry align="center">149</entry><entry align="center">25</entry></row><row><entry align="center">154</entry><entry align="center">331</entry></row></tbody></tgroup></table></tables></p><heading id="h0235"><b>Example 158: Assessment of <i>In vivo</i> Efficacy</b></heading><p id="p0222" num="0222">The efficacy of the compounds of formula (I) is assessed by measuring the circulating lymphocytes after oral administration of 3 to 30 mg/kg of a compound of formula (I) to normotensive male Wistar rats. The animals are housed in climate-controlled conditions with a 12 h-light/dark cycle, and have free access to normal rat chow and drinking water. Blood is collected before and 3, 6 and 24 h after drug administration. Full blood is subjected to hematology using Advia Hematology system (Bayer Diagnostics, Zürich, Switzerland).</p><p id="p0223" num="0223">All data are presented as mean ± SEM. Statistical analyses are performed by analysis of variance (ANOVA) using Statistica (StatSoft) and the Student-Newman-Keuls procedure for multiple comparisons. The null hypothesis is rejected when p &lt; 0.05.</p><p id="p0224" num="0224">As an example, Table 2 shows the effect on lymphocyte counts 6 h after oral administration of 10 mg/kg of some compounds of the present invention to normotensive male Wistar rats as compared to a group of animals treated with vehicle only.
<tables id="tabl0018" num="0018"><table frame="all"><title><b>Table 2:</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="39mm"/><colspec colnum="2" colname="col2" colwidth="36mm"/><thead><row><entry align="center" valign="top"><b>Compound of Example</b></entry><entry align="center" valign="top"><b>Lymphocyte counts</b></entry></row></thead><tbody><row><entry align="center">1</entry><entry align="center">-70 ± 3%</entry></row><row><entry align="center">3</entry><entry align="center">-70 ± 2%</entry></row><!-- EPO <DP n="97"> --><row><entry align="center">10</entry><entry align="center">-50 ± 2%</entry></row><row><entry align="center">16</entry><entry align="center">-74 ± 1%</entry></row><row><entry align="center">20</entry><entry align="center">-55 ± 1%</entry></row><row><entry align="center">29</entry><entry align="center">-73 ± 2%</entry></row><row><entry align="center">32</entry><entry align="center">-58 ± 1%</entry></row><row><entry align="center">33</entry><entry align="center">-65 ± 2%</entry></row><row><entry align="center">40</entry><entry align="center">-69 ± 2%</entry></row><row><entry align="center">51</entry><entry align="center">-61 ± 2%</entry></row><row><entry align="center">59</entry><entry align="center">-69 ± 2%</entry></row><row><entry align="center">65</entry><entry align="center">-60 ± 4%</entry></row><row><entry align="center">85</entry><entry align="center">-68 ± 1%</entry></row><row><entry align="center">138</entry><entry align="center">-74 ± 1%</entry></row></tbody></tgroup></table></tables></p></description><claims mxw-id="PCLM56984501" lang="DE" load-source="patent-office"><!-- EPO <DP n="106"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verbindung der Formel (I)
<chemistry id="chem0157" num="0157"><img id="ib0157" file="imgb0157.tif" wi="69" he="48" img-content="chem" img-format="tif"/></chemistry>
wobei
<claim-text><b>A</b> Folgendes repräsentiert:
<chemistry id="chem0158" num="0158"><img id="ib0158" file="imgb0158.tif" wi="124" he="21" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0159" num="0159"><img id="ib0159" file="imgb0159.tif" wi="125" he="22" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0160" num="0160"><img id="ib0160" file="imgb0160.tif" wi="103" he="22" img-content="chem" img-format="tif"/></chemistry>
wobei die Sternchen die Bindung andeuten, die mit der Pyrimidingruppe der Formel (I) verknüpft ist;
<claim-text><b>R<sup>1</sup></b> C<sub>1-4</sub>-Alkoxy, C<sub>1-4</sub>-Alkylamino, N-C<sub>1-4</sub>-Alkyl-N-C<sub>1-3</sub>-alkylamino, C<sub>3-5</sub>-Cycloalkylamino, C<sub>3-5</sub>-Cycloalkylmethylamino, Pyrrolidin oder Piperidin repräsentiert;<!-- EPO <DP n="107"> --></claim-text>
<claim-text><b>R<sup>2</sup></b> C<sub>1-2</sub>-Alkyl oder C<sub>3-4</sub>-Alkyl repräsentiert;</claim-text>
<claim-text><b>R<sup>3</sup></b> Wasserstoff, C<sub>1-4</sub>-Alkyl oder C<sub>1-3</sub>-Alkoxy repräsentiert;</claim-text>
<claim-text><b>R<sup>4</sup></b> Wasserstoff, C<sub>1-4</sub>-Alkyl oder C<sub>1-3</sub>-Alkoxy repräsentiert;</claim-text>
<claim-text><b>R<sup>5</sup></b> Folgendes repräsentiert: 2,3-Dihydroxypropyl, Di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54,</sup> -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, 1-(3-Carboxy-azetidinyl)-2-acetyl, 1-(2-Carboxy-pyrrolidinyl)-2-acetyl, 1-(3-Carboxy-pyrrolidinyl)-2-acetyl, 1-(3-Carboxy-azetidinyl)-3-propionyl, 1-(2-Carboxy-pyrrolidinyl)-3-propionyl, 1-(3-Carboxy-pyrrolidinyl)-3-propionyl, -(CH2)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, Hydroxy-C<sub>2-5</sub>-alkoxy, Di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-Dihydroxy-propoxy, 2-Hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(Azetidin-3-carbonsäure)-1-yl]-ethoxy, 2-[(Azetidin-3-carbonsäure-C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, 2-[(Pyrrolidin-3-carbonsäure)-1-yl]-ethoxy, 2-[(Pyrrolidin-3-carbonsäure-C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(Azetidin-3-carbonsäure)-1-yl]-2-hydroxypropoxy, 3-[(Azetidin-3-carbonsäure-C<sub>1-5</sub>-alkylester)-1-yl]-2-hydroxypropoxy, 2-Hydroxy-3-[(pyrrolidin-3-carbonsäure)-1-yl]-propoxy, 2-Hydroxy-3-[(pyrrolidin-3-carbonsäure-C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, 2-Hydroxy-3-[(pyrrolidin-2-carbonsäure)-1-yl]-propoxy, 2-Hydroxy-3-[(pyrrolidin-2-carbonsäure C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>,-OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup> oder -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>;</claim-text>
<claim-text><b>R<sup>51</sup></b> Wasserstoff, C<sub>1-3</sub>-Alkyl, 2-Hydroxyethyl, 2-Hydroxy-1-hydroxymethyl-ethyl, 2,3-Dihydroxypropyl, Carboxymethyl, (C<sub>1-5</sub>-Alkylcarboxy)methyl, 2-Carboxyethyl, 2-(C<sub>1-5</sub>-Alkylcarboxy)ethyl oder 2-Aminoethyl repräsentiert;</claim-text>
<claim-text><b>R<sup>52</sup></b> Wasserstoff, Methyl oder Ethyl repräsentiert;</claim-text>
<claim-text><b>R<sup>53</sup></b> C<sub>1-3</sub>-Alkyl, Methylamino, Ethylamino oder Dimethylamino repräsentiert;</claim-text>
<claim-text><b>R<sup>54</sup></b> Hydroxy-C<sub>1-2</sub>-alkyl oder R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-Alkyl repräsentiert;</claim-text>
<claim-text><b>R<sup>55</sup></b> und <b>R<sup>56</sup></b> unabhängig Wasserstoff oder Methyl repräsentieren;</claim-text>
<claim-text>k die ganze Zahl 1, 2 oder 3 repräsentiert;</claim-text>
<claim-text>m die ganze Zahl 1 oder 2 repräsentiert;</claim-text>
<claim-text>n 0, 1 oder 2 repräsentiert; und<!-- EPO <DP n="108"> --></claim-text>
<claim-text><b>R<sup>6</sup></b> Wasserstoff, C<sub>1-4</sub>-Alkyl oder Halogen repräsentiert;</claim-text>
<claim-text>oder ein Salz einer solchen Verbindung.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verbindung nach Anspruch 1, wobei <b>A</b> Folgendes repräsentiert:
<chemistry id="chem0161" num="0161"><img id="ib0161" file="imgb0161.tif" wi="123" he="22" img-content="chem" img-format="tif"/></chemistry>
wobei die Sternchen die Bindung andeuten, die mit der Pyrimidingruppe der Formel (I) verknüpft ist;<br/>
oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verbindung nach Anspruch 1, wobei <b>A</b> Folgendes repräsentiert:
<chemistry id="chem0162" num="0162"><img id="ib0162" file="imgb0162.tif" wi="44" he="21" img-content="chem" img-format="tif"/></chemistry>
wobei das Sternchen die Bindung andeutet, die mit der Pyrimidingruppe der Formel (I) verknüpft ist;<br/>
oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verbindung nach einem der Ansprüche 1 bis 3, wobei <b>R<sup>1</sup></b> C<sub>1-4</sub>-Alkylamino oder N-C1-<sub>4</sub>-Alkyl-N-C<sub>1-3</sub>-alkylamino repräsentiert; oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verbindung nach einem der Ansprüche 1 bis 3, wobei <b>R<sup>1</sup></b> C<sub>1-4</sub>-Alkoxy repräsentiert; oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verbindung nach einem der Ansprüche 1 bis 5, wobei <b>R<sup>2</sup></b> C<sub>1-2</sub>-Alkyl repräsentiert; oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verbindung nach einem der Ansprüche 1 bis 6, wobei <b>R<sup>3</sup></b> Wasserstoff repräsentiert; oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verbindung nach einem der Ansprüche 1 bis 7, wobei <b>R<sup>5</sup></b> Folgendes repräsentiert: 2,3-Dihydroxypropyl, Di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>,<!-- EPO <DP n="109"> --> - (CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, Hydroxy-C<sub>2-5</sub>-alkoxy, Di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-Dihydroxy-propoxy, 2-Hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup> oder -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>; oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verbindung nach einem der Ansprüche 1 bis 7, wobei <b>R<sup>5</sup></b> 2,3-Dihydroxy-propoxy oder-OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> repräsentiert; oder ein Salz einer solchen Verbindung.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verbindung nach Anspruch 1, wobei <b>A</b> Folgendes repräsentiert:
<chemistry id="chem0163" num="0163"><img id="ib0163" file="imgb0163.tif" wi="35" he="20" img-content="chem" img-format="tif"/></chemistry>
wobei das Sternchen die Bindung andeutet, die mit der Pyrimidingruppe der Formel (I) verknüpft ist;
<claim-text><b>R<sup>1</sup></b> C<sub>1-4</sub>-Alkoxy repräsentiert;</claim-text>
<claim-text><b>R<sup>2</sup></b> C<sub>1-2</sub>-Alkyl oder C<sub>3-4</sub>-Alkyl repräsentiert;</claim-text>
<claim-text><b>R<sup>3</sup></b> Wasserstoff repräsentiert;</claim-text>
<claim-text><b>R<sup>4</sup></b> C<sub>1-4</sub>-Alkyl oder C<sub>1-3</sub>-Alkoxy repräsentiert;</claim-text>
<claim-text><b>R<sup>5</sup></b> Folgendes repräsentiert: -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>CONR<sup>51</sup>R<sup>52</sup>, Hydroxy-C<sub>2-5</sub>-alkoxy, Di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-Dihydroxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(Azetidin-3-carbonsäure)-1-yl]-ethoxy, 2-[(Pyrrolidin-3-carbonsäure)-1-yl]-ethoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(Azetidin-3-carbonsäure)-1-yl]-2-hydroxypropoxy, 2-Hydroxy-3-[(pyrrolidin-3-carbonsäure)-1-yl]-propoxy, 2-Hydroxy-3-[(pyrrolidin-2-carbonsäure)-1-yl]-propoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup> oder -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>;</claim-text>
<claim-text><b>R<sup>51</sup></b> Wasserstoff, C<sub>1-3</sub>-Alkyl, 2-Hydroxyethyl, 2-Hydroxy-1-hydroxymethyl-ethyl, 2,3-Dihydroxypropyl, Carboxymethyl, (C<sub>1-5</sub>-Alkylcarboxy)methyl, 2-Carboxyethyl, 2-(C<sub>1-5</sub>-Alkylcarboxy)ethyl oder 2-Aminoethyl repräsentiert;</claim-text>
<claim-text><b>R<sup>52</sup></b> Wasserstoff, Methyl oder Ethyl repräsentiert;</claim-text>
<claim-text><b>R<sup>53</sup></b> C<sub>1-3</sub>-Alkyl, Methylamino, Ethylamino oder Dimethylamino repräsentiert;</claim-text>
<claim-text><b>R<sup>54</sup></b> Hydroxy-C<sub>1-2</sub>-alkyl oder R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-Alkyl repräsentiert;</claim-text>
<claim-text><b>R<sup>55</sup></b> und <b>R<sup>56</sup></b> unabhängig Wasserstoff oder Methyl repräsentieren;</claim-text>
<claim-text>m die ganze Zahl 1 oder 2 repräsentiert;<!-- EPO <DP n="110"> --></claim-text>
<claim-text>n 0, 1 oder 2 repräsentiert; und</claim-text>
<claim-text><b>R<sup>6</sup></b> Wasserstoff, C<sub>1-4</sub>-Alkyl oder Halogen repräsentiert;</claim-text>
<claim-text>oder ein Salz einer solchen Verbindung.</claim-text></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verbindung nach Anspruch 1, die ausgewählt ist aus der Gruppe bestehend aus:
<claim-text>N-(3-{2,6-Dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-((S)-3-{2-Ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2,6-Dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-((S)-3-{2-Ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-((S)-3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-(Ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>3-{4-[5-(2-Ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2,6-Dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol;<!-- EPO <DP n="111"> --></claim-text>
<claim-text>3-{4-[5-(2-Isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol; und</claim-text>
<claim-text>3-{4-[5-(2-(Ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>oder ein Salz einer solchen Verbindung.</claim-text></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verbindung nach Anspruch 1, die ausgewählt ist aus der Gruppe bestehend aus:
<claim-text>N-(3-{2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-[3-(2-Ethyl-4-{5-[2-(isobutyl-methyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-[3-(4-{5-[2-(Cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-2-ethyl-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2-Ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2-Ethyl-6-methyl-4-[5-(2-methylamino-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-((S)-3-{2-Ethyl-4-[5-(6-isobutyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2-Ethyl-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2-Ethyl-4-[5-(2-isobutoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{4-[5-(2-Ethoxy-6-ethyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2-Ethyl-4-[5-(2-methoxy-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-((S)-3-{2-Ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>N-(3-{2-Chlor-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;<!-- EPO <DP n="112"> --></claim-text>
<claim-text>2-Hydroxy-N-(2-hydroxy-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy]-propyl)-acetamid;</claim-text>
<claim-text>N-(3-{2-Chlor-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>3-{2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2-Ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-Cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2-Ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2-Ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2-Ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(6-Ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(6-Ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2-Chlor-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-Isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>3-{2-Chlor-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-1,2-diol;</claim-text>
<claim-text>N-((S)-3-{2-Ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamid;</claim-text>
<claim-text>3-(3-{4-[5-(2-Diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionsäure; und</claim-text>
<claim-text>3-{2-Ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-N-(2-hydroxy-ethyl)-propionamid;</claim-text>
<claim-text>oder ein Salz einer solchen Verbindung.</claim-text><!-- EPO <DP n="113"> --></claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Pharmazeutische Zusammensetzung, die eine Verbindung nach einem der Ansprüche 1 bis 12 oder ein pharmazeutisch akzeptables Salz davon und einen pharmazeutisch akzeptablen Träger umfasst.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verbindung nach einem der Ansprüche 1 bis 12 oder ein pharmazeutisch akzeptables Salz davon oder eine pharmazeutische Zusammensetzung nach Anspruch 13 für den Gebrauch als Medikament.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verwendung einer Verbindung nach einem der Ansprüche 1 bis 12 oder eines pharmazeutisch akzeptablen Salzes davon zur Herstellung einer pharmazeutischen Zusammensetzung zur Verhütung oder Behandlung von Krankheiten oder Störungen, die mit einem aktivierten Immunsystem assoziiert sind.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Verwendung nach Anspruch 15 zur Verhütung oder Behandlung von Krankheiten oder Störungen, die ausgewählt sind aus der Gruppe bestehend aus Abstoßung transplantierter Organe wie Niere, Leber, Herz, Lunge, Bauchspeicheldrüse, Hornhaut und Haut; Transplantat-gegen-Empfänger-Krankheiten infolge einer Stammzellentransplantation; Autoimmunsyndromen wie Rheumatoidarthritis, Multiple Sklerose, entzündliche Darmerkrankungen wie die Crohnsche Krankheit und Colitis ulcerosa, Psoriasis, psoriatische Arthritis, Thyreoiditis wie Hashimoto-Thyreoiditis, Uveoretinitis; atopischen Krankheiten wie Rhinitis, Konjunktivitis, Dermatitis; Asthma; Typ-I-Diabetes; postinfektiösen Autoimmunkrankheiten wie rheumatisches Fieber und postinfektiöse Glomerulonephritis; soliden Krebsarten und Tumormetastasen.</claim-text></claim></claims><claims mxw-id="PCLM56984502" lang="EN" load-source="patent-office"><!-- EPO <DP n="98"> --><claim id="c-en-01-0001" num="0001"><claim-text>A compound of the formula (I)
<chemistry id="chem0150" num="0150"><img id="ib0150" file="imgb0150.tif" wi="75" he="51" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>A represents
<chemistry id="chem0151" num="0151"><img id="ib0151" file="imgb0151.tif" wi="134" he="22" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0152" num="0152"><img id="ib0152" file="imgb0152.tif" wi="136" he="28" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0153" num="0153"><img id="ib0153" file="imgb0153.tif" wi="111" he="23" img-content="chem" img-format="tif"/></chemistry></claim-text>
wherein the asterisks indicate the bond that is linked to the pyrimidine group of formula (I);
<claim-text><b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylamino, N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino, C<sub>3-5</sub>-cycloalkylamino, C<sub>3-5</sub>-cycloalkylmethylamino, pyrrolidine, or piperidine;</claim-text>
<claim-text><b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl or C<sub>3-4</sub>-alkyl;</claim-text>
<claim-text><b>R<sup>3</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;<!-- EPO <DP n="99"> --></claim-text>
<claim-text><b>R<sup>4</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;</claim-text>
<claim-text><b>R<sup>5</sup></b> represents 2,3-dihydroxypropyl, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>nC</sub>H(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, 1-(3-carboxy-azetidinyl)-2-acetyl, 1-(2-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-pyrrolidinyl)-2-acetyl, 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(azetidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-ethoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 3-[(azetidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid C<sub>1-5</sub>-alkylester)-1-yl]-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>;</claim-text>
<claim-text><b>R<sup>51</sup></b> represents hydrogen, C<sub>1-3</sub>-alkyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxypropyl, carboxymethyl, (C<sub>1-5</sub>-alkylcarboxy)methyl, 2-carboxyethyl, 2-(C<sub>1-5</sub>-alkylcarboxy)ethyl, or 2-aminoethyl;</claim-text>
<claim-text><b>R<sup>52</sup></b> represents hydrogen, methyl, or ethyl;</claim-text>
<claim-text><b>R<sup>53</sup></b> represents C<sub>1-3</sub>-alkyl, methylamino, ethylamino, or dimethylamino;</claim-text>
<claim-text><b>R<sup>54</sup></b> represents hydroxy-C<sub>1-2</sub>-alkyl or R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyl;</claim-text>
<claim-text><b>R<sup>55</sup></b> and <b>R<sup>56</sup></b> independently represent hydrogen or methyl;</claim-text>
<claim-text>k represents the integer 1, 2, or 3;</claim-text>
<claim-text>m represents the integer 1 or 2;</claim-text>
<claim-text>n represents 0, 1, or 2; and</claim-text>
<claim-text><b>R<sup>6</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or halogen;</claim-text>
<claim-text>or a salt of such a compound.</claim-text><!-- EPO <DP n="100"> --></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A compound according to claim 1, wherein A represents
<chemistry id="chem0154" num="0154"><img id="ib0154" file="imgb0154.tif" wi="131" he="23" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisks indicate the bond that is linked to the pyrimidine group of formula (I); or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A compound according to claim 1, wherein <b>A</b> represents
<chemistry id="chem0155" num="0155"><img id="ib0155" file="imgb0155.tif" wi="47" he="22" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisk indicates the bond that is linked to the pyrimidine group of formula (I); or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A compound according to any one of claims 1 to 3, wherein <b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkylamino or N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino; or or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A compound according to any one of claims 1 to 3, wherein <b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy; or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A compound according to any one of claims 1 to 5, wherein <b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl; or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A compound according to any one of claims 1 to 6, wherein <b>R<sup>3</sup></b> represents hydrogen; or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A compound according to any one of claims 1 to 7, wherein <b>R<sup>5</sup></b> represents 2,3-dihydroxypropyl, di-(hydroxy-C<sub>1-4</sub>-alkyl-C<sub>1-4</sub>-alkyl, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OHFCH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-methoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or-OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>; or a salt of such a compound.<!-- EPO <DP n="101"> --></claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A compound according to any one of claims 1 to 7, wherein <b>R<sup>5</sup></b> represents 2,3-dihydroxy-propoxy or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>; or a salt of such a compound.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A compound according to claim 1, wherein <b>A</b> represents
<chemistry id="chem0156" num="0156"><img id="ib0156" file="imgb0156.tif" wi="38" he="22" img-content="chem" img-format="tif"/></chemistry>
wherein the asterisk indicates the bond that is linked to the pyrimidine group of formula (I);
<claim-text><b>R<sup>1</sup></b> represents C<sub>1-4</sub>-alkoxy;</claim-text>
<claim-text><b>R<sup>2</sup></b> represents C<sub>1-2</sub>-alkyl or C<sub>3-4</sub>-alkyl;</claim-text>
<claim-text><b>R<sup>3</sup></b> represents hydrogen;</claim-text>
<claim-text><b>R<sup>4</sup></b> represents C<sub>1-4</sub>-alkyl, or C<sub>1-3</sub>-alkoxy;</claim-text>
<claim-text><b>R<sup>5</sup></b> represents -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub> NR<sup>51</sup>R<sup>52</sup>, 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup> , 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup>, or -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>;</claim-text>
<claim-text><b>R<sup>51</sup></b> represents hydrogen, C<sub>1-3</sub>-alkyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxypropyl, carboxymethyl, (C<sub>1-5</sub>-alkylcarboxy)methyl, 2-carboxyethyl, 2-(C<sub>1-5</sub>-alkylcarboxy)ethyl, or 2-aminoethyl;</claim-text>
<claim-text><b>R<sup>52</sup></b> represents hydrogen, methyl, or ethyl;</claim-text>
<claim-text><b>R<sup>53</sup></b> represents C<sub>1-3</sub>-alkyl, methylamino, ethylamino, or dimethylamino;</claim-text>
<claim-text><b>R<sup>54</sup></b> represents hydroxy-C<sub>1-2</sub>-alkyl or R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyl;</claim-text>
<claim-text><b>R<sup>55</sup></b> and <b>R<sup>56</sup></b> independently represent hydrogen or methyl;</claim-text>
<claim-text>m represents the integer 1 or 2;</claim-text>
<claim-text>n represents 0, 1, or 2; and</claim-text>
<claim-text><b>R<sup>6</sup></b> represents hydrogen, C<sub>1-4</sub>-alkyl, or halogen;</claim-text>
<claim-text>or a salt of such a compound.</claim-text></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A compound according to claim 1 selected from the group consisting of:
<claim-text>N-(3-{2,6-dimethyl-4-[5-(6-methyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;<!-- EPO <DP n="102"> --></claim-text>
<claim-text>N-(3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-ph enoxy}-2-hydroxy-propyl)-2-hydroxy-aceta mide;</claim-text>
<claim-text>N-((S)-3-{2-ethyl-4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-((S)-3-{2-ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-aceta mide;</claim-text>
<claim-text>N-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-dimethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>3-{4-[5-(2-ethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2,6-dimethyl-4-[5-(6-methyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol; and</claim-text>
<claim-text>3-{4-[5-(2-(ethyl-methylamino)-6-methyl-pyrimidin-4-yl)-[12,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>or a salt of such a compound.</claim-text><!-- EPO <DP n="103"> --></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A compound according to claim 1 selected from the group consisting of:
<claim-text>N-(3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-[3-(2-ethyl-4-{5-[2-(isobutyl-methyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-[3-(4-{5-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-2-ethyl-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2-ethyl-6-methyl-4-[5-(2-methylamino-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-((S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2-ethyl-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2-ethyl-4-[5-(2-isobutoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{4-[5-(2-ethoxy-6-ethyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2-ethyl-4-[5-(2-methoxy-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-((S)-3-{2-ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>N-(3-{2-chloro-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>2-hydroxy-N-(2-hydroxy-3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propyl)-acetamide;</claim-text>
<claim-text>N-(3-{2-chloro-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide;</claim-text>
<claim-text>3-{2-ethyl-4-(5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2-ethyl-4-[5-(2-isobutylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;<!-- EPO <DP n="104"> --></claim-text>
<claim-text>3-{4-[5-(2-cyclopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2-ethyl-4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2-ethyl-4-[5-(6-isobutyl-2-methoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(6-ethyl-2-ethylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2-chloro-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>3-{2-chloro-4-[5-(2-isopropoxy-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol;</claim-text>
<claim-text>N-((S)-3-{2-ethyl-4-[3-(2-isopropylamino-6-methyl-pyrimidin-4-yl}-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl-2-hydroxy-acetamide;</claim-text>
<claim-text>3-(3-{4-[5-(2-diethylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionic acid; and</claim-text>
<claim-text>3-{2-ethyl-4-[5-(2-isopropylamino-6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-N-(2-hydroxy-ethyl)-propionamide;</claim-text>
<claim-text>or a salt of such a compound.</claim-text></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 13, for use as a medicament.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>Use of a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the<!-- EPO <DP n="105"> --> prevention or treatment of diseases or disorders associated with an activated immune system.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The use according to claim 15 for the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumor metastasis.</claim-text></claim></claims><claims mxw-id="PCLM56984503" lang="FR" load-source="patent-office"><!-- EPO <DP n="114"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Composé de formule (I)
<chemistry id="chem0164" num="0164"><img id="ib0164" file="imgb0164.tif" wi="69" he="47" img-content="chem" img-format="tif"/></chemistry>
où
<claim-text><b>A</b> représente
<chemistry id="chem0165" num="0165"><img id="ib0165" file="imgb0165.tif" wi="124" he="21" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0166" num="0166"><img id="ib0166" file="imgb0166.tif" wi="125" he="22" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0167" num="0167"><img id="ib0167" file="imgb0167.tif" wi="103" he="22" img-content="chem" img-format="tif"/></chemistry></claim-text>
où les astérisques indiquent la liaison qui est rattachée au groupement pyrimidine de la formule (I) ;
<claim-text><b>R<sup>1</sup></b> représente un groupement C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylamino, N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino, C<sub>3-5</sub>-cycloalkylamino, C<sub>3-5</sub>-cycloalkylméthylamino, pyrrolidine ou pipéridine ;</claim-text>
<claim-text><b>R<sup>2</sup></b> représente un C<sub>1-2</sub>-alkyle ou un C<sub>3-4</sub>-alkyle ;<!-- EPO <DP n="115"> --></claim-text>
<claim-text><b>R<sup>3</sup></b> représente un hydrogène, un C<sub>1-4</sub>-alkyle ou un C<sub>1-3</sub>-alkoxy ;</claim-text>
<claim-text><b>R<sup>4</sup></b> représente un hydrogène, un C<sub>1-4</sub>-alkyle ou un C<sub>1-3</sub>-alkoxy ;</claim-text>
<claim-text><b>R<sup>5</sup></b> représente un 2,3-dihydroxypropyle, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkyle, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, 1-(3-carboxy-azétidinyl)-2-acétyle, 1-(2-carboxy-pyrrolidinyl)-2-acétyle, 1-(3-carboxy-pyrrolidinyl)-2-acétyle, 1-(3-carboxy-azétidinyl)-3-propionyle, 1-(2-carboxy-pyrrolidinyl)-3-propionyle, 1-(3-carboxy-pyrrolidinyl)-3-propionyle, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup> , hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-méthoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(acide azétidin-3-carboxylique)-1-yl]-éthoxy, 2-[(ester C<sub>1-5</sub>-alkylique de l'acide azétidin-3-carboxylique)-1-yl]-éthoxy, 2-[(acide pyrrolidin-3-carboxylique)-1-yl]-éthoxy, 2-[(ester C<sub>1-5</sub>-alkylique de l'acide pyrrolidin-3-carboxylique)-1-yl]-éthoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(acide azétidin-3-carboxylique)-1-yl]-2-hydroxypropoxy, 3-[(ester C<sub>1-5</sub>-alkylique de l'acide azétidin-3-carboxylique)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(acide pyrrolidin-3-carboxylique)-1-yl]-propoxy, 2-hydroxy-3-[(ester C<sub>1-5</sub>-alkylique de l'acide pyrrolidin-3-carboxylique)-1-yl]-propoxy, 2-hydroxy-3-[(acide pyrrolidin-2-carboxylique)-1-yl]-propoxy, 2-hydroxy-3-[(ester C<sub>1-5</sub>-alkylique de l'acide pyrrolidin-2-carboxylique)-1-yl]-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sub>53</sub>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup> ou -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> ;</claim-text>
<claim-text><b>R<sup>51</sup></b> représente un hydrogène, C<sub>1-3</sub>-alkyle, 2-hydroxyéthyle, 2-hydroxy-1-hydroxyméthyl-éthyle, 2,3-dihydroxypropyle, carboxyméthyle, (C<sub>1-5</sub>-alkylcarboxy)méthyle, 2-carboxyéthyle, 2-(C<sub>1-5</sub>-alkylcarboxy) éthyle ou 2-aminoéthyle ;</claim-text>
<claim-text><b>R<sup>52</sup></b> représente un hydrogène, un méthyle ou un éthyle ;</claim-text>
<claim-text><b>R<sup>53</sup></b> représente un C<sub>1-3</sub>-alkyle, un méthylamino, un éthylamino ou un diméthylamino ;</claim-text>
<claim-text><b>R<sup>54</sup></b> représente un hydroxy-C<sub>1-2</sub>-alkyle ou un R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyle ;</claim-text>
<claim-text><b>R<sup>55</sup> et R<sup>56</sup></b> représentent indépendamment un hydrogène ou un méthyle ;</claim-text>
<claim-text>k représente le nombre entier 1, 2 ou 3 ;</claim-text>
<claim-text>m représente le nombre entier 1 ou 2 ;</claim-text>
<claim-text>n représente 0, 1 ou 2 ; et</claim-text>
<claim-text><b>R<sup>6</sup></b> représente un hydrogène, un C<sub>1-4</sub>-alkyle ou un halogène ;<!-- EPO <DP n="116"> --></claim-text>
<claim-text>ou sel d'un tel composé.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composé selon la revendication 1, où <b>A</b> représente
<chemistry id="chem0168" num="0168"><img id="ib0168" file="imgb0168.tif" wi="119" he="22" img-content="chem" img-format="tif"/></chemistry>
où les astérisques indiquent la liaison qui est rattachée au groupement pyrimidine de la formule (I) ;<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composé selon la revendication 1, où A représente
<chemistry id="chem0169" num="0169"><img id="ib0169" file="imgb0169.tif" wi="44" he="21" img-content="chem" img-format="tif"/></chemistry>
où l'astérisque indique la liaison qui est rattachée au groupement pyrimidine de formule (I) ; ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composé selon l'une quelconque des revendications 1 à 3, où <b>R<sup>1</sup></b> représente un C<sub>1-4</sub>-alkylamino ou un N-C<sub>1-4</sub>-alkyl-N-C<sub>1-3</sub>-alkylamino<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composé selon l'une quelconque des revendications 1 à 3, où <b>R<sup>1</sup></b> représente un C<sub>1-4</sub>-alkoxy ;<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composé selon l'une quelconque des revendications 1 à 5, où <b>R<sup>2</sup></b> représente un C<sub>1-2</sub>-alkyle ;<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Composé selon l'une quelconque des revendications 1 à 6, où <b>R<sup>3</sup></b> représente un hydrogène ;<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Composé selon l'une quelconque des revendications 1 à 7, où <b>R<sup>5</sup></b> représente un 2,3-dihydroxypropyle, di-(hydroxy-C<sub>1</sub>-<sub>4</sub>-alkyl)-C<sub>1-4</sub>-alkyle, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHSO<sub>2</sub>R<sup>53</sup>, - (CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>k</sub>-NHCOR<sup>54</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>,<!-- EPO <DP n="117"> --> -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, 2-hydroxy-3-méthoxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup> ou -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> ;<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Composé selon l'une quelconque des revendications 1 à 7, où <b>R<sup>5</sup></b> représente un 2,3-dihydroxy-propoxy ou un -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> ;<br/>
ou sel d'un tel composé.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Composé selon la revendication 1, où <b>A</b> représente
<chemistry id="chem0170" num="0170"><img id="ib0170" file="imgb0170.tif" wi="36" he="20" img-content="chem" img-format="tif"/></chemistry>
où l'astérisque indique la liaison qui est rattachée au groupement pyrimidine de formule (I) ;
<claim-text><b>R<sup>1</sup></b> représente un C<sub>1-4</sub>-alkoxy ;</claim-text>
<claim-text><b>R<sup>2</sup></b> représente un C<sub>1-2</sub>-alkyle ou un C<sub>3-4</sub>-alkyle ;</claim-text>
<claim-text><b>R<sup>3</sup></b> représente un hydrogène ;</claim-text>
<claim-text><b>R<sup>4</sup></b> représente un C<sub>1-4</sub>-alkyle ou un C<sub>1-3</sub>-alkoxy ;</claim-text>
<claim-text><b>R<sup>5</sup></b> représente un -(CH<sub>2</sub>)<sub>n</sub>CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup>, -CH<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-CONR<sup>51</sup>R<sup>52</sup>, hydroxy-C<sub>2-5</sub>-alkoxy, di-(hydroxy-C<sub>1-4-a</sub>lkyl)-C<sub>1-4</sub>-alkoxy, 2,3-dihydroxy-propoxy, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>51</sup>R<sup>52</sup>, 2-[(acide azétidin-3-carboxylique)-1-yl]-éthoxy, 2-[(acide pyrrolidin-3-carboxylique)-1-yl]-éthoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NR<sup>51</sup>R<sup>52</sup>, 3-[(acide azétidin-3-carboxylique)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(acide pyrrolidin-3-carboxylique)-1-yl]-propoxy, 2-hydroxy-3-[(acide pyrrolidin-2-carboxylique)-1-yl]-propoxy, -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHSO<sub>2</sub>R<sup>53</sup>, -OCH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub>-NHCOR<sup>54</sup> ou -OCH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NHCOR<sup>54</sup> ;</claim-text>
<claim-text><b>R<sup>51</sup></b> représente un hydrogène, C<sub>1-3</sub>-alkyle, 2-hydroxyéthyle, 2-hydroxy-1-hydroxyméthyl-éthyle, 2,3-dihydroxypropyle, carboxyméthyle, (C<sub>1-5</sub>-alkylcarboxy)méthyle, 2-carboxyéthyle, 2-(C<sub>1-5</sub>-alkylcarboxy)éthyle ou 2-aminoéthyle ;</claim-text>
<claim-text><b>R<sup>52</sup></b> représente un hydrogène, un méthyle ou un éthyle ;</claim-text>
<claim-text><b>R<sup>53</sup></b> représente un C<sub>1-3</sub>-alkyle, un méthylamino, un éthylamino ou un diméthylamino ;</claim-text>
<claim-text><b>R<sup>54</sup></b> représente un hydroxy-C<sub>1-2</sub>-alkyle ou un R<sup>55</sup>R<sup>56</sup>N-C<sub>1-2</sub>-alkyle ;</claim-text>
<claim-text><b>R<sup>55</sup></b> et <b>R<sup>56</sup></b> représentent indépendamment un hydrogène ou un méthyle ;<!-- EPO <DP n="118"> --></claim-text>
<claim-text>m représente le nombre entier 1 ou 2 ;</claim-text>
<claim-text>n représente 0, 1 ou 2 ; et</claim-text>
<claim-text><b>R<sup>6</sup></b> représente un hydrogène, un C<sub>1-4</sub>-alkyle ou un halogène ;</claim-text>
<claim-text>ou sel d'un tel composé.</claim-text></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Composé selon la revendication 1, sélectionné parmi le groupe consistant en les suivants :
<claim-text>N-(3-{2,6-diméthyl-4-[5-(6-méthyl-2-méthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-éthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-((S)-3-{2-éthyl-4-[5-(2-éthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2,6-diméthyl-4-[5-(6-méthyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-((S)-3-{2-éthyl-4-[5-(2-isobutylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-isobutylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-((S)-3-{4-[5-(2-diéthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-diéthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-diméthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-(éthyl-méthylamino)-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-isopropoxy-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>3-{4-[5-(2-éthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2,6-diméthyl-4-[5-(6-méthyl-2-propylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ;<!-- EPO <DP n="119"> --></claim-text>
<claim-text>3-{4-[5-(2-isobutylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{4-[5-(2-diéthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ; et</claim-text>
<claim-text>3-{4-[5-(2-(éthyl-méthylamino)-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>ou sel d'un tel composé.</claim-text></claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Composé selon la revendication 1, sélectionné parmi le groupe consistant en les suivants :
<claim-text>N-(3-{2-éthyl-4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-[3-(2-éthyl-4-{5-[2-(isobutyl-méthyl-amino)-6-méthyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-6-méthyl-phénoxy)-2-hydroxy-propyl]-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-cyclopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-[3-(4-{5-[2-(cyclopropylméthyl-amino)-6-méthyl-pyrimidin-4-yl]-[1,2,4]oxadiazol-3-yl}-2-éthyl-6-méthyl-phénoxy)-2-hydroxy-propyl]-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2-éthyl-4-[5-(6-éthyl-2-éthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2-éthyl-6-méthyl-4-[5-(2-méthylamino-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-((S)-3-{2-éthyl-4-[5-(6-isobutyl-2-méthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2-éthyl-4-[5-(2-isopropoxy-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2-éthyl-4-[5-(2-isobutoxy-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{4-[5-(2-éthoxy-6-éthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2-éthyl-4-[5-(2-méthoxy-6-propyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-((S)-3-{2-éthyl-4-[5-(6-isobutyl-2-méthoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>N-(3-{2-chloro-4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;<!-- EPO <DP n="120"> --></claim-text>
<claim-text>2-hydroxy-N-(2-hydroxy-3-{4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-méthoxy-6-méthyl-phénoxy}-propyl)-acétamide ;</claim-text>
<claim-text>N-(3-{2-chloro-4-[5-(2-isopropoxy-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>3-{2-éthyl-4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2-éthyl-4-[5-(2-isobutylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{4-[5-(2-cyclopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2-éthyl-4-[5-(6-éthyl-2-éthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2-éthyl-4-[5-(6-éthyl-2-éthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2-éthyl-4-[5-(6-isobutyl-2-méthoxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{4-[5-(6-éthyl-2-éthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{4-[5-(6-éthyl-2-éthylamino-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2,6-diméthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2-chloro-4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-méthoxy-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>3-{2-chloro-4-[5-(2-isopropoxy-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phénoxy}-propane-1,2-diol ;</claim-text>
<claim-text>N-((S)-3-{2-éthyl-4-[3-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-5-yl]-6-méthyl-phénoxy}-2-hydroxy-propyl)-2-hydroxy-acétamide ;</claim-text>
<claim-text>acide 3-(3-{4-[5-(2-diéthylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-2-hydroxy-propylamino)-propionique ; et</claim-text>
<claim-text>3-{2-éthyl-4-[5-(2-isopropylamino-6-méthyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-méthyl-phényl}-N-(2-hydroxy-éthyl)-propionamide</claim-text>
<claim-text>ou sel d'un tel composé.</claim-text></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Composition pharmaceutique qui comprend un composé selon l'une quelconque des revendications 1 à 12 ou un sel pharmaceutiquement acceptable de celui-ci et un véhicule pharmaceutiquement acceptable.<!-- EPO <DP n="121"> --></claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Composé selon l'une quelconque des revendications 1 à 12 ou sel pharmaceutiquement acceptable de celui-ci ou composition pharmaceutique selon la revendication 13, pour une utilisation en tant que médicament.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Utilisation d'un composé selon l'une quelconque des revendications 1 à 12 ou d'un sel pharmaceutiquement acceptable de celui-ci dans la préparation d'une composition pharmaceutique pour la prévention ou le traitement de maladies ou d'affections associées à un système immunitaire activé.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Utilisation selon la revendication 15 dans la prévention ou le traitement de maladies ou d'affections sélectionnées dans le groupe consistant en les suivantes : rejet d'organes transplantés tels que rein, foie, coeur, poumon, pancréas, cornée et peau ; maladies du greffon contre l'hôte déclenchées par une greffe de cellules souches ; syndromes auto-immuns, y compris polyarthrite rhumatoïde, sclérose en plaques, affections intestinales inflammatoires comme la maladie de Crohn et la rectocolite hémorragique ; psoriasis ; rhumatisme psoriasique ; thyroïdite, comme la thyroïdite chronique de Hashimoto ; uvéo-rétinite ; maladies atopiques comme la rhinite, conjonctivite, dermatite ; asthme ; diabète de type I ; maladies auto-immunes post-infectieuses, y compris rhumatisme articulaire aigu et glomérulonéphrite post-infectieuse ; cancers solides et métastases tumorales.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
